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Abstract  
There are many RNA virus pathogens of humans including influenza, 
parainfluenza, enteroviruses, parechoviruses, coronaviruses, pneumoviruses, 
and metapneumoviruses. These commonly invade and infect the respiratory 
and gastrointestinal tracts, giving rise to acute and chronic respiratory tract 
infections, and some may also reach the central nervous system (CNS) either 
via haematogenous or neural routes resulting in a variety of clinical 
presentations, (e.g. meningitis, encephalitis) which may lead to severe 
irreparable damage such as poliomyelitis especially in young children. Early 
correct diagnosis of viral infections is indispensable in order to prevent 
potential outbreaks which threaten the public health worldwide and might lead 
to high morbidity and some with significant mortality. 
Several laboratory techniques such as virus isolation, direct visualization of 
viral particles, detection of viral antigens and/or nucleic acids, and detection of 
host immune response (e.g. anti-viral antibodies) to infection, are available for 
diagnosis, but may have significant drawbacks such as time-inefficiency, cost 
and certain individual limitations. Microarray technology offers one way to 
overcome some of these limitations.  
In this study, a microarray chip containing 7967 oligonucleotides (probes) 
covering the whole genomes of human enteroviruses, rhinoviruses, respiratory 
syncytial viruses, metapneumoviruses and influenza viruses was designed and 
constructed using both OligoArray and Agilent eArray software, to allow 
simultaneous detection of any of the above viruses present in any clinical 
specimen. 
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This virochip was tested against positive controls and clinical samples known 
to contain RNA nucleic acids of these viruses. Viral RNA was reverse 
transcribed, and amplified. Considerable effort was expended in trying to 
optimise a multiple displacement amplification (MDA) protocol for whole 
genome amplification, and in addition, long-range PCR was also utilised. 
Amplification products were fragmented, labelled and loaded into a 
hybridization reaction with the designed viral probes printed on the virochip.  
The results revealed (i) a number of technical problems associated with MDA; 
(ii) that some probes either failed to recognise their intended targets, or 
produced cross-reactive signals with non-intended targets; (iii) that many of the 
designed probes hybridized to their relevant viral nucleic acids and generated 
hybridization signals of high fluorescent intensity offering an opportunity to 
develop this probe array in order to be used for the identification of a wide 
variety of virus species up to the serogroup level or beyond (if required) 
specifically those causing CNS and respiratory tract infections.  
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Viruses are the plural of virus, a Latin word which means poison or venom. 
They are described as simple, acellular and tiny particles which have the ability 
to pass through the finest filters that retain mycoplasma, the smallest type of 
bacteria. Nanometre (1 nm =10-9 m) is the most appropriate unit used to 
measure their diminutive size. Therefore, they are very difficult to be seen even 
with the light microscope (Carter and Saunders, 2007, Condit, 2013). Viruses 
have been divided according to their genomic nature into two groups: 
deoxyribonucleic acid (DNA) viruses and ribonucleic acid (RNA) viruses 
(Willey et al., 2008).   
The argument concerning the living nature of these agents is still continuing 
since their early description and then their first naming as viruses in 1898 by 
Martinus Beijerinck. Most scientists agree that viruses are non-living because 
there is no evidence to confirm their ability to reproduce independently, which 
is considered as one of the main features of life. They must attack and 
parasitize the cells of all living beings such as humans, animals, plants, yeasts 
and fungi which are known as eukaryotes. These organisms all possess a 
nucleus, an enveloped organelle surrounding their genetic materials, normally 
deoxyribonucleic acid (DNA). Even prokaryotes, those primitive unicellular 
microorganisms that lack a nucleus, such as bacteria, are invaded by viruses. 
Therefore, viruses are generally known as obligate intracellular parasites 
which control the metabolic activities and genetic functions of living cells and 
direct them towards their benefits; reproduction and existence. Viral 
parasitism damages the host cells which mostly appear as symptoms of disease 
indicating viral infection (Collier and Oxford, 2000, Wagner and Hewlett, 
2008, Flint et al., 2009). 
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1.1 Diagnoses of viral infections:  
Viruses are the common causative agents of different types of human 
infections which may lead to significant morbidity and a considerable rate of 
mortality (Kannangai et al., 2010). Early correct diagnosis of viral infections is 
indispensable in order to prevent their potential outbreaks which threaten the 
public health worldwide and might lead to high morbidity and some with 
significant mortality, and allows for introduction of appropriate antiviral 
therapy (e.g. acyclovir, ganciclovir, foscarnet and neuraminidase inhibitors), 
and decreases the potential cost and toxicity of inappropriate therapy  (Storch, 
2000, Morshed et al., 2007, Mizutani et al., 2007, Kannangai et al., 2010). 
Some of these infections are asymptomatic whereas others are diverse in their 
clinical signs. Accurate diagnosis of these infections requires demonstration of 
the virus or at least its components in appropriate clinical samples ideally by 
using highly sensitive laboratory methods within a short time, or of a host 
immune response to infection. Different techniques have been used in order to 
fulfil these purposes either directly or indirectly through developments in the 
immunological, biotechnological and molecular fields, such as virus isolation, 
direct visualization of viral particles, detection of viral antigens and/or nucleic 
acids, and detection of host immune response (e.g. anti-viral antibodies) to 
infection (Muir et al., 1998, Boriskin et al., 2004, Lodes et al., 2007, Rabenau 
et al., 2007, Kannangai et al., 2010). 
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1.1.1 Cell Culture: 
Success in propagating human cells in vitro at the beginning of 20th century, 
was the starting point for the isolation and growing of viruses in the 
laboratory. Embryonated eggs and laboratory animals were firstly used and 
then replaced by cell culture techniques which utilize isolated cells separated 
from either human or animal trypsinized tissues (Freshney, 2000). This 
method is the only one able to generate viable isolate of virus which can be 
employed to investigate characteristics such as virulence, pathogenicity and 
antiviral susceptibility in more detail (Charlton et al., 2009). An additional 
major advantage of cell culture was the ability to generate effective viral 
vaccines, some of which are still commercially produced in this way (Dwyer 
et al., 2006). However, it is difficult to detect every possible virus which might 
be present in any clinical sample by using one type of cell culture because the 
latter will be unable to supply all the requirements necessary for the growth of 
all medically related viruses. Thus, diagnostic laboratories would use various 
types of cell culture such as cell lines derived from monkey kidney in addition 
to those obtained from human fibroblast and epithelial cells in order to 
enhance the range of viruses which could be isolated and identified 
(Chonmaitree et al., 1989, Leland and Ginocchio, 2007).  
The presence of a virus within a cell culture can be recognized by the 
production of a cytopathic effect (CPE). This term describes pathological 
effects of viruses on their host cells including alteration in cell morphology, 
formation of multinucleated giant cells, or syncytia, through fusion between 
two or more singular cells, cell vacuolation and cell lysis. These effects can be 
typically detected by light microscopy (Lodes et al., 2007). 
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This technique, however, has a number of disadvantages: 
1- Potential high cost of the different types of cell culture and their 
maintenance in-house, such that not all types may be available in all 
diagnostic laboratories (Hsiung, 1984). 
2- It requires technical expertise to examine the probable viral CPE every 
couple of days for more than one week of incubation period in order to 
confirm viral diagnosis. 
3- Many viruses are slow-growing in tissue culture, meaning that diagnosis 
by this technique may take up to two weeks. This is exacerbated when there 
are low titres of virus in the starting material. 
4- There are health and safety issues associated with working with live 
viruses in the laboratory (Storch, 2000, Leland and Ginocchio, 2007, 
Charlton et al., 2009).  
5- Not all viruses can be isolated in tissue culture e.g. hepatitis C virus and 
human papilloma viruses are extremely difficult to culture in this way. 
 
1.1.2 Electron microscopy: 
Electron microscopy (EM) has been used in the diagnosis of viral infections 
since 1939, eight years after its early discovery by Ernest Ruska, who was also 
the first to visualize tobacco mosaic virus (a plant pathogen). Subsequently, 
EM was applied in the differentiation and diagnosis of smallpox and 
chickenpox infections, and provided the first image of poliovirus, contributing 
to the discovery of enteroviruses (Nagler and Rake, 1948, Van Rooyen and 
Scott, 1948, Melnick and Phillips, 1970). Current knowledge of the accurate 
morphological and structural features of viruses as well as their mechanisms of 
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attachment and replication was obtained by electron microscopy. This 
information was very beneficial and led to an early scheme of viral 
classification, determination of viral types parasitizing humans and contributed 
to the development of vaccines and antiviral therapy (Hazelton and 
Gelderblom, 2003). 
Detection of viral particles by means of this technique mainly depends on the 
negative staining principle by use of phosphotungstic acid. This stain is unable 
to penetrate virus particles which therefore appear as white spots against a 
dark field. Therefore, it does not necessitate use of any particular reagents 
which makes it faster and easier than some other methods such as cell culture, 
which requires use of specific nutrition media in order to maintain the viability 
of the cultured cells which are still difficult to produce as commercial kits. 
Therefore, EM is preferred to diagnose viruses which cannot be cultivated, and 
has been commonly used in the surveillance systems of detection and 
identification of any strange emerging pathogens especially viruses (Collier 
and Oxford, 2000). Electron microscopy is efficient in the detection of both 
viable and unviable isolates of viruses even those which were stored for 
decades e.g. variola (Goldsmith and Miller, 2009).  
On the other hand, diagnosis of viral infections by EM is accompanied with 
some difficulties which are:  
1- Due to its high equipment cost, it is not available in all diagnostic 
laboratories, and even where it is available, it is not widely used for routine 
screening of a great number of specimens (Hazelton and Gelderblom, 
2003). 
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2- Lack of sensitivity. EM can only detect virus particles present at a minimal 
concentration of 106 ml-1, therefore, it is hard to diagnose any clinical 
sample which may contain less than this concentration. In this case, it is 
recommended to add virus-specific antibodies to the samples in order to 
cluster viral particles and facilitate their detection. This process is termed 
immunoelectron microscopy (IME), but this adds an extra cost to the 
technique (Collier and Oxford, 2000, Murray et al., 2009). 
3- Fluid specimens may require concentration via centrifugation especially 
those in small amounts (e.g. cerebrospinal fluid samples), which necessitate 
use of an ultracentrifuge (e.g. at 100,000 xg) in order to concentrate viral 
particles which have low density mass (Goldsmith and Miller, 2009). 
4- An experienced microscopist is required in order to provide a reliable 
diagnosis (Collier and Oxford, 2000). 
5- It is not recommended for specimens which require inoculation in viral 
transport media e.g. swabs, in order to maintain the viability of suspected 
viruses especially influenza and respiratory syncytial viruses, since this 
results in dilution of virus-titre (Jensen and Johnson, 1994, Hazelton and 
Gelderblom, 2003). 
6- It can only identify viruses at the family level. For that reason, other 
methods are required for further identification of specific isolates beyond 
this taxonomic stage (Goldsmith and Miller, 2009).  
7- It requires a high standard of cautiousness to deal with risky infectious 
samples.    
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1.1.3 Antigen detection technique: 
Viruses produce abundant amounts of proteins and enzymes during their 
replication. These viral particles accumulate inside the infected host cell and 
behave as antigens to stimulate the immune system to generate specific protein 
factors called antibodies against them in order to neutralize their pathogenic 
effect, which leads to the formation of large insoluble complexes of antigen-
antibody. Viruses can be identified through the detection of viral proteins 
(antigens) which can be secreted or leak out from the injured host cells into 
body fluids, or are expressed on cell membrane surfaces or within the cell 
(Grandien, 1996, Murray et al., 2009).    
Liu in 1956 was the first one who tried to diagnose influenza infections by 
using an immunofluorescence technique (IF) as a specific tool for direct 
identification of viral antigens in clinical samples. The principle of this 
method is based on utilizing laboratory prepared antiviral antibody which is 
attached covalently to a fluorescent molecule (e.g. fluorescein-isothiocyanate-
labelled rabbit antiviral antibody) in order to facilitate the detection of the viral 
antigen-antibody complex by using ultraviolet (UV) light.  Enzyme 
immunoassay (EIA) is another means for the indirect detection of viral 
antigens, but the antibody is conjugated to a particular enzyme e.g. horseradish 
peroxidase or alkaline phosphatase, which can catalyse the conversion of a 
chromophore compound in order to mark the presence of antigen (Grandien, 
1996, Storch, 2000, Murray et al., 2009).   
Antigen detection techniques may be improved for both identification and 
estimation purposes of the viral antigen by using antibodies labelled with 
radioactive reagents such as iodine-125. During this radioimmunoassay (RIA), 
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the probable viral antigens which are suspected in the patient's specimen, are 
captured by the radiolabelled antibodies. Then, the complexes of antigen-
antibody are precipitated to measure their radioactivity. Advantages of antigen 
detection techniques include:  
1- Rapidity. Staining and visualisation can be completed within 2 hours of 
receipt of specimen. 
2- It is highly flexible-in principle it can be used to diagnose any virus for 
which a poly- or mono-clonal antibody is available. Amongst other 
applications, detection of viral antigens is a useful method for the diagnosis 
of virus infections of the respiratory tract, the gastrointestinal tract, and 
vesicular skin lesions. 
3- It does not require the presence of viable isolates as the recognition 
process is immunological. 
Disadvantages include:   
1- Some viruses (e.g. enteroviruses and rhinoviruses) cannot be identified by 
this technique due to their extensive antigenic heterogeneity as well as the 
absence of cross reacting antigens. 
2- Body fluids such as cerebrospinal fluid (CSF) contain low concentrations 
of causative viruses which may result in missing the detection of the above 
viruses and lead to false negative results (Chonmaitree et al., 1989, Storch, 
2000). 
3- It requires preparation of large number of animal antisera which should be 
kept on hand (Chonmaitree et al., 1989, Grandien, 1996). 
4- The required dilutions of the reagents which are used in this method in 
DGGLWLRQWRWKHLQWHUIHUHQFHRIWKHFOLQLFDOVDPSOHV¶SHUR[LGDVHVGLPLQLVKLWV
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sensitivity to about 44% (Leland and Ginocchio, 2007, Chonmaitree et al., 
1989, Linde et al., 1997, Charlton et al., 2009). 
5- It requires technical expertise. Weak fluorescent signals may arise from 
use of strong UV light or from improper mounting (Grandien, 1996), giving 
rise to difficult-to-interpret or even false negative results. 
6- Performance of commercial kits may vary considerably between 
manufacturers, meaning that results from different laboratories may not be 
comparable.  
 
1.1.4 Detection of viral genetic material:     
Detection and analysis of the viral genome in clinical samples is mainly based 
on the molecular biological methods which have been widely used over the 
past two decades as powerful emerging tools in clinical diagnostic laboratories 
for routine diagnoses of viral infections. These methods improved the poor 
sensitivity and specificity, and time-inefficiency of the traditional means by 
using nucleic acid amplification techniques which opened a novel strategy to 
overcome the problem of very low quantity of viral genetic materials and 
produce more detectable concentration directly from any clinical samples 
especially those unculturable or slow-growing viruses (Tang et al., 1997, 
Kittler et al., 2002, Morshed et al., 2007).  Polymerase chain reaction (PCR) is 
one of the most common utilized techniques, which was invented during the 
early 1980s by Kary Mullis to produce millions of copies of the target 
sequence of genome in vitro within a few hours (Mullis, 1990, Murray et al., 
2009). This enzymatic technique involves use of complementary synthetic 
oligonucleotides which bind covalently to a specific region of nucleic acid 
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sequence (usually DNA), and act as primers for a thermostable polymerase 
enzyme to synthesize new copies of target DNA through approximately 30-50 
repeated thermal cycles. Each cycle starts with nucleic acid denaturation at 
around 94oC, followed by annealing of the primers to their complementary 
target at around 50 oC and ends with primer elongation at around 70oC which 
leads to doubling the quantity of the nucleic acids (Lu et al., 2002).  
This process is mainly used to amplify DNA viruses, but reverse transcriptase 
(RT)-PCR was devised to amplify the genomic materials of RNA viruses 
which firstly should be converted to the complementary sequence of DNA 
(cDNA) by employing a reverse transcriptase enzyme. Other types of PCR 
were developed to enhance the sensitivity of the conventional one. Nested PCR 
was designed to detect the diminutive quantities of the target nucleic acids by 
using two different sets of primers through dual amplification steps (Poggio et 
al., 2000). Multiplex PCR was developed and applied for the amplification of 
more than one target sequence in specimens throughout a single PCR run. 
Contamination is the major problem of PCR assay technique especially the 
nested-amplification mode, which arises during the transferring period of the 
amplification products from the first round to the second one. However, this 
hitch was solved either by utilizing a layer of wax or oil in order to separate the 
two mixtures of amplification or by using sets of designed primers appropriate 
for annealing in different temperatures. In general, it is recommended to locate 
PCR machines in specific cabinets which should be provided with independent 
sets of micropipettes equipped with filtered tips, sterile tubes and batch of 
reagents inside isolated laboratories away from the analyzing area of amplified 
products (Tang et al., 1997, Casas et al., 1999, Lu et al., 2002).      
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The applicable combination between the chemistry of PCR and fluorescent 
detection of the amplified products in one vessel, led to a new generation of 
PCR-based assay known as Real-time PCR which revolutionized the clinical 
microbiology fields (Nissen and Sloots, 2002). It is faster than the conventional 
PCR due to its simultaneous amplification and detection of the target nucleic 
acids. Furthermore, it is more sensitive and specific than all other conventional 
methods, and valuable in the analysis of large numbers of clinical specimens as 
it can be performed in a 96 microwell format. Real-time (PCR) has been 
adopted in many clinical diagnostic laboratories since its application became 
easier (semi-automatically) now due to the availability of its reagents (primers 
and enzymes) as commercial kits, and robotic machines to perform the various 
stages of the assay. Furthermore, GHFUHDVLQJRI WKHDPSOLFRQV¶FRQWDPLQDWLRQ
risk in addition to accurate detection of the copy number of the target nucleic 
acid were the enormous benefits of real-time PCR since both amplification and 
detection steps of the target nucleic acids can be achieved in one closed vessel 
(Niesters, 2002, Espy et al., 2006).  
In spite of the significant role of PCR techniques in the detection of viral 
nucleic acids in clinical samples, it has some difficulties:  
1- The required expertise which is limited to special referral laboratories. 
2- Samples should be collected and analyzed at definite periods of infection. 
Any delay in these two processes might affect the sensitivity of PCR due to 
the reduction of the viral concentration which can be lost and lead to false 
negative results. False negative results are also attributed to the existence of 
polymerase inhibitors such as hairpin or endonucleases in the clinical 
samples (Koskiniemi et al., 2002, Debiasi and Tyler, 2004). 
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3- The high cost of the instrument as well as its reagents and probe detection 
requirements. Moreover, it necessitates suitable physical space. 
4- The reliability of the results mainly depends on the efficient extraction 
processes of the nucleic acids from variant clinical specimens (Niesters, 
2002). 
5- It requires highly conserved sequence of the target nucleic acids for 
efficient reaction with the primers (Yolken et al., 1989). 
6- Serotyping or subclassification of some viruses (e.g. enteroviruses) is quiet 
difficult (Muir et al., 1998).  
However, the overall advantages of using PCR in the diagnosis of human viral 
infections through the amplification of viral nucleic acids presented in clinical 
samples outweighs its disadvantages. 
 
1.1.5 Indirect detection methods: 
Serological techniques which detect the host humoral immune response can be 
used for the diagnosis of some viral infections. It is recommended when other 
means of viral detection such as virus isolation or antigen detection are 
unavailable or their results are negative (Dwyer et al., 2006). It is helpful for 
the identification of acute (or recent) infection, through the detection of 
specific viral immunoglobulin (Ig)-M antibodies in serum samples. The 
detection of this type of antibody which reaches its peak concentration during 
the first 2-3 weeks of viral infections indicates the acute recent primary 
infection. On the other hand, recognition of antiviral specific ±IgG indicates a 
past infection (Murray et al., 2009). However, serological techniques also have 
a number of potential drawbacks due to: 
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1- Possible false negative and false positive results. 
2- Some viruses (e.g. mumps and parainfluenza) possess related antigens and 
lead to serological cross reaction, confusing identification of the accurate 
pathogen. While others viruses such as rhinoviruses have too specific 
antibodies which are unable to recognize other members of the same 
family. 
3- Antigenic composition of different viruses cannot be identified by this 
procedure. 
4- Most patients hold some pre-existing antibodies for some particular viral 
infections (e.g. influenza) therefore; it is difficult to recognize the recent 
infection (Dwyer et al., 2006, Murray et al., 2009). 
 
This thesis will be concerned with the development of molecular assays for the 
diagnosis of central nervous system (CNS) and respiratory tract viral 
infections. These particular infections are therefore reviewed in the following 
sections.  
 
1.2 Central nervous system viral infections: 
Although, the central nervous system is protected by the skull, bony cage, thick 
dura mater and blood brain barrier (BBB) represented by cerebral capillaries, it 
is vulnerable for infection by more than 100 different viruses. These viruses  
might invade and infect the spinal cord, the brain stem, the cerebellum or the 
cerebrum causing myelitis, rhomboencephalitis, cerebellitis and encephalitis 
respectively as well as aseptic meningitis (Lu et al., 2002, Debiasi and Tyler, 
2004, Irani, 2008). Some of these viral infections (e.g. viral meningitis) are 
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widespread in clinical practice and responsible for considerable rates of 
morbidity and mortality throughout the world especially in the United States, 
Europe, Japan and Southeast Asia (Tyler, 2009, Big et al., 2009). More than 
12,700 cases of aseptic meningitis were reported every year to the Centres for 
Disease Control during the period from 1973 to 1983. This infection is 
responsible for approximately 5-15 cases per 100,000 cases of annual hospital 
admission in the United Kingdom (Chonmaitree et al., 1989, Chadwick, 2005). 
On the other hand, focal infections which are accompanied by viral myelitis 
can be confused with those of non-infectious origin. 
 
1.2.1 Pathogenesis of the CNS viral infections  
Viruses usually reach the CNS by either haematogenous or neuronal route. 
Through the haematogenous route; viruses are transmitted by the blood from 
their portal of entry and initial multiplication sites in the mucosal surfaces of 
the respiratory tract, gut and lymph nodes throughout the body towards the 
secondary multiplication sites (extraneural sites) in the spleen, liver muscles 
and vascular tissues, and then cross the BBB towards the CNS via the infected 
leukocytes, cerebral capillary endothelial cells or choroid plexus (figure 1-1). 
The peripheral nerves and/or the olfactory nerve represent the possible conduits 
for certain viruses to reach and infect the CNS through the neuronal route 
(Kaslow and Evans, 1997, Pokorn, 2003, Cassady and Whitley, 2004, 
Sundaram et al., 2011, Heise and Virgin, 2013). 
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Figure 1-1: Routes of viral entry to the central nervous system. 
Adopted from (Cassady and Whitley, 2004). 
 
 
 
1.2.2 The neurotropic viruses   
Many types of viruses including DNA and RNA viruses have been identified as 
neurotropic viruses due to their ability to colonize and infect the nerve cells, 
and causing CNS viral infections (table 1-1). Some of these neurotropic viruses 
have caused outbreaks of CNS viral infections during the past decades (e.g. 
West Nile virus encephalitis in the 90s) and since that time the researches were 
directed toward diagnosis of CNS viral infections. 
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Table 1-1: Shows the important DNA and RNA viruses causing CNS infections, and their invasion routes.  
 Family Genus Species Route to CNS CNS infection 
D
N
A
 
v
ir
u
se
s 
Adenoviridae Mastadenovirus Human mastadenovirus A-G Haematogenous - Meningitis 
- Encephalitis 
Herpesviridae 
Simplexvirus 
Human herpesvirus 1 
Neuronal 
- Encephalitis 
- Meningitis 
- Meningoencephalitis Human herpesvirus 2 
Varicellovirus Human herpesvirus 3 - Haematogenous 
- Neuronal 
- Cerebellitis 
- Encephalitis 
- Meningitis 
- Myelitis 
Lymphocryptovirus Human herpesvirus 4 Haematogenous 
- Encephalitis 
- Meningitis 
- Myelitis 
Cytomegalovirus Human herpesvirus 5 Haematogenous 
- Encephalitis Roseolovirus Human herpesvirus 6 ? 
Poxviridae Orthopoxvirus Vaccinia virus Haematogenous - Encephalomyelitis 
R
N
A
 
v
ir
u
se
s 
Arenaviridae Arenavirus Lymphocytic choriomeningitis virus 
Haematogenous - Meningitis 
- Encephalitis 
Bunyaviridae Orthobunyavirus California encephalitis virus 
Reoviridae Coltivirus Colorado tick fever virus 
Togaviridae Alphavirus Eastern equine encephalitis virus 
Retroviridae Lentivirus Human immunodeficiency virus 1 Haematogenous - Encephalopathy 
- Encephalitis 
Rhabdoviridae Lyssavirus Rabies virus Neuronal - Encephalitis 
- Encephalomyelitis 
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 Family Genus Species Route to CNS CNS infection 
R
N
A
 
v
ir
u
se
s 
Picornaviridae Enterovirus 
Nonpolio enteroviruses: 
- Coxsackieviruses 
- Echoviruses 
Haematogenous - Meningitis 
- Myelitis 
Polioviruses - Haematogenous 
- Neuronal 
- Meningitis 
- Meningoencephalitis 
- Myelitis 
Flaviviridae Flavivirus 
West Nile virus 
Haematogenous - Meningitis 
- Encephalitis Japanese encephalitis virus St. Louis encephalitis virus 
Murray Valley encephalitis virus Haematogenous Encephalitis Tick-born encephalitis virus 
Western equine encephalitis virus Haematogenous - Meningitis 
- Encephalitis Venezuelan equine encephalitis virus 
Paramyxoviridae 
Morbillivirus Measles virus Haematogenous 
- Encephalitis 
- Subacute sclerosing 
panencephalitis 
Rubulavirus Mumps virus Haematogenous 
- Meningitis 
- Encephalitis 
- Myelitis 
Orthomyxoviridae Influenza viruses Influenza A, B virus Haematogenous - Encephalitis 
Adapted from (Cassady and Whitley, 2004). 
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1.2.2.1 Human enteroviruses 
Human enteroviruses are the prominent etiological agents of many of the 
human diseases every year which associated with different clinical 
manifestations ranging from asymptomatic to mild or severe infections which 
may threaten patient life (Hyoty and Taylor, 2002, Diaz-Horta et al., 2011). 
Human enteroviruses belong to the Picornaviridae family, and include more 
than 100 different viral serotypes which are the major invaders of the CNS 
(Simmonds, 2006, Michos et al., 2007). Nonpolio human enteroviruses which 
include various serotypes of coxsackieviruses, echoviruses and enterovirus 
types 68 to 71 are classified into four species: Enterovirus A, B, C and D are 
the causative agents of more than 90% of viral meningitis and encephalitis 
which are the reason for approximately 10% of mortality rates in the neonates 
(Irani, 2008, Tebruegge and Curtis, 2009). Euscher and his colleagues 
((Euscher et al., 2001) reported that the neurodevelopmental delays in the 
newborn is a consequence of the enterovirus infections during pregnancy. 
Polioviruses comprise three additional serotypes of the human enteroviruses 
and are classified within the Enterovirus C, which can infect the spinal cord 
and causing paralytic poliomyelitis (Chonmaitree et al., 1989, Chadwick, 
2005, Rhoades et al., 2011). Commonly, children are at high risk of enteroviral 
CNS infections especially during the summer/autumn of their first year of age 
in tropical and subtropical countries. Generally, polio viral infections are now 
controlled worldwide, except in the Middle East region. These infections might 
lead to a severe unrepairable damage of the nervous tissues such as 
poliomyelitis (Redington and Tyler, 2002).  
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1.2.2.1.1 Structure of human enteroviruses 
Human enteroviruses are spherical particles consist of non-enveloped, 
icosahedral capsid of 27-30 nm in diameter containing the viral genome which 
consists of single strand RNA of approximately 7400 nucleotides having the 
same sense as mRNA which can be immediately translated into viral proteins 
by the host cell. Therefore, it is referred to such viruses as positive sense single 
stranded RNA viruses. The genomic RNA of the human enteroviruses consists 
of a single long open reading frame (ORF) encodes an individual viral 
polyprotein which comprises three units (P1 to P3) of approximately 2200 
amino acids, flanked by WKH ¶ DQG ¶ XQWUDQVODWHG UHJLRQV 875V The 
translated viral polyprotein units are cleaved by viral proteases in order to 
generate four structural proteins (VP4, VP2, VP3 and VP1) from P1 unit, and 
seven nonstructural proteins (2A to 2C and 3A to 3D) from both P2 and P3 
units (figure 1-2). The four viral structural proteins are assembled together in 
order to form the enterovirus capsid, while the nonstructural viral proteins are 
involved in viral replication and RNA synthesis (Oberste et al., 2004, Agol, 
2006, Nakashima and Ishibashi, 2010, Boros et al., 2011, Diaz-Horta et al., 
2011, Rhoades et al., 2011, Racaniello, 2013). 
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Figure 1-2: Schematic diagram shows the size and organization of the human enterovirus genome.  
Adopted from ((Diaz-Horta et al., 2011, Racaniello, 2013).
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1.3 Respiratory tract viral infections 
Infectious diseases were controlled at least to a degree for much of the 
twentieth century in Western human populations, but since 1980s many viral 
infections have emerged as well as those previously identified which were 
thought to be under control (Kuiken et al., 2003). Respiratory tract infections 
are common and caused by multiple different types of pathogens, but viruses 
are responsible for more than 85% of these infections (Chiu et al., 2008). 
Seasonal outbreaks of viral respiratory tract infections are the major causes of 
LOOQHVV ORVVRILQGLYLGXDOV¶SURGXFWLYLW\DQGKRVSLWDOL]DWLRQZKLFKDGGIXUWKHU
burden on the budgets of the national health care (Bertino, 2002, Gillim-Ross 
and Subbarao, 2006). In general most infants and children suffer from a 
common cold-like illness 3-8 times each year which increases by 30% in 
developing countries (Bertino, 2002, Bharaj et al., 2009).These respiratory tract 
infections are also considered to be a major problem in immunocompromised 
and elderly people (Garbino et al., 2004).  
The respiratory system includes upper respiratory tract (URT) which consists 
of each of the nasal cavity, pharynx, larynx and trachea, and lower respiratory 
tract (LRT) which comprises of the bronchi, bronchioles and lungs. The organs 
of both URT and LRT except lungs are lined with a layer of ciliated epithelial 
cells covered with a layer of mucus secreted by specific glandular cells 
scattered among the epithelial cells, called goblet cells. This mucociliary 
structure represents a physical barrier responsible for the protection of the 
respiratory system against microbial pathogens through ciliary movement and 
continuous mucus flow which end up with expelling such pathogens. Alveolar 
macrophages play an important role in eliminating pathogens that can evade 
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the mucociliary structure, and reach the lungs (Rubins, 2003, Manjarrez-Zavala 
et al., 2013).  
 
1.3.1 Pathogenesis of the respiratory viral infections  
Most viruses enter the URT carried by aerosols and droplets produced by 
sneezing and/or coughing of other patients. Some viruses especially those of a 
large size which are trapped in the turbinates and sinuses may colonize these 
sites and then spread to other adjacent organs causing upper respiratory tract 
infections. Other viruses of a smaller size which are able to avoid the 
mucociliary action of the URT can spread downwards via the bronchi and 
bronchioles, reach the alveoli inside the lungs and cause lower respiratory tract 
infections (Andersen, 1998, Flint et al., 2009).   
 
1.3.2 Respiratory viruses    
Several types of viruses have been isolated from the respiratory tract of patients 
at different ages, which are belonging to different families (table 1-2). Many of 
these viruses have been identified as etiological agents of both URT and LRT 
infections (figure 1-3), while few other viruses enter the respiratory tract in 
order to move to other organs (Mackie, 2003, Peiris and Madeley, 2009, 
Manjarrez-Zavala et al., 2013).  
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Table 1-2: Viruses causing respiratory tract infections 
 Family Genus Species 
D
N
A
 v
iru
se
s Adenoviridae Mastadenovirus Human mastadenovirus A-G 
Herpesviridae 
Simplexvirus Human herpesvirus 1 Human herpesvirus 2 
Varicellovirus Human herpesvirus 3 
Lymphocryptovirus Human herpesvirus 4 
Cytomegalovirus Human herpesvirus 5 
R
N
A
 
v
iru
se
s 
Orthomyxoviridae 
Influenzavirus A Influenza A virus 
Influenzavirus B Influenza B virus 
Influenzavirus C Influenza C virus 
Paramyxoviridae 
Respirovirus Human parainfluenza virus 1 Human parainfluenza virus 3 
Rubulavirus 
Human parainfluenza virus 2 
Human parainfluenza virus 4 
Mumps virus 
Metapneumovirus Human metapneumovirus 
Pneumoviruses Human respiratory syncytial virus 
Morbillivirus Measles virus 
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 Family Genus Species 
R
N
A
 
v
iru
se
s 
Picornaviridae Enteroviruses Rhinovirus A, B , C 
Coronaviridae 
Alphacoronavirus Human coronavirus NL63 Human coronavirus 229 E 
Betacoronavirus 
Human coronavirus HKU1 
Sever acute respiratory syndrome -related 
coronavirus (SARS-CoV) 
Middle East respiratory syndrome 
coronavirus (MERS-CoV) 
Parvoviridae Bocaparvovirus Primate Bocaparvovirus 1 Primate Bocaparvovirus 2 
Bunyaviridae Hantavirus 
Hantaan virus 
Bayou virus 
Black Creek Canal virus 
New York virus 
Sin Nombre virus 
Adapted from (Mackie, 2003, Peiris and Madeley, 2009). 
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Figure 1-3: The common clinical syndromes of the URT and LRT caused by the 
different types of viruses.    
Adopted from (Manjarrez-Zavala et al., 2013). 
 
 
1.3.2.1 Influenza viruses 
Influenza viruses have been reported as significant dangerous causes of 
respiratory diseases, which may lead to high rates of morbidity and mortality 
especially in infants, elderly and immunocompromised people (Thompson et 
al., 2003). They have been classified into three genera within the family 
Orthomyxoviridae which include Influenzavirus A, B and C. Each genus 
contains only single species represented by Influenza A virus, Influenza B virus 
and Influenza C virus, respectively. The high continuous mutation rates of the 
influenza virus genes coding the two surface glycoproteins (hemagglutinin HA 
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and neuraminidase NA), change some amino acids in the antibody binding sites 
of these viral proteins and lead to new antigens each year which are able to 
evade the acquired immunity from the same previous infection (antigenic drift) 
(Fouchier et al., 2005). Therefore, the viruses of the influenza A type are 
further classified into subtypes based on the antigenicity of the HA and NA. 
Accordingly, Influenza A virus contains 17 HA subtypes and 9 NA subtypes 
which all of them have been found in wild bird (the natural hosts) (Wright et 
al., 2013). The subtypes H1, H2, H3 and N1 and N2 represent the most virulent 
human pathogens which were transmitted from wild aquatic birds, pigs and 
ferrets as a result of mutational alteration in the HA and/or NA genes of the 
influenza virus subtypes which is called genetic shift and usually associated 
with the pandemics (Garman and Laver, 2004, Mahony, 2008). In contrast, 
avian pathogenesis can cause fatal infections in human, affect many organs and 
can even cross the placental barrier which may affect the growing foetus 
(Korteweg and Gu, 2008).    
H1N1, H2N2 and H3N2 are the common human virulent subtypes of 
influenzavirus A which caused major memorable pandemics of Spanish Flu in 
1918, Asian Flu in 1957 and Hong Kong Flu in 1968, respectively. The most 
recent influenza pandemic was the Swine Flu in 2009 which was caused by a 
new strain of H1N1.These influenza pandemics resulted in more than 50 
million, 2 million, 1 million and 18 thousand deaths worldwide, respectively 
according to the World health Organization. Influenza B and C viruses are 
predominantly circulating among humans causing less severe infections than 
influenza A viruses (Johnson and Mueller, 2002, Barry, 2004, Morens and 
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Fauci, 2007, Osterhaus, 2008, Taubenberger and Morens, 2008, 
http://www.ictvonline.org/index.asp, 2009, Sato et al., 2010).  
 
1.3.2.1.1 Structure of the influenza viruses 
Influenza viruses are mostly spherical particles of approximately 80-120 nm in 
diameter consist of viral genome inside a helically symmetric nucleocapsid, 
surrounded by a lipid envelope. Viral envelope is derived from the host cell 
membrane and consists of an inner layer of protein known as matrix protein 
(M1) which is spanned by a number of ion channels composed of M2 protein, 
and an outer layer of lipid. The HA and NA glycoproteins which consist of 500 
rod-shaped spikes and 100 mushroom-shaped spikes, respectively project from 
this viral envelope (White and Fenner, 1994, Garman and Laver, 2005, Parija, 
2009) (Figure 1-4).  
The influenza virus genome is a single-stranded RNA which has a 
complementary sequence of the mRNA. Accordingly, it cannot be translated 
directly into viral protein; therefore it must be transcribed firstly into mRNA in 
order to start encoding influenza viral proteins. Thus, it is referred to such 
viruses as negative sense single stranded RNA viruses. The viral genome of 
influenza A and B viruses consists of eight separate segments while the 
genome of the influenza C viruses consists of seven segments; each segment 
encodes one of the influenza virus proteins (Fujii et al., 2003, Huang et al., 
2009). The size of the segments is variable and ranges from 890 to 
approximately 2500 nucleotides (Steinhauer and Skehel, 2002). RNA 
polymerase complex which includes polymerase basic 2 (PB2) and 1 (PB1), 
and polymerase acid (PA), hemagglutinin (HA), nucleocapsid protein (NP), 
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neuraminidase (NA), matrix protein (M1) and (M2), and non-structural 
proteins (nuclear export protein NEP and NS2) represent the influenza viral 
proteins which are encoded by the genomic segments (1-8), respectively of 
both of influenza viruses A and B. The fourth genomic segment of the 
influenza virus C encodes for the hemagglutinin esterase fusion (HEF) protein 
which performs the functions of both HA and NA proteins (Porter et al., 1980, 
Webster et al., 1992, Steinhauer and Skehel, 2002, Palese and Shaw, 2013) 
(figure 1-4). 
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Figure 1-4: Schematic diagram of influenza virus particle showing the 
arrangement of the viral genome segments, and their functions. 
Adapted from (Palese and Shaw, 2013). 
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1.3.2.2 Respiratory syncytial virus  
Respiratory syncytial virus (RSV) belongs to the genus Pneumovirus which 
represents one of the genera of the Paramyxoviridae family, and contains 
Human respiratory syncytial virus (HRSV); the major causative agent of 
pediatric lower respiratory tract illness (LRI) in babies. Young children 
especially those under 2 years old, elderly and immunosuppressed persons are 
more affected by HRSV. This virus infects epithelial cells of the LRT causing 
bronchiolitis and pneumonia which may be accompanied by serious 
complications such as breathing difficulties or apnoea especially in infants 
leading to high rates of hospitalization (Glezen et al., 1986, Tsai et al., 2001, 
Nokes et al., 2004, Hall et al., 2009). HRSV has the ability to infect many cells 
without leaving, which leads to form syncytia (multinucleated cells) and 
protects the virus against the antibody attack, therefore the vast majority of the 
first natural HRSV infections do not provide lifelong immunological protection 
(Manjarrez-Zavala et al., 2013). Accordingly, more than 90% of children are 
commonly reinfected by the same or different strain of HRSV during their 
second birthday, but without complications (Ohuma et al., 2012, Papenburg et 
al., 2012). The detailed structure of RSV genome is discussed in section 
1.3.2.3.1.  
 
1.3.2.3 Metapneumovirus  
Metapneumovirus (MPV) represents other genus of the Paramyxoviridae 
family, which contains the species Human metapneumovirus (HMPV). The 
virus circulates among human populations mostly in children less than five 
years old. It was only identified as a causative agent of respiratory tract 
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infections in 2001 (van den Hoogen et al., 2001). This virus was reported in the 
Asia, Europe, Australia and North America causing recurrent respiratory 
diseases in both children and adults causing LRI similar to those caused by 
HRSV which also require hospitalization (Kuiken et al., 2003, Banerjee et al., 
2007). Several studies reported that the HMPV are considered as the second 
cause of bronchiolitis and pneumonia during the early childhood after the 
HRSV infections (Kahn, 2006, Heikkinen et al., 2008). The detailed structure 
of MPV genome is discussed in section 1.3.2.3.1.  
 
1.3.2.3.1 Structure of the HRSV and HMPV  
Both HRSV and HMPV are spherical enveloped particles of approximately 
100-350 nm in diameter, but the long filamentous form of 10 µm in length and 
60-200 nm in diameter is the predominant shape of these paramyxoviruses 
(Collins and Karron, 2013). Their genome consists of a single-stranded, 
nonsegmented negative sense RNA of approximately 15.2 and 13 kb, 
respectively, with similar but non identical genomic organization (Biacchesi et 
al., 2003). The genome of the HRSV consists of 10 genes encoding 11 viral 
proteins which are: non-structural 1 (NS1), NS2, nucleocapsid (N), 
phosphoprotein (P), Matrix (M), small hydrophobic (SH), attachment (G), 
fusion (F), transcription elongation factors (M2-1), RNA regulatory factor 
(M2-2) and large polymerase subunit (L). In contrast, the genome of the 
HMPV lacks the first two genes (NS1 and NS2), therefore it consists of 8 
genes encode 9 viral proteins (figure 1- 5) (Mackie, 2003, Guerrero-Plata, 
2013).  
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Figure 1-5: Schematic diagram of the genomic maps of the HRSV (figure A) and HMPV (figure B), and the viral particle (figure C) consisting of 
viral proteins generated from their genome translation. 
Adapted from (Collins and Karron, 2013, Guerrero-Plata, 2013). 
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1.3.2.4 Rhinoviruses 
Rhinoviruses represent other species of human pathogenic viruses which also 
belong to the genus enterovirus. This viral group include more than 100 
serotypes which have been recently classified into three species, Rhinovirus A, 
B and C based on their genome sequence analysis, differential susceptibility to 
particular antiviral compounds in a given serum and receptor specificity 
(Oberste et al., 1999, Ledford et al., 2004, Lamson et al., 2006). These viruses 
are commonly associated with acute respiratory illness (ARI) especially in 
infants as well as elderly and immunosuppressed people, which include 
common cold, bronchiolitis and pneumonia. Several studies reported that more 
than half of the common cold cases caused by rhinoviruses may be exacerbated 
to wheezing and asthma especially in children of school age (Johnston et al., 
1995, Chung et al., 2007). The capsid structures and the genome organization 
of the rhinoviruses are similar to those of enteroviruses, but they differ in their 
genome size which is approximately 7.2 kb. Therefore, it is thought that both 
enteroviruses and rhinoviruses diverged from the last ancestor (Gern and 
Palmenberg, 2013).  
 
1.4 Microarray-based technology  
Microarray technique has emerged as a new functional tool in genomic 
research and clinical laboratories (Peytavi et al., 2005). Figure 1-6 clarifies the 
principle of this nanoscale technique. It includes use of synthesized fragments 
of recombinant nucleic acids or oligonucleotides (probes) affixed on a specific 
chip which is either a nylon membrane or the surface of a glass slide. These 
probes are able to hybridize with complementary nucleic acid sequences. 
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Fluorescent labelling dyes (e.g. platinum compounds) can facilitate the 
detection of this type of hybridization (Shieh and Li, 2004). Based on its high 
capacity to accommodate hundreds to thousands of individual viral gene probes 
and allow simultaneous detection of any amplifiable pathogen present in a 
specimen, microarray technology is able to overcome the limitations of the 
conventional methods which are applied for the diagnoses of viral infections 
which are virus or pathogen specific.  
 
Figure 1-6: Shows the schematic drawing of multivirus chip. 
  Adopted from (Shieh and Li, 2004). 
 
Chapter one                                                                                               General Introduction 
 
36 
  
This technique has certain advantages over the conventional methods used for 
detection and identification of the microbial pathogens, which they are: 
1- The complication rates of false positive results due to contamination are 
highly limited.  
2- The microarray chip can be designed with high flexibility to detect all of 
the viral pathogens. It can be also rapidly modified to match the emergence 
of new viruses. 
3- Viral gene expression as well as genotyping of viral isolates can be 
achieved by this process (Shieh and Li, 2004). 
4- Many viruses can be identified by microarray at the same time. Therefore, 
it is highly recommended for the diagnosis of specimens which are 
suspected to contain multiple pathogenic viruses (Elnifro et al., 2000). 
This technique has been employed together with PCR amplification for the 
simultaneous identification of several pathogens in only one process (Miller 
and Tang, 2009). A microarray viral system was firstly described by (Wang et 
al., 2002) aiming to identify the pathogens of severe viral respiratory 
infections. This chip contained about 1600 probes covering 140 viral genomes 
including the serotypes of RSV, parainfluenza, adenoviruses and human 
rhinoviruses. This was later developed into a pan-viral microarray by using 
approximately 10,000 highly conserved sequences of 70-mer oligonucleotides 
representing the full reference sequence of 1000 viral genomes from GeneBank 
in order to improve the identification possibility of both known and unknown 
members through cross-hybridization to this array of specific probes. A 
modified random PCR protocol was used to amplify viral genomes in clinical 
specimens. This procedure starts with the synthesis of first- and second strand 
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by using specific primer-$ ¶- GTTTCCCAGTCACGATCNNNNNNNNN), 
this will be completed with 40 cycles of PCR amplification process with 
another specific primer-% ¶-GTTTCCCAGTCACGATC). Generally, this 
protocol includes three rounds of PCR (A, B and C). In round A, cDNA is 
synthesized using primer A. In round B, the generated templates (first and 
second strand cDNA) are then amplified using primer B. The amplification is 
completed in round C through incorporation of an additional group, which is 
either an amino allyl deoxyuridine triphosphate (dUTP) or a cyanine-dye-
coupled nucleotide, using additional PCR cycles. More additional details are 
found at http://dx.doi.org/10.1371/journal.pbio.0000002.sd002 (Wang et al., 
2003). The virochip was applied globally to discover the virus associated with 
SARS (Ksiazek et al., 2003).  
DNA microarray technology was devised by Boriskin and his group in 2004 
for the detection of viral neuropathogens (e.g. VZV, HSV and enteroviruses) in 
persons with encephalitis and meningitis especially those very young and 
immunocompromised patients. Multiplex PCR was used to amplify viral 
genetic materials in clinical samples especially those with low quantities such 
as CSF. This array was able to identify up to 13 different viruses in one panel.  
The Affymetrix GeneChip system was designed by (Malanoski et al., 2006) for 
the instantaneous identification of respiratory pathogens through resequencing 
the short oligonucleotides of the original platform which aided in the 
identification of new subtypes of influenza virus H5N1 and H1N1 in 2007 and 
2009, respectively. GreenChipResp platform was designed later by (Quan et 
al., 2007) and utilized for the detection of subtypes of influenza-A viruses and 
other respiratory viruses, and was then developed for the identification of the 
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coronaviruses (Miller and Tang, 2009). MChips was created by (Dawson et al., 
2006) and employed for the identification of the influenza-A in recent and 
historical specimens through the detection of the polymorphisms in their M 
gene. This MChip was also used for the identification of influenza-B in similar 
samples and those subtypes of both influenza A and B (H1N1, H3N2 and 
H5N1) which infect humans (Mikhailovich et al., 2008). 
Simultaneous identification of seven human herpes viruses (HSV-1, HSV-2, 
VZV, EBV, CMV, HHV-6A and HHV-6B) in a single reaction was achieved 
by (Zheng et al., 2008) based on the conserved regions of DNA polymerase 
gene of the previous viruses which are used to develop a cheap DNA 
microarray chip. 
Microarray technology was used as a novel approach to identify and quantify 
hepatitis B and C; and Human immunodeficiency virus type 1 (HIV-1) in the 
plasma specimens of donors (Khodakov et al., 2008). 
Amplification process is necessary in microarray technology in order to 
amplify the minute amounts of viral genomes in clinical samples. PCR is the 
common method used for exponential amplification of nucleic acids, but this 
method can only generate fragments with maximum length 500 base pairs. 
Degenerate oligonucleotide primed-PCR (DOP-PCR) represents the recent 
technique used to amplify the entire genomes of different organisms from any 
source through using partially degenerate primers (primers containing few of 
the degenerate nucleotides shown in table 2-9) which can facilitate binding 
these primers to their complementary nucleic acid sequences in a PCR protocol 
with two different annealing temperatures (Fortina et al., 2001).  
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The successful isolation of the isothermal Phi 29 DNA polymerase from 
Bacillus subtilis bacteriophage Phi 29 which has the ability to replicate the 
target nucleic acid isothermally, opened the door for continuous nucleic acids 
amplification along the entire microbial genome using random hexamer 
primers in a productive isothermal process called whole genome amplification 
(WGA).  
In this process, some molecules of the Phi 29 DNA polymerase start elongation 
of random hexamers annealed to the complementary sequences of the target 
denatured DNA without disassociation from the original template. At the same 
time, other molecules of the Phi-29 DNA polymerase partially displace the 
beginning of the new extending complementary strands, which provides new 
templates ready for more isothermal multiple displacement amplification 
(MDA) reactions. Continuous priming and strand displacement led to 
exponential amplification and generated high molecular weight of 
hyperbranched amplicons containing various lengths of linear dsDNA, ssDNA 
and some forks of nucleic acids. Therefore, MDA is being used as an 
appropriate method for WGA of nucleic acids in the absence of prior 
knowledge of organisms that may be present at a rate of more than (104) 
copies/ml (figure 1-7) (Lage et al., 2003, Monstein et al., 2005, Lovmar and 
Syvanen, 2006, Binga et al., 2008, Maragh et al., 2008, Wang et al., 2011, 
Zheng et al., 2011).  
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Figure 1-7: Schematic diagram shows the working principle of Phi 29 DNA 
polymerase during MDA process.  
In figure A, the random hexamers primers represented by the short green lines anneal 
to the single strand DNA represented by the long blue line. In figure B, the Phi 29 
DNA polymerase molecules represented by the black circles start extending the 
annealed random hexamers primers till reaching the newly synthesized 
complementary strands of DNA represented by the orange lines. In figure C, the Phi 
29 DNA polymerase molecules displace the newly synthesized strands and continue 
the polymerization, at the same time more primers of random hexamers annealed to 
the newly synthesized complementary strand of DNA. In figure D, polymerization 
starts on the new strands, forming a hyperbranched structure. The black arrows show 
the direction of the new strands synthesis.  
Adopted from (Spits et al., 2006). 
 
 
 
In general, it has emerged as an ideal method for the extensive parallel 
identification and differentiation of various pathogens and their strains in 
clinical samples (Maughan et al., 2001). 
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1.5 Aim of the study 
The study aims to provide a unique methodology-detection system through 
generating a probe array for simultaneous detection of a wide variety of virus 
species (specifically those causing CNS and respiratory tract infections). 
1.5.1 Objectives 
The main objects of this study were: 
- Design single platform chip containing multiple specific independent 
hybridization probes of 28-30 bases covering the viral strains of each of 
human enteroviruses, human rhinoviruses, human metapneumoviruses, 
human respiratory syncytial viruses and influenza viruses (described in 
chapter 2). This specific length is preferred in order to avoid long time 
hybridization for the longer probes and omit nonspecific hybridization for 
the shorter probes.   
- Optimize the steps used for validating the chip against some viral positive 
control and clinical samples, which includes amplifying the entire genome 
of the selected viruses, labelling and fragmenting the amplified viral nucleic 
acid, and hybridizing the labelled materials with the designed viral probes 
(described in chapter 3 and 4).  
- Determine the properties of individual probes, and then select the optimal 
probes for constructing an optimal cheap virochip applicable to use in 
clinical laboratories for robust detection and identification of many RNA 
viruses up to subgroup level, directly from the clinical samples (described 
in chapter 4).       
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2 Designing multiple hybridization 
probes for the selected RNA viruses 
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2.1 Introduction  
Designing probes is the cornerstone for constructing a nucleic acid microarray. 
These probes should be complementary to specific sequences of the target 
nucleic acid required to be detected or identified in order to facilitate their 
annealing together and forming the probe-target combination which is 
normally called a hybrid. Labelling of either the probes or the nucleic acid of 
interest with an appropriate detectable molecule can facilitate detection of the 
generated hybrid when it is formed (Call, 2001a, Li et al., 2002, de Muro, 
2005, Jayapal and Melendez, 2006, Trevino et al., 2007). The availability of 
the nucleic acid sequences for the vast majority of organisms including viruses, 
in addition to the existence of many of free probe design programmes, makes it 
very easy to design the required probes for any specific gene or nucleic acid 
sequence of any organism in order to be used in a microarray technology. The 
designed probes can be synthesized and then printed on any supporting solid 
surface such as glass or nylon membrane using a microarray spotter (Hegde et 
al., 2000, Ehrenreich, 2006). Nowadays, nucleic acid microarrays can be 
synthesized in situ on a chip by many commercial companies like Agilent 
Technologies based on a principle called custom-made arrays which makes 
cost much lower than printing it in the laboratory using an expensive 
microarrayer (Hughes et al., 2001, Nordberg, 2005, Ehrenreich, 2006).     
 
2.2 Aims 
Designing multiple specific probes of similar lengths targeting the entire 
sequence of each of the human enterovirus, human rhinoviruses, HMPV, 
HRSV and human influenza virus genomes using two of the free probe design 
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software programmes (OligoArray 2.1, 
http://berry.engin.umich.edu/oligoarray2_1/ and Agilent Technologies eArray, 
https://earray.chem.agilent.com/earray/,) was the first aim of this chapter. The 
second aim was to test in silico the specificity of the designed probes against 
the original sequences of the selected viral genomes using the Basic Local 
Alignment Search Tool (BLAST) software. Finally, the third aim was to select 
the most specific probes in order to be synthesised and spotted simultaneously 
on a chip by Agilent Technologies Company.  
 
2.3 Methods  
 
2.3.1 Downloading viral genome sequences 
The 2009 virus taxonomy list of the International Committee on Taxonomy of 
Viruses (ICTV), http://ictvonline.org/virusTaxonomy.asp?msl_id=25 was used 
as a reference for the selected RNA viruses causing human viral infections 
which were: enteroviruses, metapneumoviruses, respiratory syncytial viruses 
and influenza viruses.  
 
2.3.1.1 Enterovirus genome sequence 
Enteroviruses contain several human pathogenic species including Human 
enterovirus A, Human enterovirus B, Human enterovirus C, Human 
enterovirus D, Human rhinovirus A, Human rhinovirus B and Human 
rhinovirus C (Racaniello, 2013). Full-length nucleotide sequences of viral 
genomes for each of the 16, 53, 15 and 3 strains of the Human enterovirus A, 
B, C and D species, respectively, were downloaded from the recent database of 
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the GeneBank at the National Centre for Biotechnology Information (NCBI) 
and saved in a FASTA format (tables-2-1 to 2-4). The genomes of the above 
human enteroviruses contain three UHJLRQV ¶XQWUDQVODWHG UHJLRQ ¶875
FRGLQJ VHTXHQFHV &'6 DQG ¶ XQWUDQVODWHG UHJLRQ ¶875, respectively. 
Therefore, the nucleotide sequence of each one of the enteroviral genomes was 
split according to these three regions. 
Complete viral genome sequences of only seventeen of the human rhinoviruses 
were also downloaded from the same above website of the NCBI and saved 
using the same mentioned FASTA format (table 2-5). These sequences were 
selected based on a previous study (Wang et al., 2008), as a preliminary step to 
use the microarray assay for the diagnosis of infections caused by rhinoviruses.  
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Table 2-1: Shows the strains of the Human enterovirus A and their NCBI accession numbers, and genome size 
and regions. 
No Serotype Strain Accession Genome length (bp) 
*HQRPHUHJLRQV¶ size 
¶875 CDS ¶875 
1- Coxsackievirus A2  Fleetwood AY421760 7398 1-742 743-7315 7316-7398 
2- Coxsackievirus A3  Olson AY421761 7395 1-742 743-7312 7312-7395 
3- Coxsackievirus A4  High Point AY421762 7434 1-747 748-7353 7354-7434 
4- Coxsackievirus A5  Swartz AY421763 7400 1-741 742-7317 7318-7400 
5- Coxsackievirus A6  Gdula AY421764 7434 1-745 746-7351 7352-7434 
6- Coxsackievirus A7  Parker AY421765 7404 1-742 743-7321 7322-7404 
7- Coxsackievirus A8  Donovan AY421766 7396 1-743 744-7313 7314-7396 
8- Coxsackievirus A10  Kowalik AY421767 7409 1-744 745-7326 7327-7409 
9- Coxsackievirus A12  Texas AY421768 7404 1-745 746-7321 7322-7404 
10- Coxsackievirus A14  G-14 AY421769 7415 1-755 756-7334 7335-7415 
11- Coxsackievirus A16  G-10 U05876 7413 1-750 751-7332 7333-7413 
12- Enterovirus 71   BRCR U22521 7408 1-743 744-7325 7326-7408 
13- Enterovirus 76   FRA91-10369 AY697458 7438 1-747 748-7344 7345-7438 
14- Enterovirus 89   BAN00-10359 AY697459 7429 1-747 748-7335 7336-7429 
15- Enterovirus 90   BAN99-10399 AY697460 7425 1-749 750-7331 7332-7425 
16- Enterovirus 91   BAN00-10406 AY697461 7427 1-745 746-7333 7334-7427 
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Table 2-2: Shows the strains of the Human enterovirus B and their NCBI accession numbers, and genome size 
and regions. 
No Serotype Strain Accession Genome 
size 
*HQRPHUHJLRQV¶VL]H 
¶875 CDS ¶875 
1- Coxsackievirus A9 *ULJs/Bozek D00627 7452 1-743 744-7349 7350-7452 
2- Coxsackievirus B1 C0nn-5 M16560 7389 1-741 742-7290 7291-7389 
3- Coxsackievirus B2 Ohio-1 AF085363 7411 1-742 743-7306 7307-7411 
4- Coxsackievirus B3 Nancy M16572 7396 1-740 741-7298 7299-7396 
5- Coxsackievirus B4 JVB X05690 7395 1-743 744-7295 7296-7395 
6- Coxsackievirus B5 Faulkner AF114383 7400 1-742 743-7300 7301-7400 
7- Coxsackievirus B6 Schmidt AF105342 7398 1-743 744-7298 7296-7398 
8- Echovirus  1 Farouk AF029859 7397 1-743 744-7298 7298-7397 
9- Echovirus 2 Cornelis AY302545 7435 1-741 742-7335 7336-7435 
10- Echovirus 3 Morrisey AY302553 7428 1-743 744-7328 7329-7428 
11- Echovirus 4 Pesascek AY302557 7394 1-742 743-7294 7295-7394 
12- Echovirus 5 Noyce AF083069 7433 1-742 743-7333 7334-7433 
13- Echovirus 6 D'Amori AY302558 7418 1-742 743-7318 7319-7418 
14- Echovirus 7 Wallace AY302559 7427 1-742 743-7327 7327-7427 
15- Echovirus 9 Hill X84981 7420 1-739 740-7321 7322-7420 
16- Echovirus 11 Gregory X80059 7438 1-751 752-7339 7340-7438 
17- Echovirus 12 Travis X79047 7501 1-741 742-7323 7324-7501 
18- Echovirus 13 Del Carmen AY302539 7410 1-742 743-7309 7310-7410 
19- Echovirus 14 Tow AY302540 7450 1-741 742-7350 7351-7450 
20- Echovirus 15 CH96-51 AY302541 7437 1-743 744-7337 7338-7437 
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No Serotype Strain Accession Genome 
size 
*HQRPHUHJLRQV¶VL]H 
¶875 CDS ¶875 
21- Echovirus 16 Harrington AY302542 7437 1-742 743-7333 7334-7433 
22- Echovirus 17 CHHE-29 AY302543 7416 1-743 744-7316 7317-7416 
23- Echovirus 18 Metcalf AF317694 7410 1-740 741-7310 7311-7410 
24- Echovirus 19 Burke AY302544 7433 1-742 743-7333 7334-7433 
25- Echovirus 20 JV-1 AY302546 7394 1-742 743-7294 7295-7394 
26- Echovirus 21 Farina AY302547 7426 1-741 742-7326 7327-7426 
27- Echovirus 24 DeCamp AY302548 7433 1-742 743-7333 7334-7433 
28- Echovirus 25 JV-4 AY302549 7426 1-741 742-7326 7327-7426 
29- Echovirus 26 Cornel AY302550 7424 1-741 742-7323 7324-7424 
30- Echovirus 27 Bacon AY302551 7412 1-744 745-7311 7312-7412 
31- Echovirus 29 JV-10 AY302552 7427 1-742 743-7327 7328-7427 
32- Echovirus 30 Bastianni AF162711 7440 1-750 751-7335 7336-7440 
33- Echovirus 31 Caldwell AY302554 7432 1-741 742-7332 7333-7432 
34- Echovirus 32 PR-10 AY302555 7420 1-732 733-7320 7321-7420 
35- Echovirus 33 Toluca-3 AY302556 7394 1-742 743-7294 7295-7394 
36- Enterovirus 69 Toluca-1 AY302560 7411 1-744 745-7311 7312-7411 
37- Enterovirus 73 CA55-1988 AF241359 7411 1-744 745-7311 7312-7411 
38- Enterovirus 74 USA/CA75-10213 AY556057 7410 1-742 743-7309 7310-7410 
39- Enterovirus 75 USA/OK85-10362 AY556070 7429 1-747 748-7329 7330-7429 
40- Enterovirus 77 CF496-99 AJ493062 7415 1-742 743-7315 7316-7415 
41- Enterovirus 79 USA/CA79-10384 AY843297 7430 1-745 746-7330 7331-7430 
42- Enterovirus 80 USA/CA67-10387 AY843298 7428 1-743 744-7328 7329-7428 
43- Enterovirus 81 USA/CA68-10389 AY843299 7415 1-739 740-7315 7316-7415 
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No Serotype Strain Accession Genome 
size 
*HQRPHUHJLRQV¶VL]H 
¶875 CDS ¶875 
44- Enterovirus 82 USA/CA64-10390 AY843300 7427 1-745 746-7333 7334-7427 
45- Enterovirus 83 USA/CA64-10392 AY843301 7394 1-742 743-7294 7295-7394 
46- Enterovirus 84 CIV2003-10603 DQ902712 7423 1-744 745-7323 7324-7423 
47- Enterovirus 85 BAN00-10353 AY843303 7418 1-742 743-7321 7322-7418 
48- Enterovirus 86 BAN00-10354 AY843304 7400 1-742 743-7300 7301-7400 
49- Enterovirus 87 BAN01-10396 AY843305 7422 1-743 744-7322 7323-7422 
50- Enterovirus 88 BAN01-10398 AY843306 7433 1-744 745-7332 7333-7433 
51- Enterovirus 97 BAN99-10355 AY843307 7413 1-742 743-7312 7313-7413 
52- Enterovirus 100 BAN2000-10500 DQ902713 7421 1-744 745-7320 7321-7421 
53- Enterovirus 101 CIV03 -10361 AY843308 7445 1-742 743-7345 7346-7445 
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Table 2-3: Shows the strains of the Human enterovirus C and their NCBI accession numbers, and genome size 
and regions. 
No Serotype Strain Accession Genome 
size 
*HQRPHUHJLRQV¶VL]H 
¶875 CDS ¶875 
1- Coxsackievirus A1 Tompkins AF499635 7397 1-711 712-7326 7327-7397 
2- Coxsackievirus A11 Belgium-1 AF499636 7453 1-746 747-7385 7386-7453 
3- Coxsackievirus A13 Flores AF499637 7458 1-745 746-7390 7391 7458 
4- Coxsackievirus A15 G9 AF499638 7441 1-734 735-7373 7374-7441 
5- Coxsackievirus A17 G12 AF499639 7457 1-747 748-7389 7390-7457 
6- Coxsackievirus A18 G13 AF499640 7458 1-744 745-7389 7390-7458 
7- Coxsackievirus A19 8663 AF499641 7410 1-715 716-7339 7340-7410 
8- Coxsackievirus A20 IH35 AF499642 7436 1-744 745-7368 7369-7436 
9- Coxsackievirus A21 Kuykendall AF546702 7406 1-713 714-7337 7338-7406 
10- Coxsackievirus A22 Chulman AF499643 7406 1-715 716-7336 7337-7406 
11- Coxsackievirus A24 Joseph EF026081 7459 1-745 746-7390 7391-7459 
12- Poliovirus 1 Brunhilde AY560657 7445 1-746 747-7376 7377-7445 
13- Poliovirus 2 Lansing M12197 7440 1-747 748-7371 7372-7440 
14- Poliovirus 3 Leon/37 K01392 7431 1-742 743-7363 7364-7431 
15- Enterovirus 96 Banoo-10488 EF015886 7478 1-746 747-7406 7407-7478 
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Table 2-4: Shows the strains of the Human enterovirus D and their NCBI accession numbers, and 
genome size and regions. 
No Serotype Strain Accession Genome 
size 
*HQRPHUHJLRQV¶VL]H 
¶875 CDS ¶875 
1- Enterovirus 68   Fermon AY426531 7367 1-732 733-7299 7300-7367 
2- Enterovirus 70   J670/71 D00820 7390 1-726 727-7311 7312-7390 
3- Enterovirus 94   E210 DQ916376 7364 1-714 715-7287 7288-7364 
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Table 2-5: Shows the strains of the human rhinoviruses, their NCBI 
accession numbers and genome size. 
No Serotype Strain Accession Genome 
size 
1- Rhinovirus 1B   ATCC VR-1366 D00239 7133 
2- Rhinovirus 2      ATCC VR-482 X02316 7102 
3- Rhinovirus 8      ATCC VR-1118 FJ445113 7108 
4- Rhinovirus 9      ATCC VR-489 FJ445177 7132 
5- Rhinovirus 12    ATCC VR-1122 EF173415 7124 
6- Rhinovirus 14    ATCC VR-284 NC_001490 7212 
7- Rhinovirus 17    ATCC VR-1127 EF173420 7219 
8- Rhinovirus 32    ATCC VR-1142 FJ445127 7133 
9- Rhinovirus 39    ATCC VR-340 AY751783 7137 
10- Rhinovirus 50    ATCC VR-517 FJ445135 7118 
11- Rhinovirus 69    ATCC VR-1179 FJ445151 7211 
12- Rhinovirus 82    ATCC VR-1192 FJ445160 7123 
13- Rhinovirus 84    ATCC VR-1194 FJ445162 7201 
14- Rhinovirus 85    ATCC VR-1195 FJ445163 7140 
15- Rhinovirus 86    ATCC VR-1196 FJ445164 7213 
16- Rhinovirus 89    ATCC VR-1199 FJ445184 7152 
17- Rhinovirus 90    ATCC VR-1291 FJ445167 7124 
 
 
 
2.3.1.2 Metapneumovirus genome sequence 
Metapneumoviruses contain only one pathogenic species for the human which 
is (HMPV). Therefore, the full genome sequences of eleven serotypes of 
HMPV covering its two subtypes A and B (Biacchesi et al., 2003, van den 
Hoogen et al., 2004), were downloaded from the NCBI website and saved in a 
FASTA format (table 2-6).      
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Table 2-6: Shows strains of HMPV, their NCBI accession numbers 
and genome size. 
No Serotype Strains Accession Genome 
size 
1- 
H
um
a
n
 m
et
ap
ne
um
o
vi
ru
s 
Jpn03-1 AB503857 13337 
2- BJ1887 DQ843659 13327 
3- BJ1816 DQ843658 13271 
4- TW05-00125 EF535506 13282 
5- HMPVgz01 GQ153651 13327 
6- CAN97-83 AY297749 13335 
7- CAN98-75 AY297748 13280 
8- 00-1 AF371337 13350 
9- NL/00/17 type A2 FJ168779 13336 
10- NL/94/01 subtype B2 FJ168778 13282 
11- NL/1/99 AY525843 13293 
 
 
 
2.3.1.3 Human respiratory syncytial virus (HRSV) genome sequence 
HRSV represents another viral species causing viral infections of humans. The 
whole genome sequences of seven serotypes of HRSV covering its two 
subtypes A and B (Jafri et al., 2013) were obtained from the NCBI website and 
saved in a FASTA format (table 2-7).  
 
Table 2-7: Shows strains of HRSV, their NCBI accession 
numbers and genome size. 
No Serotype Strain Accession Genome 
size 
1- 
H
um
a
n
 
re
sp
ira
to
ry
 
sy
n
cy
tia
l v
iru
s 
 
98-25147-X FJ948820 15223 
2- rA2cp AF035006 15223 
3- cp52 AF013255 13933 
4- ATCC VR-26 AY911262 15226 
5- cpts 248 U50363 15222 
6- strain B1 AF013254 15225 
7- S2 U39662 15190 
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2.3.1.4 Influenza virus genome sequences 
Influenza A virus, Influenza B virus and Influenza C virus are the human 
pathogenic species of the influenza viruses.  Out of eight genomic segments of 
the human influenza viruses A and B, the full length sequences of the HA, NA 
and matrix protein (M) genomic segments of European origin were 
downloaded from the Influenza Virus Sequence Database of the NCBI. On the 
other hand the sequences of the hemagglutinin-esterase-fusion (HEF) and the 
matrix protein genomic segments of the human influenza virus C were selected 
from the seven segments of this virus genome also within European population 
and downloaded from the same database of the NCBI website. All the 
downloaded sequences were saved in a FASTA format, and then the identical 
sequences were collapsed (table 2-8). Searching the National Centre for 
Biotechnology Information (NCBI) website to download the nucleic acid 
sequences of the influenza viruses come with some subtypes of H7 that causing 
viral infection for human within Europe, therefore it was decided to include 
those subtypes belong to H7.   
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Table 2-8: Shows the selected genomic segments of the human influenza 
viruses A, B and C, their size and the subtype numbers. 
Virus species Genomic 
segment 
Segment 
size (kb) 
Virus 
subtype 
Subtypes 
No. Total 
Influenza A 
virus 
HA ~1.7 
H1N1 1186 
1667 
H1N2 9 
H2N2 15 
H3N2 453 
H7N7 4 
NA ~1.4 
H1N1 711 
1184 
H1N2 7 
H2N2 21 
H3N2 443 
H7N7 2 
MP ~0.98 
H1N1 331 
640 
H1N2 6 
H2N2 21 
H3N2 280 
H7N7 2 
Influenza B 
virus 
HA ~1.8 HA 23 
75 NA ~1.4 NA 36 
MP ~1.1 MP 16 
Influenza C 
virus 
HEF ~1.9 HEF 24 25 MP ~1.1 MP 1 
Total 3591 
 
 
 
2.3.2 Viral sequence analysis 
The genetic diversity among the strains and subtypes of the selected RNA 
viruses makes it very difficult if not impossible to design probes targeting all 
their sequences. Therefore, it was decided to analyse the genomic sequences of 
the selected viral strains or subtypes of each species in order to generate 
consensus sequences that could be used for designing specific probes for each 
viral species through the following steps:      
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2.3.2.1 Viral sequence alignment 
Nucleic acid sequence alignments for each of the three regions of each of the 
Human enterovirus A, B, C and D serotypes as well as the genomic sequences 
of those other serotypes of the human rhinovirus, HMPV and HRSV were 
implemented using CLUSTALW of the molecular evolutionary genetics 
analysis (MEGA) software version 4. The alignment was done in two steps: 
pairwise alignment and multiple alignment with the same alignment parameters 
which were adjusted on 15 for gap opening penalty and 6.66 for gap extension 
penalty. Multiple sequence alignments for each of the selected genomic 
segments of the human influenza virus A, B and C subtypes were carried out 
through the Influenza Virus Resource of the NCBI website.  
  
2.3.2.2 Phylogenetic analysis of the human enteroviruses  
The aligned nucleic acid sequences of the ¶875&'6DQG¶875regions of 
each of the Human enterovirus A, B, C and D serotypes were saved in MEGA 
format and then the maximum-likelihood phylogenetic and molecular 
evolutionary analyses were also conducted by using the MEGA software 
version 4. Molecular evolution design and nucleotide-level tree for the above 
three regions of the human enterovirus strains were made by selecting the 
unweighted pair group method with arithmetic mean (UPGMA) within the 
phylogeny option of the software toolbar. More alignment trials were 
performed for the nucleic acid sequences of the human enterovirus strains 
based on their phylogenetic analysis outcome. 
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2.3.2.3 Generation of the viral consensus sequences 
Consensus sequences for each of the three genomic regions of the 
phylogenetically related strains of the human enteroviruses, in addition to the 
human rhinovirus, HMPV, HRSV strains and each of the selected genomic 
segments of the human influenza virus A, B and C subtypes were designed 
based on their nucleic acid sequence alignments, using MAC VECTOR 
software. The generated consensus sequences were saved in a FASTA format 
and then chopped into many segments; each segment contained 380 bases 
while the last segment contained the remaining nucleotides.     
 
2.3.3 Multiple viral probes design 
Designing specific probes for the selected RNA viruses was performed using 
two software programs to maximize the yields of probes and to compare 
between the two methods, as follows: 
     
2.3.3.1 Probes design using OligoArray software 
The OligoArray software version 1 was used for designing specific multiple 
probes for each consensus sequence of the human enterovirus, human 
rhinovirus, HMPV and HRSV strains, and human influenza virus subtypes. 
The software required two files of nucleotide data: the input file and the 
custom database file. The target consensus sequences of the above viral strains 
and subtypes were loaded into the input file separately while the custom file 
should contain the full genome sequences of all viral strains and subtypes of 
interest. Both input and custom files should be loaded in a FASTA format. 
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OligoArray software was run 4 times for each consensus sequence. The 
parameters of the software in the first trial were set as follows:  
Probe or Oligo length was 30-31 bases, Temperature range Tm was 60 oC to 80 
oC, GC content ratio was 25-50%, Maximum temperature for a secondary 
structure was 65 oC, Minimum temperature to consider X-Hybrid was 50 oC , 
0D[LPXPQXPEHURIROLJRZDV0D[LPXPGLVWDQFHEHWZHHQWKH¶HQGRI
HDFK SUREH DQG WKH ¶ HQG RI HDFK WDUJHW VHTXHQFH ZDV  EDVHV 7he 
minimum distance between 2 oligos was 10 bases and the Prohibited sequences 
were CCCC, GGGG, AAAA, TTTT. The target consensus sequences were also 
loaded as prohibited sequences during each trial in order to avoid complete 
compatibility among the designed probes and these consensus sequences, 
which may interfere with the subsequent hybridization process. All these 
parameters were set similarly in the 4 trials except the Maximum temperature 
to consider X-hybrid was changed in the last three trials to be 55oC, 60oC and 
65oC, respectively.  
 
2.3.3.2 Probes design using Agilent Technologies eArray software 
The Agilent Technologies eArray software was also used for designing specific 
probes for each of the above viral strains and subtypes. A compressed folder 
containing the original full length nucleotide sequences of all of the viral 
strains and subtypes included in this study was uploaded in a FASTA format 
into this software while the probe details such as probe length and probe 
number per target were set to 30 bp and 10 respectively.   
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2.3.4 Testing the specificity of the designed probes: 
The designed OligoArray probes for the human entero-, influenza-, 
metapneumo- DQGUHVSLUDWRU\V\QF\WLDOYLUXVHV¶VHURW\SHVwere tested using the 
(BLAST) software of the GeneBank against the NCBI database in order to 
detect the binding specificity of these designed probes towards their related 
VHURW\SHV¶ VHTXHQFHV DQG DOVR WR UHYHDO DQ\ VHTXHQFH KRPRORJ\ DPRQJ WKH
designed viral probes and the human genomes, or other viral genome 
sequences. 
 
2.3.5 Printing the designed probes 
All the probe sequences generated from the probe design process using both of 
the OligoArray and Agilent eArray software were synthesized and printed 
simultaneously on two chips (glass slide) by Agilent Technologies Company as 
mentioned in section 2.3.3. In addition, another group of probes designed by a 
previous PhD student (Abdel-Hakeem, 2010), were also printed on the same 
two chips. This group included 80 probes covering the sequences of human 
herpes viruses (HHV) and was used as a control for the probes design in the 
current study. Further details about some of these probes will be mentioned in 
section 4.3.4. The printed chips were stored in a vacuum desiccator in order to 
be used later for evaluating the performance of the designed probes against 
some of their target viral nucleic acids.   
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2.4 Results 
2.4.1 Phylogenetic analysis results of the human enterovirus 
genomic sequences 
The first trial of aligning the whole genomes of each of the Human enterovirus 
A, B, C and D strains revealed very short conserved sequences (up to 10 bp) 
among their nucleic acids due to the high genetic diversity especially at the 
¶875DQG¶875UHJLRQV Accordingly, the generated consensus sequence for 
each of the above human enterovirus species, included many sequences of 
degenerate nucleotides in order to avoid excluding the hypervariable regions of 
these generated consensus sequences, which can facilitate designing more 
probes covering the whole genome of the selected human enterovirus species. 
The probe design process using these generated consensus sequences will 
generate probes containing many degenerate nucleotides which may affect 
probe specificity towards their target viral nucleic acids. Therefore, it was 
decided to align the nucleic acidVVHTXHQFHVRIWKH¶875&'6DQG¶875RI
each of the above human enterovirus strains, use the alignment results of the 
above regions for each of the Human enterovirus A, B, C and D strains in order 
to find the phylogenetic relationships among them and then align the nucleic 
acid sequences of those closely related strains which may generate more 
specific consensus sequences.  
Based on the phylogenetic analysis of the aligned nucleic acid sequences of the 
WKUHHUHJLRQV¶875&'6¶875RI the human enteroviruses, their strains 
clustered within several groups in a rooted phylogenetic tree specific for each 
VSHFLHV7KHSK\ORJHQHWLFWUHHRIWKHDOLJQHG¶875VHTXences of the Human 
enterovirus A strains contains 6 clusters (figure 2-1) while only 3 clusters can 
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EHQRWLFHGLQWKHSK\ORJHQHWLFWUHHRIWKHDOLJQHG&'6DQG¶875VHTXHQFHV
of the same strains, respectively (figures 2-2 and 2-3). It can be noticed that 
coxsackieviruses A 4, 14, 6, 16, 12, 3, 7, 5, 10, 2, 8 and enterovirus 71 strains 
are closely related to each other in their genetic structure in comparison to 
those of enteroviruses 76, 89, 90 and 91. However, Human coxsackievirus A6 
as an example, clustered with Human coxsackievirus A4, 14 and 16 in one 
JURXS LQ WKHDOLJQHG¶875VHTXHQFHVZKLOH LQ WKHDOLJQHG&'6DQG¶875
sequences it clustered in another group with Human coxsackievirus A6, 10, 2, 
12, 3, 8, 7 and Human enterovirus 71.  
 
 
Figure 2-13K\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875nucleic acid sequences of 
the Human enterovirus A strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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Figure 2-2: Phylogenetic analysis of the aligned CDS nucleic acids sequences of 
the Human enterovirus A strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
 
 
 
Figure 2-33K\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875nucleic acids sequences of 
the Human enterovirus A strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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On the other hand, three phylogenetic trees were generated from the 
SK\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875&'6DQG¶875VHTXHQFHVRIWKH
Human enterovirus B strains. Figure 2-4 shows that 31 of these strains 
clustered together in cluster-1 and 20 strains grouped in cluster-2 while each 
one of the remaining two strains clustered alone in clusters 3 and 4. All these 
strains distributed differently into 5 and 8 clusters according to their aligned 
&'6 DQG ¶875 VHTXHQFHV as shown in figures 2-5 and 2-6, respectively. 
Based on the genetic relationships, it can be noticed that Human echovirus 12 
as an example clustered alone in the aligned sequences of the ¶875 region, in 
the aligned CDS sequences it clustered with 10 other strains (Human echovirus 
3, 6, 14, 16, 25, 13, 26, 27, Human coxsackievirus B4 and 6) while it was 
related to VWUDLQVLQWKHDOLJQHG¶875 sequences (Human echovirus 5, 20, 
31, 2, 33, 12, 24, 17, 19, 3, 32, 7, 29, Human enterovirus 69, 73,  and Human 
coxsackievirus B4 and A9).  
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Figure 2-43K\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875nucleic acid sequences of 
the Human enterovirus B strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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Figure 2-5: Phylogenetic analysis of the aligned CDS nucleic acid sequences of the 
Human enterovirus B strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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Figure 2-63K\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875nucleic acid sequences of 
the Human enterovirus B strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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The strains of Human enterovirus C were also clustered in three different 
phylogenetic trees based on the alignment of their ¶875 &'6 DQG ¶875
sequences, respectively (figures 2-7 to 2-9). Human enterovirus 96 as an 
example was genetically close to the Human coxsackievirus A18, 15, 11, 24, 
17 and Human poliovirus 2 therefore it clustered with them in one group in the 
¶875VHTXHQFHVILJXUH-7). However, it clustered alone in the phylogenetic 
tree of the aligned CDS sequences (figure 2-8), and with Human 
coxsackievirus A1 and 19 (figure 2-9) according to the alignment results of the 
nucleotide sequences of  HDFK RI &'6 DQG ¶875 UHJLRQV RI WKH +uman 
enterovirus C strains.  
 
 
Figure 2-7: Phylogenetic analysis of the aligned 5¶875nucleic acid sequences of 
the Human enterovirus C strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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Figure 2-8: Phylogenetic analysis of the aligned CDS nucleic acid sequences of the 
Human enterovirus C strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
  
 
 
Figure 2-9: Phylogenetic analysis of the aligned ¶875 nucleic acid sequences of 
the Human enterovirus C strains using UPGMA of the MEGA software. The scale 
refers to percentage of differences among viral strains.   
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$OLJQPHQW UHVXOWV RI WKH ¶875 &'6 DQG ¶875 sequences of the Human 
enterovirus D showed the same phylogenetic tree for three regions as the 
Human enterovirus 70 and 94 were close to each other in the alignment results 
of their ¶875&'6DQG¶875sequences therefore, they gathered together in 
one cluster while Human enterovirus 68 clustered alone in the phylogenetic 
trees (figure 2-10).  
 
 
Figure 2-103K\ORJHQHWLFDQDO\VLVRIWKHDOLJQHG¶875&'6DQG¶875nucleic 
acid sequences of the Human enterovirus D strains using UPGMA of the MEGA 
software. The scale refers to percentage of differences among viral strains.   
 
 
 
2.4.2 Alignment results of the viral genomes sequences 
Nucleic acid sequence alignment results of WKH ¶875 &'6 DQG ¶875
regions of the closely related stains of each of the Human enterovirus A, B, C 
and D, and the human rhinovirus, HMPV and HRSV strains using the 
CLUSTALW of the MEGA software version 4 revealed many conserved 
regions among each of the above viral strains which were highlighted with 
stars (figure 2-11).  
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Figure 2-11: 3DUWRIWKHPXOWLSOHVHTXHQFHDOLJQPHQWRIWKH¶875QXFOHLFDFLGRI
a group of the closely relative stains of the Human enterovirus C showing the 
conserved  regions among their nucleic acids sequences. 
A=Adenine. G=Guanine. T=Thymine. C=cytosine. 
(*) refers to the conserved nucleotides.  
 
 
Similar conserved regions highlighted with dots were also noticed among the 
nucleic acid sequences of the HA, NA, MP and HEF genomic segments of the 
human influenza virus subtypes after aligning their nucleic acids sequences 
using the Influenza Virus Resource of the NCBI website (figure 2-12).   
 
 
    
Chapter Two            Designing multiple hybridization probes for the selected RNA viruses                              
 
71 
  
 
Figure 2-12: Part of the multiple sequence alignment of the nucleic acid 
sequences of the HA genomic segment of the H1N1 subtypes showing the 
conserved regions.   
A=Adenine. G=Guanine. T=Thymine. C=cytosine. 
(·) refers to the conserved nucleotides. (-) refers to the mismatch among the 
nucleotides. 
 
 
 
2.4.3 Generation of the consensus sequences 
%DVHGRQWKHSK\ORJHQHWLFDQDO\VLVDQGDOLJQPHQWUHVXOWVRIWKH¶875&'6
DQG¶875QXFOHLFDFLGVHTXHQFHVRIHDFKRIWKHHuman enterovirus A, B, C 
and D strains, consensus sequence was generated for the closely related strains 
which were clustered together in one group using MAC VECTOR software. 
More consensus sequences were generated for each of the human rhinovirus, 
HMPV, HRSV strains, and each of the HA, NA, MP and HEF genomic 
segments of the human influenza subtypes in the same way based on the 
alignment results of their whole genome sequences.  
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The length of the generated consensus sequences varied as it depends on viral 
genome size. Any nucleotide mismatch among the aligned nucleic acid 
sequences of the above viral strains or subtypes was encoded by the MAC 
VECTOR software with one of the degenerate nucleotides shown in red colour 
letters in figure 2-13 indicating that the nucleotide at this mismatch position 
could be either A, T, C or G according to the International Union of Pure and 
Applied Chemistry (IUPAC) nucleotide ambiguity code shown in table 2-9.      
 
Figure 2-13: Nucleic acid consensus sequence of cluster 1 of the phylogenetic tree 
RIWKHDOLJQHG¶875RI the Human enterovirus A (coxsackievirus A4, 14, 6 and 
16).  
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Table 2-9: The code of the degenerate nucleotides used at the mismatches 
positions of the aligned viral nucleic acid sequences (Cornish-Bowden, 1985). 
UPAC nucleotide code Base 
A Adenine 
C Cytosine 
G Guanine 
T Thymine 
R A or G 
Y C or T 
S G or C 
W A or T 
K G or T 
M A or C 
B C or G or T 
D A or G or T 
H A or C or T 
V A or C or G 
N Any base 
                 
 
 
2.4.4 Probe design 
The generated consensus sequences were used as templates for probe design 
which was done in 4 trials by using OligoArray software. In order to acquire 
more probes within a shorter time, each consensus sequence was segmented 
into several fragments with 380 nucleotides for each segment except the last 
one which contained the remainder nucleotides of the consensus sequence. All 
these segments were loaded as input files into the OligoArray software which 
generated hundreds of 30 base probes for each of the selected RNA viruses. 
Since the consensus sequences which were used as templates for probe design 
included degenerate nucleotides, many of the probes designed using 
OligoArray software contained some of these degenerate nucleotides scattered 
along the probe length. Those OligoArray probes containing more than two 
GHJHQHUDWHQXFOHRWLGHVHVSHFLDOO\DWWKHLU¶HQGZHUHH[FOXGHGWDEOH-10). 
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Table 2-10: Characteristics of the probes designed for the consensus sequence of 
WKH¶875nucleic acid sequences of the Human coxsackievirus A4, 14, 6 and 16 
which were clustered together in cluster-LQWKH¶875SK\ORJHQHWLFWUHHRIWKH
Human enterovirus A strains (see figure 2-1).  
Probe ¶-¶ Position Length  Tm oC 
GGGTYAACCCATRGGACGCTCTAATACAGA 12-41 30 74.22 
CCCATRGGACGCTCTAATAYRGACATGGTG 19-48 30 76.2 
TAGGACGCTCTAATAYRGACATGGTGTGAA 23-52 30 75.14 
TAATAAGGACATGGTGTGAAGAGTCTATTG 33-62 30 70.81 
GGACATGGTGTGAAGAGTCTATTGAGCTAG 39-68 30 77.43 
ATGGTGTGAAGAGTCTATTGAGCTAGTTAG 43-72 30 75.11 
GGCGCTAGCACACTGATTYTVCGGAATCCT 44-73 30 78.76 
TGAAGAGTCTATTGAGCTAGTTAGTAGTCC 49-78 30 74.28 
CACTGATTYTACGGAATCYTTGTGCGCCTG 54-83 30 77.95 
GCRCCAGYCATGTCTTGGTCAAGCACTTCT 156-185 30 78.69 
GGACTGAGTATCAATAAACTGCTCACGCGG 194-223 30 79.77 
TATABTGGCTGCTTATGGTGACAATTGAAG 206-235 30 75.67 
GCTTATGGTGACAATTGAARRATTGTTACC 216-245 30 72.5 
ATTGAARRATTGTTACCATATAGCTATTGG 229-258 30 69.08 
TTCGTTACCCGGCTAACTACTTCGAGAAAC 239-268 30 78.95 
TACCATATAGCTATTGGATTGGCCATCCGG 242-271 30 78.94 
TATTGGATTGGCCATCCGGTGTVTAACAGA 253-282 30 79.24 
TCGAGAAACCTAGTARCACCATGAAAGTTG 260-289 30 74.94 
TAGTARCACCATGAAAGTTGCRGAGTGTTT 270-299 30 73.32 
 
 
 
Loading the original whole genome sequences of the human enterovirus, 
human rhinovirus, HMPV, HRSV, and HA, NA, MP and HEF genomic 
segments of the human influenza virus into the Agilent Technologies eArray 
software also generated hundreds of specific probes for each of the above viral 
strains or subtypes (table 2-11). 
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Table 2-11: Shows the number of the probes designed for each species or subtype of the selected RNA viruses, using OligoArray 
and Agilent eArray software  
Family Genus Species Subtype Number of probes OligoArray Agilent eArray 
Picornaviridae Enterovirus 
Human enterovirus-A 
------------ 
703 142 
Human enterovirus-B 1081 439 
Human enterovirus-C 858 126 
Human enterovirus-D 310 30 
Human rhinovirus A and B 108 170 
Paramyxoviridae Pneumovirus Human respiratory syncytial virus  649 42 Metapneumovirus Human metapneumovirus 473 66 
Orthomyxoviridae Influenzavirus A Influenza A virus 
HA-H1N1 63 302 
HA-H1N2 61 21 
HA-H2N2 66 25 
HA-H3N2 61 165 
HA-H7N7 93 20 
NA-H1N1 52 375 
NA-H1N2 57 11 
NA-H2N2 57 22 
NA-H3N2 57 212 
NA-H7N7 62 10 
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Family Genus Species Subtype Number of probes OligoArray Agilent eArray 
Orthomyxoviridae 
Influenzavirus A Influenza A virus 
MP-H1N1 28 143 
MP-H1N2 26 7 
MP-H2N2 27 19 
MP-H3N2 26 97 
MP-H7N7 42 15 
Influenzavirus B Influenza B virus 
HA 57 77 
NA 50 123 
MP 31 61 
Influenzavirus C Influenza C virus HEF 71 22 MP 44 12 
Total 5213 2754 
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2.4.5 Probe printing 
The 7967 probes generated from the probe design process using both of the 
OligoArray and Agilent eArray software were printed as spots on two chips; 
each chip has 8 repeated arrays (figure 2-14). Each array contained duplicates 
of the 5213 OligoArray probes, 2754 Agilent eArray probes in addition to 45 
copies of a specific single probe for HPRT and 80 specific probes for HHV 
which were designed by a previous PhD student (Abdel-Hakeem, 2010). As a 
result, each array has 16374 probes. 
 
Figure 2-14: Schematic drawing of the printed chip containing 8 arrays of the 
designed viral probes. 
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2.5 Discussion 
Application of the nucleic acid microarrays for the diagnosis of viral infections 
is mainly based on the detection of the target viral nucleic acids suspected to be 
found in clinical samples through a hybridization reaction with complementary 
sequences of nucleic acid called probes spotted on a solid support surface. The 
definite identity and the spatial position of the probe which hybridizes with the 
target complementary viral nucleic acid will lead to uncover the identity of 
viruses in a clinical sample (Brown and Botstein, 1999, Russell, 2003). Double 
stranded DNA microarrays and Oligonucleotide DNA microarrays are the two 
common types of nucleic acid microarrays. Double stranded DNA probes or 
the so-called gene probes (single probe per one gene) generated from either 
gene clone process or PCR amplification process, are used for constructing 
double stranded DNA microarrays (Schena et al., 1995, Heller et al., 1997, 
Duggan et al., 1999). The long length of the gene probes (200-800 bp) enables 
incorporating more detectable molecules per each probe and increases their 
hybridization sensitivity and specificity which represents the advantage of this 
type of nucleic acid microarray in addition to their low production cost. 
Nevertheless, production of the gene probes requires long time and laborious 
work especially by using gene cloning method which is considered the main 
drawback of the double stranded DNA microarrays (Knight, 2001, de Muro, 
2005, Ehrenreich, 2006). Oligonucleotide DNA microarrays are the most 
common type of nucleic acid microarrays used in different aspects of 
biomedical research, especially in the diagnosis of viral infections. They 
involve using synthetic oligonucleotide probes targeting specific nucleic acid 
sequences within the genes of any organism in order to be used for analyzing 
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and monitoring their expression. Different length of oligonucleotide probes 
were used for constructing this type of microarray. Short oligonucleotide 
probes (18-30 nt) were used for mutation detection among the influenza virus 
subtypes based on the single base mismatch among their nucleic acids 
sequences (Sengupta et al., 2003, Kessler et al., 2004). Chou and his colleagues 
used long oligonucleotide probes (60-70 nt) for detecting and identifying viral 
pathogens in clinical samples. Direct chemical synthesis of the oligonucleotide 
probes on a solid surface allows spotting up to 100 000 of these 
oligonucleotide probes on a one inch area. This type of nucleic acid microarray 
is called a high density oligonucleotide array and can be produced 
commercially by many companies (Lander, 1999, Hughes et al., 2001). 
Therefore, it was decided to use this type of nucleic acid microarray for 
designing a single microarray chip containing thousands of probes in order to 
be used for diagnosing of viral infections caused by four different groups of 
RNA viruses. The length of the designed probes was determined to be 30 nt as 
shorter probes may lack specificity while the longer probes require more time 
to hybridize with their target complementary nucleic acid sequences. All the 
probes were designed with a GC content ratio not more than 60% in order to 
avoid possible cross hybridization resulted from higher GC content ratio. 
Furthermore, the OligoArray and Agilent Technology eArray software were set 
to exclude probes containing complementary regions or long stretches 
sequences (> 4) of the same nucleotide in order to avoid forming secondary 
and/or hair pin structures which may inhibit their hybridization to the target 
nucleic acids (Keller et al., 1989).  
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Due to the short size of the oligonucleotide probes, they can easily attach to the 
solid substrate through covalent coupling and electrostatic attraction, but this 
attachment is not strong enough to keep them linked to the microarray surface 
as a considerable amount of them may be lost through the hybridization 
process and post-hybridization wash harshness (Rickman et al., 2001, 
Ehrenreich, 2006). Modifying the oligonucleotide probes by adding amino 
JURXS DW WKHLU ¶ HQG FDQ HQKDQFH WKHLU FRYDOHQW OLnkage to the microarray 
surface, but it may add some cost for constructing the oligonucleotide 
microarrays (Zammatteo et al., 2000, Call et al., 2001). Coating the supporting 
surface used for accommodating oligonucleotide probes with chemical 
compounds such as amino silane provides positively charged amine groups 
which can attach to the negatively charged phosphate groups of the 
oligonucleotide probes (Todt and Blohm, 2009, Maskos and Southern, 1992). 
Nitrocellulose (Nylon) membrane can be used for constructing nucleic acid 
microarrays, but its high autofluorescence and fragility in addition to their 
ability to release the probes during hybridization process limit its application 
for this purpose. On the contrary, glass slides have low inherent fluorescence 
and superior optical features for fluorescent scanning as well as being more 
resistant to break. Therefore, slides are more convenient for probe printing than 
the other types of membranes and it is considered as the perfect choice for 
microarray spotting (Chiu et al., 2003, de Muro, 2005).  
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3 Application of the multiple 
displacement amplification technique 
for testing the specificity of the 
designed viral microarray 
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3.1 Introduction 
Microarray technology represents the latest invaluable method used widely in 
molecular biology laboratories for research purposes (Jayapal and Melendez, 
2006). It was first used in immunological assays by Ekins in 1989 (Ekins, 
1989, Howbrook et al., 2003). Kononen and his colleagues developed nucleic 
acid microarrays as a tool for comprehensive screening of gene expression of a 
large number of genes within a tumor in one experiment (Kononen et al., 
1998). (Wang et al., 1998)) designed a microarray chip for wide scale 
identification of human single nucleotide polymorphisms (SNP) responsible for 
many genetic diseases (Call, 2001b). Microarray has also been applied for 
identification of human and animal pathogens (Severgnini, 2011) and 
accordingly, many new drugs and therapeutic compounds have been  
discovered and validated for human use using the microarray technique in the 
Pharmacology field (Gerhold et al., 2002, Trevino et al., 2007, Khan, 2010). 
Sachse and his colleagues used microarray for the identification of Chlamydia 
and Chlamydophila spp. (Sachse et al., 2005), while other researchers 
identified 11 bacterial- and 5 viral species using only a single microarray 
(Wilson et al., 2002). Many other research groups applied this technique for 
identification of human viral pathogens only (Wang et al., 2002, Sengupta et 
al., 2003, Klaassen et al., 2004, Nordstrom et al., 2005, Albrecht et al., 2006, 
Lopez-Campos et al., 2007, Baek et al., 2008). 
Microarray consists of tiny spots (10-500 microns) of biomolecules, affixed in 
a grid pattern to a solid support platform which may be either silicon, plastic or 
glass surface, using a suitable robotic arrayer. Either the attached biomolecules 
or the target materials should carry a reporter molecule such as cyanine 3 (Cy-
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3), Cy-5 or biotin in order to detect the fluorescent signals generated from their 
interaction using an appropriate reader (Call, 2001b, Zajac et al., 2007).  
DNA microarray is the most common type of biological microarray used in the 
healthcare field not only for the diagnosis of infectious diseases, but also to 
define tumor genes. DNA microarrays may contain from a few dozen to many 
thousands of oligonucleotides (up to 50-mer) called probes, fabricated either 
covalently or noncovalently on the solid surface. The work principle of the 
DNA microarray mainly depends on the base pairing and hybridization 
reaction between the attached probes and complementary sequences of nucleic 
acids labelled with a detectable molecule. The resultant hybrids can be detected 
using a laser scanner.  
DNA microarray became superior to other traditional techniques used for the 
same application such as Southern or Northern blots due to its ability to screen 
thousands of genes simultaneously (Heller, 2002, Trevino et al., 2007).  
Both purity and concentration of the target genetic materials may affect the 
performance and success of the nucleic acids microarray. Using low 
concentrations of microbial biomass may inhibit the hybridization reaction 
between complementary sequences and make it difficult to apply nucleic acids 
microarray for the detection of microbial pathogens (Wu et al., 2006).   
Therefore, it is highly recommended to amplify either the sample content of 
nucleic acids before starting microarray hybridization regardless of their 
available initial concentration, or amplify the generated signals after 
hybridization (Stears et al., 2000, Zhou and Thompson, 2002).  
Difficulties associated with using conventional PCR based methods for 
amplification of microbial genome samples, such as probable bias during 
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amplification and/or the need to use many sets of primers for comprehensive 
amplification of each sample, urged researchers to think about using an 
alternative method for amplification of the nucleic acids (Vora et al., 2004).  
WGA involves using of Phi 29 DNA polymerase enzyme which binds tightly 
to the DNA template and synthesizes several new complementary strands 
through MDA process (Kittler et al., 2002).    
 
3.2 Aims 
There were two main aims for this chapter of the project. The first was to 
randomly amplify the entire genome of some human enteroviral nucleic acids 
extracted from clinical samples and tissue cultures using multiple displacement 
activity of the Phi 29 DNA polymerase. The second aim was to validate the 
hybridization behaviour of the viral amplicons against six specific probes for 
human enteroviruses which were designed and tested successfully by a 
previous PhD student (Abdel-Hakeem, 2010), before using these amplicons for 
testing the hybridization performance of the viral probes designed in chapter 
two.  
 
3.3 Materials and methods 
3.3.1 Specimens 
Some samples including i) RNA transcripts for Human echovirus 30 , ii)  
clinical  samples known to be positive for enteroviruses, iii) pTZ18R plasmid, 
iiii) hypoxanthine-guanine phosphoribosyltransferase (HPRT) were used as a 
source for nucleic acids in order to optimize the microarray hybridization and 
test the designed microarray assay under real-world conditions.  
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The viral transcripts were comprised of 10^6 copies/µl of an extracted RNA for 
Human echovirus 30, and provided kindly by Professor Peter Simmonds, 
Centre of Infectious Diseases, University of Edinburgh, Summerhall, 
Edinburgh, UK. The clinical samples were provided from the clinical Virology 
ODERUDWRU\4XHHQ¶V0HGLFDO&HQWUH40&), Nottingham, UK.  
 
3.3.2 Samples preparation 
Different processing steps were used to prepare samples for hybridization 
experiment, as follow:  
 
3.3.2.1 Isolation of the ribonucleic acid (RNA) 
µMACS one-step cDNA kit (Miltenyi Biotec, Surry, UK) was used to extract 
RNA, which can also fulfil the reverse transcription of the viral mRNA which 
is normally called complementary DNA (cDNA) synthesis in a further step. 
This method was used only with enteroviruses, as their genomes harbour poly-
A tail. The principle of this isolating method is to pull down RNA containing a 
poly-A tail by using microbeads coated with oligo-dT.  
The enterovirus clinical sample was first lysed by adding 1 ml of lysis/binding 
buffer per 0.5 ml of the above sample and vortexing for 3-5 minutes. The 
sheared lysate was loaded into the provided lysate clear column and 
FHQWULIXJHGDWUSP for 3 minutes. Then, the eluate was mixed with 50 
µl of oligo-dT microbeads. The MACS micro column was positioned in the 
magnetic field of the provided thermoMACS separator and rinsed with 100 µl 
of lysis/binding buffer. The magnetically labelled eluate was loaded on to the 
micro column matrix which retained the RNA-oligo-dT microbeads hybrid 
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while the eluate was passed through the micro column. The hybrid was washed 
twice with 200 µl of lysis/binding buffer and four times with 100 µl of wash 
buffer. cDNA synthesis proceeded directly on the same separating micro 
column which was rinsed twice with 100 µl of the equilibration/wash buffer.  
Immediately, the lyophilized reverse transcriptase was dissolved in 20 µl of 
resuspension buffer and loaded on the column matrix. The column was 
incubated in the thermoMACS separator for 60 minutes at 42 oC to achieve 
reverse transcription process and generate cDNA. The column was rinsed twice 
with 100 µl of the equilibration/wash buffer, followed by addition of 20 µl of 
the cDNA release solution. After incubation for a further 10 minutes at 42 oC, 
the generated cDNA was eluted with 50 µl of elution buffer.  
 
3.3.2.2 Extraction of viral RNA from clinical samples 
Viral RNA was extracted from the clinical samples using the QIAamp Viral 
RNA Mini kit (Qiagen, west Sussex-UK). This method was used with viral 
types other than enteroviruses, which their genomes lack poly-A tail. Samples 
were first lysed using AVL buffer which contains guanidine thiocyanate. This 
highly denaturing buffer is necessary for the release of the viral RNA from the 
viral particles and infected human cells. Furthermore, it inactivates RNases and 
adjusting the buffering conditions to improve viral RNA binding to the 
QIAamp membrane. 
According to the manufacturer¶V guideline, samples were lysed by mixing 560 
µl of AVL buffer containing 5.6 µg of carrier RNA with 140 µl of the clinical 
sample by pulse-vortexing for 15 seconds. After 10 minutes of incubation at 
room temperature, 560 µl of absolute ethanol were added to the lysate. Then 
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the mixture was applied to a QIAamp Mini column and spun at >8000 rpm for 
1 minute. Any further protein and salt contaminants were washed away from 
the bound RNA in the column membrane through centrifugation for 1 minute 
at >8000 rpm using 500 µl washing buffers AW1 and AW2, respectively. 
Finally, the viral RNA was eluted in 60 µl of elution buffer (AVE) after 
centrifugation for 1 minute at 8000 rpm.  
 
3.3.2.3 Reverse transcription of the viral RNA 
SuperScript III First-Strand Synthesis SuperMix kit (provided by Invitrogen) 
was used as an additional method to generate viral cDNA from viral RNA. 
This step is required to generate the starting template for the initiation of viral 
nucleic acid amplification.  
Six microliters of the total viral RNA were mixed with 1 µl of oligo-dT 
primers (50 pmol) and 1 µl of the annealing buffer in order to initiate and 
improve the primers annealing to the viral RNA target. After 5 minutes of 
incubation at 65 oC in a thermal cycler, the mixture was immediately chilled on 
ice for 1 minute and spun briefly. Generation of the cDNA was achieved by 
adding 10 µl of the 2X First-Strand Reaction Mix which contains 1mM of each 
dNTP, and 2 µl of the SuperScript III/ RNaseOut Enzyme mix containing the 
reverse transcriptase enzyme. The mixture was incubated at 50 oC for 30 
minutes. The reaction was terminated by heating the mixture at 85 oC for 5 
minutes. The generated viral cDNA was stored at -80 oC for further use.   
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3.3.2.4 Second strand synthesis of the viral cDNA 
NEBNext Second Strand Synthesis Module (New England Biolabs) was used 
to generate double stranded cDNA from the first strand viral cDNA, which 
may be more appropriate for amplification process using PCR.  
The total 20 µl of the reverse transcription reaction generated in section 3.3.2.3 
were mixed with 48 µl of nuclease free water, 8 µl of 10X second strand 
synthesis reaction buffer and 4 µl of second strand synthesis enzyme mix, and 
incubated at 16 oC for 2.5 hours.   
 
3.3.2.5 Preparation of the pTZ18R plasmid 
The pTZ18R plasmid was introduced to amplification and subsequent 
hybridization steps. This allowed for comparing the effect of the fragile RNA 
on such processing and subsequent weak hybridization signals.  
 
3.3.2.5.1 Linearization of the pTZ18R  
The pTZ18R is a circular double stranded DNA plasmid with 2861 bp length. 
Therefore, the plasmid was digested by a restriction endonuclease in order to 
produce linear copies with sticky ends. This step enables binding of the linear 
chunks of the plasmid together through ligation of their resulted compatible 
ends to generate longer products which can improve the performance of the 
MDA process later.  
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SapI restriction enzyme supplied in 2000 units/ml by New England Biolabs 
was used to digest the pTZ18R. This enzyme will cut the pTZ18R plasmid at 
the recognition site 470-476 with the following sequence, and generates a 
linear product (figure 3-1). 
¶*&7&77&«¶ 
¶«&*$*$$*«¶ 
$FFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO  µg of the circular plasmid was 
digested using 1 unit of SapI and 5 µl of 10X NE Buffer, the final reaction 
volume was adjusted to 50 µl using nuclease free water. The reaction mixture 
was incubated at 37 oC for 1 hour followed by heating to 65 oC for 20 minutes 
in order to inactivate the enzyme and stop the digestion reaction.  
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Figure 3-1: Schematic diagram showing the linearization process of the pTZ18R 
plasmid. 
Figure (A) the circular shape of the plasmid showing the site, size and the sequence of 
each of the T7 promoter and the recognition site of the SapI. Figure (B) the linear 
shape of the plasmid showing the starting point and the direction of the plasmid 
transcription, and the length of the generated RNA.  
 
 
3.3.2.5.2 Purification of the digested pTZ18R 
A Qiaquick PCR purification kit (Qiagen, UK) was used to purify the digested 
plasmid. The combination between the spin column technique and the selective 
binding properties of the included silica membrane improves the kit 
purification performance.  
High concentrations of chaotropic salts in addition to pH  7.5 will be required 
to facilitate and enhance the adsorption and capturing of the digested products 
of the plasmid UDQJLQJ EHWZHHQ  WR  NE LQ VL]H WR WKH FROXPQ¶V VLOLFD
membrane when applying the digestion reaction mixture.  
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Any contaminants, oligonucleotides or enzymes will be washed away through 
the column by using the PE buffer. The clean digested products of the pTZ18R 
will be eluted using nuclease free water or elution buffer in the final step. 
Seventy five µl of Buffer PB were mixed with 15 µl of the digestion reaction 
mixture, and then 10 µl of 3M sodium acetate, pH 5 were added to the mixture 
to adjust the pH reaction below 7.5.  The mixture was applied to the assembled 
spin column with its 2 ml collection tube, and centrifuged for 1 minute at 
13000 rpm. After discarding the flow-through, the column was placed back in 
the tube and the digested products were washed with 750 µl Buffer PE using 
centrifugation with the same above conditions. The flow-through was also 
discarded and the spin column was re-placed in the same collection tube to 
repeat centrifugation for an additional 1 minute to remove any residual ethanol 
from the washing step. The column was placed in a sterile eppendorf tube and 
the digested pTZ18R was eluted in 30 µl elution buffer after spinning for 1 
minute at the same above speed. 
 
3.3.2.5.3 Agarose gel electrophoresis 
In order to detect the expected size of the digested products and compare it 
with the undigested plasmid, both samples were run on a 1% agarose gel 
(Invitrogen, Paisley, UK) using 1X Tris-acetic acid-EDTA (TAE) running buffer 
containing 0.2 ng/ml ethidium bromide (SIGMA-ALDRICH, UK). Five 
microliters of each plasmid sample were mixed with the DNA loading buffer 
and run on the gel for 45 minutes using 90 volts. Smeared bands of the plasmid 
products were visualized using an ultraviolet light scanner, and their size was 
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compared to the 1 kb DNA Step Ladder (Fermentas life Sciences, UK) used as a 
size marker.   
 
3.3.2.5.4 Evaluating the digested plasmid products 
In order to determine the quantity and the quality of the digested products after 
purification, they were measured spectrophotometrically using the NanoDrop 
ND 1000 (Thermo Scientific). One microliter of the digested pTZ18R was 
uploaded to the machine and their optical absorbance was measured at two 
wavelengths 260 and 280 nm.   
 
3.3.2.5.5 Transcription of the digested pTZ18R 
Transcription of the plasmid was done in order to generate an RNA template 
comparable to the viral nucleic acids used in this study which can facilitate 
optimizing the processing steps for the successful hybridization between the 
selected viral nucleic acids and the probes designed in chapter 2.  
The MEGAscript T7 kit (Life technologies) was used for plasmid transcription. 
According to the manufaFWXUHU¶V SURWRFRO 25 µg of the linear plasmid was 
mixed with 2 µl of each of the ribonucleoside triphosphate (rNTPs), 2 µl of 
10X reaction buffer and 2 µl of the enzyme-T7 RNA polymerase. The final 
volume of the reaction mixture was adjusted to 20 µl using nuclease free water. 
The transcription reaction proceeded via incubation of the mixture at 37 oC for 
4 hours, followed by incubation at the same temperature for 15 minutes after 
adding 1µl of the Turbo DNase in order to remove the template DNA of the 
plasmid. 
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3.3.2.5.6 Purification of the pTZ18R RNA 
The transcribed RNA was subjected to purification step before proceeding with 
any further preparation processes for the microarray hybridization as it may be 
inhibited by any residual of the enzymatic reaction such as plasmid DNA, 
rNTPs or enzymes especially RNases and RNA polymerase. Furthermore, any 
short segment of the RNAs less than 200 nucleotides such as ribosomal 
ribonucleic acid (rRNA) and transfer ribonucleic acid (tRNA) will be removed. 
RNeasy Plus Mini kit (Qiagen, west Sussex-UK) was used to purify the 
transcribed RNA which was mixed with 350 µl of RLT buffer containing 
0.01% ȕ-PHUFDSWRHWKDQRO ȕ-ME) and 250 µl of absolute ethanol. Using the 
provided RNeasy spin column, the mixture was centrifuged for 15 seconds at 
10000 rpm. The retained RNA was washed with 700 µl of buffer RW1 
followed by 500 µl of buffer RPE using centrifugation with the same previous 
conditions. Final washing step was done using the same volume of buffer RPE 
with centrifugation at 10000 rpm for 2 minutes. The clean RNA was eluted in 
50 µl of nuclease free water. Based on the NanoDrop results, the final copy 
number of the transcribed RNA was determined per each microliter. 
 
3.3.2.5.7 Analysis of the pTZ18R RNA  
The quality of the RNA generated from the plasmid DNA transcription process 
was determined using the RNA 6000 Nano Assay Kit (Agilent Technologies) 
DQG WKH$JLOHQW%LRDQDO\]HU%\IROORZLQJ WKHPDQXIDFWXUH¶VJXLGHOLQH
the bioanalyzer electrode was cleaned with the RNase ZAP and rinsed with 
RNase free water using a nano chip electrode cleaner. Nine µl of the prepared 
gel-dye mixture were loaded into each one of the 3 wells of the RNA nano chip 
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marked with G. By the same way, 5 µl of the Nano Marker (green) were added 
to each one of the remaining 13 wells. Finally, one microliter of the RNA 6000 
ladder was denatured for 2 minutes at 70 o C and injected into the well which 
marked with the ladder symbol, while 1 µl of the denatured RNA sample at the 
same previous conditions was loaded into the RNA sample well. Then, the 
RNA nano chip was placed in the Agilent 2100 Bioanalyzer and the RNA 
sample was analysed using the 2100 Expert Software (prokaryotic total RNA 
program) loaded on the machine. 
 
3.3.2.6 Preparation of the HPRT sample to be used as an internal 
positive control 
HPRT is one of the housekeeping genes expressed in all human tissues and 
cells. Therefore it was selected to be an internal positive control as an indicator 
for the performance of the hybridization experiments. A sequence of steps was 
done to prepare the HPRT sample for hybridization test which included:  
 
3.3.2.6.1 Extraction of human DNA  
Nucleic acid DNA from human peripheral blood samples was extracted using 
the QIAamp DNA mini extraction kit (Qiagen, west Sussex-UK). In a 1.5 ml 
eppendorf tube, 200 µl of the blood sample were mixed with 20 µl of the 
Qiagen protease and 200 µl AL buffer containing guanidinium hydrochloride 
solution in order to lyse the blood cells and release their nucleic acids. Two 
hundred microliters of absolute ethanol were added to the lysate after 10 
minutes of incubation at 56 oC. The mixture was applied to the provided 
QIAamp mini spin column and centrifuged at 8000 rpm for 1 minute. 
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The DNA bound to the mini column was washed with 500 µl of wash buffer 1 
(AW1) and centrifuged at the same above conditions. The washing step was 
repeated using 500 µl AW2 and centrifuged for 3 minutes at 14000 rpm. 
Finally, the pure DNA was eluted in 50 µl elution buffer (AE) with 
centrifugation for 1 minute at 8000 rpm. 
 
3.3.2.6.2 HPRT amplification  
The isolated human DNA was subjected to PCR in order to amplify part of the 
HPRT gene with the accession number: NM_000194 in the NCBI database. 
HotStarTaq DNA Polymerase kit (Qiagen, west Sussex-UK) was used for this 
purpose with a set of in-house 20-mer primers for PCR amplification of the 
HPRT (table 3-1).  
 
 
Table 3-1: Features of the primers used for HPRT-PCR 
(Adopted from (Abdel-Hakeem, 2010) 
Primer ID 6HTXHQFHCĺC Tm oC GC% Amplicon Size 
HPRT-FW GACCAGTCAACAGGGGACAT 55.9 55 160 bp HPRT-RV CGACCTTGACCATCTTTGGA 54.2 50 
FW=Forward primer, RV= Reverse primer 
 
 
 
$FFRUGLQJ WR WKH PDQXIDFWXUHU¶V JXLGHOLQH  O RI WKH 3&5 UHDFWLRQ PL[
containing 1X PCR buffer, 200 µM of each dNTP, 0.2 µM of each primer, 2.5 
units of HotStarTaq DNA polymerase and 0.5 µl of the extracted human DNA 
was prepared. The reaction mix was amplified using the thermal cycler 
(Techne TC-3000) with the cycling programme shown in table 3-2. 
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Table 3-2: The optimal cycling programme used for HPRT-PCR amplification 
Stage Temperature Time Cycles 
Initial enzyme activation 95 oC 5 minutes 1 
Amplification 
Denaturation 94 oC 1 minute 
35 Annealing 58oC 1 minute 
Extension 72 oC 1 minute 
Final extension 72 oC 10 minutes 1 
 
 
3.3.2.6.3 HPRT Purification and measurement 
The PCR products were purified using a Qiaquick PCR purification kit as 
described in section 3.3.2.5.2. The purified products were run on a 1% agarose 
gel as described in section 3.3.2.5.3 to determine their size, while their 
concentration was measured using the NanoDrop as described in section 
3.3.2.5.4. 
 
3.3.3 Amplification of the whole viral RNA 
Amplification of viral nucleic acids may be necessary with viral samples 
containing a low copy number of the viral genomes in order to achieve 
detectable hybridization. Three different methods were used for this purpose:  
 
3.3.3.1 MDA process  
Viral cDNA was randomly amplified using a REPLI-g UltraFast mini kit 
(Qiagen, UK) utilizing Phi 29 DNA polymerase. This enzyme has the ability to 
replicate the viral genome isothermally in a technique called multiple 
displacement amplification (MDA) see chapter 1.  
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According to the manufactureU¶V recommendations, 1 µl of the diluted 
denaturation buffer (1:7) was added to a tube containing 1 µl of the viral cDNA 
template and incubated at room temperature. The denaturation process was 
stopped after 3 minutes by adding 2 µl of the diluted neutralization buffer 
(1:9). Replication of the viral nucleic acids was completed by adding 16 µl of a 
mixture containing 1 µl of the Phi 29 DNA polymerase and 15 µl of the 
reaction buffer containing dNTPs, and incubating at 30 oC for 1.5 hour in a 
thermal cycler. The amplification was stopped by heating the mixture for 3 
minutes at 65 oC. A Parallel reaction was performed as a negative control by 
adding 1 µl of nuclease free water instead of the viral cDNA. The amplified 
products were purified as described in section 3.3.2.5.2 followed by running 
the purified amplicon on agarose gel, and measuring their concentration using 
nanodrop as describe in sections 3.3.2.5.3 and 3.3.2.5.4, respectively.  
 
3.3.3.2 Amplification of the RNA templates using QuantiTect whole    
transcriptome kit 
Based on the same principle of the MDA, QuantiTect whole transcriptome kit 
(Qiagen, west Sussex-UK) was used as an alternative kit for WGA of the 
pTZ18R RNA in parallel with enteroviral RNA. The kit is designed to 
synthesise a cDNA strand from its relevant RNA template and ligate the 
generated cDNA segments together to provide a longer template for a MDA 
step in three sequential reactions.  
In this alternative kit, 5 µl of the RNA template were added to 5 µl of reverse 
transcription mix containing 1 µl of T-script enzyme and 4 µl of T-Script 
buffer. The cDNA synthesis process was started by incubation of the reaction 
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mixture at 37 o C for 30 minutes and stopped by inactivation of the T-Script 
enzyme at 95 o C for 5 minutes. Ten microliters of the ligation mix containing 6 
µl of the ligation buffer, 2 µl of the ligation reagent and 1 µl of each of the 
ligation enzymes 1 and 2 were added to the cooled cDNA reaction mixture at 
22 o C, and incubated at the same temperature for 2 hours to initiate ligation of 
the generated cDNA together. The ligated cDNA was amplified by adding 29 
µl of the REPLI-g midi reaction buffer and 1 µl of REPLI-g midi DNA 
polymerase, and incubated at 30 o C for 2 hours. All incubation steps were 
performed using thermal cycler (Applied Biosystems). The amplified cDNA 
products were purified and run on 1% agarose gel to detect their bands as 
described in section 3.3.2.5.2 and 3.3.2.5.3, respectively. 
 
3.3.3.3 Amplification of the target RNA using GenomePlex complete 
WGA kit  
A third approach to the amplification of the viral genome was to use the 
GenomePlex complete WGA kit (Sigma-Aldrich, UK). This technique 
generates nucleic acid fragments with the target size for microarray 
hybridization flanked by universal priming sites ready for amplification using 
universal primers in 3 sequential steps of one reaction. 
With this kit, both of i) the first strand cDNA template prepared in section 
3.3.2.3 and ii) double stranded cDNA generated in section 3.3.2.4 were 
amplified using this technique. The reaction was started with the fragmentation 
step which was achieved by adding 1 µl of 10X fragmentation buffer to 10 µl 
of the pTZ18R plasmid cDNA (1ng/µl) in a PCR tube. The mixture was heated 
for 5 minutes at 95 o C followed by immediate cooling on ice. The mixture was 
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directly incubated with 2 µl of 1X library preparation buffer and 1 µl of library 
stabilization solution for 2 minutes at 95 oC for the initiation of the second step 
called library preparation. One µl of library preparation enzyme was added to 
the mixture after cooling it on ice, and incubated for 20 minutes at each of the 
following temperatures 16, 24, 37 oC, respectively, using a thermal cycler 
which also terminated this reaction by heating the mixture to 75 o C for 5 
minutes.  
The generated library molecules were amplified through the final step by 
adding 7.5 µl of 10X amplification master mix, 47.5 µl of nuclease free water 
and 5 µl of WGA-DNA polymerase to the previous 15 µl reaction mixture. 
After 3 minutes of initial denaturation at 95 oC 14 cycles of denaturation at 94 o 
C for 15 seconds and annealing/extension at 65 oC for 5 minutes, were used as 
a thermal profile. The generated products were purified and run on 1% agarose 
gel to detect their bands as described in section 3.3.2.5.2 and 3.3.2.5.3, 
respectively.  
 
3.3.4 Labelling the samples amplicons  
Use of fluorescent dyes to label either the designed probes or the viral nucleic 
acids, is a common method used for the detection of any hybridization that may 
occur among them. Successful labelling requires the following steps: 
 
3.3.4.1  Amplicon fragmentation 
The optimal length of nucleic acids for successful hybridization is between 
100-300 bp, while the typical size of the MDA product is >10 kb. This length 
of nucleic acid will lead to a high spotted background in in situ hybridization. 
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Therefore, the MDA amplicons were fragmented using the following 
fragmentation methods:   
 
3.3.4.1.1 Amplicons sonication 
The amplicons generated in section 3.3.3.1 were diluted to concentration of 20 
ng/µl with 0.3 mM ethylenediaminetetraacetic acid (EDTA) and 10 mM Tris-
HCl, pH 8.0 in total volume of 100 µl. The MDA mixture was then sonicated 
for 3 cycles at amplitude 5 using the Soniprep 150 MSE sonicator in the Centre 
for Biomolecular Sciences (CBS)/University of Nottingham. Each cycle was 
run for 1 minute sonication with 5 seconds stopping intervals every 15 minutes 
of sonication, 1 minute incubation on ice and 5 seconds centrifugation. This 
method is fast, simple to conduct and with generally acceptable results. The 
main drawback of sonication is the generation of uneven fragments of nucleic 
acids that may affect the hybridization process.    
 
3.3.4.1.2  Amplicon fragmentation using DNase I 
The amplified products generated in section 3.3.3.2 were sheared using DNase 
I as an alternative fragmentation method to the sonication technique during the 
optimization steps of the microarray hybridization. DNase I was provided as a 
lyophilized enzyme containing 2000 units/mg by (Roche, USA). 
$FFRUGLQJ WR WKH PDQXIDFWXUHU¶V JXLGHOLQH '1DVH , VWRFN ZDV SUHSDUHG E\
dissolving 1 mg of the lyophilized DNase I in 1 ml of dilution buffer 
containing 5 mM NaAc pH 5.2, 1 mM CaCl2 and 50% glycerol. The DNase I 
stock was diluted to a working concentration 0.0004 unit/µl by adding 1 µl of 
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the DNase I stock to 5000 µl of 1X nicking buffer containing 50 mM Tris-HCl 
pH7, 10mM CaCl2 and 10 mM MgCl2.  
The fragmentation process was performed by adding 3-5 µl (0.0012 ± 0.002 
unit) of the diluted DNase I and 2.5 µl of 10X nicking buffer per 1 µg of the 
amplicons generated in section 3.3.5.3 in a total reaction volume of 25 µl.  
After 10 minutes of incubation at 37 oC for 10 minutes, the fragmentation 
reaction was stopped by placing the tube on ice.  
This method generates a more regular length of nucleic acids than the 
sonication process. However, DNase I fragmentation requires extra time and 
effort for optimization which affect its application in research work.  
  
3.3.4.2 Fragments precipitation 
The nucleic acid fragments were then purified in order to re-concentrate them 
and to remove salts from the fragmentation step, which may affect their 
labelling efficiency. Ethanol precipitation was used to fulfil this purpose.  
The sonicated solution was mixed with 1/10 of its volume with 3M sodium 
acetate (NaAc) and 2 volumes of 100% ethanol while the mixture of the 
products generated from amplicons digestion using DNase I were mixed with 
its ¼ volume of 10 M Ammonium acetate (NH4Ac) and 2.5 volumes of 100% 
ethanol. Both mixtures were incubated for 20 minutes at -80 oC followed 
directly by centrifugation at full speed (>15000 rpm) for 30 minutes at 4 oC. 
The supernatant was disposed and the pellet was washed with 70% ethanol and 
re-centrifuged for 15 minutes at the same above conditions. The nucleic acids 
sediment was eluted in 20 µl nuclease free water after discarding the 
supernatant. The fragmented amplicons were run on 1% agarose gel to 
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determine their size as described in section 3.3.2.5.3. Due to the small size of 
the amplified HPRT product (160 bp), the fragmentation step was considered 
not necessary.  
 
3.3.4.3 Labelling the fragmented amplicons 
The Platinum Bright Nucleic Acid Labelling Kit (Kreatech biotechnology) was 
used for labelling the viral nucleic acids in a one-step non-enzymatic 
fluorescent reaction. The principle of this kit is based on the presence of a 
universal linkage system (ULS) represented by the platinum complex which 
has the ability to bind to a fluorescein, dyomics 547 fluorescent dye or biotin as 
a marker or detectable group, through one of its two free binding sites.  
The marker/platinum complex binds to nucleic acids through a stable 
coordinative bond between the N7 atom of guanine base and the leaving group 
which represents the other free site of the ULS/complex. The leaving group 
will be displaced after reaction with the target biomolecules in the presence of 
the detectable molecule (figure 3-2). 
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Figure 3-2: Schematic drawing showing the working principle of the universal 
linkage system used for labelling nucleic acids. 
 
 
The amplified products were labelled by adding 2 µl of the ULS dye/1µg of 
nucleic acid and 1/10 volume of 10X labelling solution. The final volume was 
adjusted with nuclease free water for a minimum final concentration of 50 
ng/µl of nucleic acids solution. The mixture was incubated for 30 minutes at 85 
oC and then directly chilled on ice. The labelled materials were purified using 
the provided purification columns and centrifuged for 1 minute at 20800 xg. 
Based on the Nanodrop readings, the degree of labelling (DOL) was 
determined.   
Chapter Three                      Application of MDA for testing the designed viral microarray  
 
104 
  
The fragmented amplicons generated from the sonication step were labelled 
with dyomics 547 fluorescent dye while the amplified products sheared by 
DNase I were labelled with biotin dye. The different dyes would differentiate 
sample according to the fragmentation method used, and to use more samples 
in one experiment.   
 
3.3.4.4 Detection of the labelled amplicons using Southern blotting  
The labelled materials with biotin were subjected to southern blotting in order 
to detect their size and the labelling efficiency which may affect the microarray 
hybridization. Firstly, the amplified pTZ18R products were labelled with biotin 
dye as described in section 3.3.4.3 followed by running on 1% agarose gel as 
described in section 3.3.2.5.3. The gel was placed upside down onto a few well 
wetted layers of Whatman 3 MM filter paper supported by a small solid stage. 
A piece of nylon membrane (Amersham Hybond N) with similar dimensions to 
the agarose gel was put over the gel in order to transfer the separated bands of 
the labelled amplicons from the gel to the membrane. A few wetted sheets of 
Whatman 3 MM filter paper and a number of dry Quikblot papers (7-10) were 
assembled together and placed over the nylon membrane to provide an even 
surface for the best nucleic acids blotting and to prevent membrane flotation 
(figure 3-3).  
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Figure 3-3: Schematic drawing of the amplicons bands blotting. 
 
The blotting assembly was incubated overnight at room temperature in order to 
transfer the labelled bands from the gel to the membrane. The membrane was 
observed using a transilluminator in order to mark the ladder bands and then 
dipped in phosphate buffered saline (PBS) solution containing 0.02 % Tween 
20 (PBS-Tween) and 5 % milk for one hour followed by 3 times washing with 
PBS-Tween for 5 minutes each. Finally, the membrane was covered with a 
layer of diluted Streptavidin (1:7000) in PBS-Tween solution for 30 minutes 
and scanned using an infrared scanner after washing with PBS-Tween solution 
as above.  
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3.3.5 Manufacturing experimental microarrays 
In order to test the efficiency of the MDA technique and to optimize the 
experimental conditions for manual hybridization using the designed printed 
chip, microarray templates were constructed using sets of experimental probes 
for enterovirus and pTZ18R plasmid. 
 
3.3.5.1 Generation of the N-hydroxysuccinimide (NHS)-activated-
bovine serum albumin (BSA) coated slides    
3.3.5.1.1 Slide cleaning 
Glass slides were marked using a diamond marker, and then incubated in a 
solution of 16.1% ammonia and 11.7% hydrogen peroxide in water for 20 
minutes with gentle shaking. The slides were then washed 3 times using ultra-
pure water with gentle shaking each time for 5 minutes and spun for 3 minutes 
at 1100 rpm using a slide centrifuge. 
 
3.3.5.1.2 Coating the slides with aminosilane 
The cleaned slides were coated with aminosilane using a solution of 2% of 3-
aminopropyltriethoxysilane ethanol (APTS) and incubated for 30 minutes with 
shaking. The coated slides were washed 3 times with 100% ethanol and dried 
immediately using a slide centrifuge as above. Finally, the slides were baked in 
an oven at 130 oC for 45 minutes, cooled and stored at room temperature in a 
vacuum desiccator for further use. 
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3.3.5.1.3 Slide activation with N, N,-disuccinimidyl carbonate followed by 
coating with BSA  
Slides were activated in batches of 4 by soaking for 3 hours with shaking at 
room temperature in a solution of anhydrous N, N-dimethylformamide (DMF) 
containing 100 mM of each of N, N-disuccinimidyl carbonate and N, N-
diisopropylethylamine, then rinsed in absolute ethanol. The slides were then 
incubated overnight in PBS, pH 7.5 containing 1% BSA. The slides were then 
washed twice with ultrapure water followed by 100% ethanol. The dried 
activated slides were stored under vacuum or directly used in the next step. As 
a final step for preparing slides for microarray printing, the activated slides 
were subjected to a repeat activating step as described above. The slides were 
ready for microarray printing directly after rinsing with an absolute ethanol for 
4 times and drying using slide centrifuge, or can be stored in a vacuum 
desiccator for later printing.   
 
3.3.5.2 Spotting the experimental enterovirus microarray 
Six 30-mer oligonucleotides specific for enterovirus (ENTC 1-6) shown in 
table (3-3), in addition to a single probe for HPRT (table 3-4) designed by a 
previous PhD student (Abdel-Hakeem, 2010), were provided at a concentration 
of 100 µ0 E\ ³(XURILQV 0:* 2SHURQ´ DQG XVHG IRU FRQVWUXFWLQJ WKH
experimental enterovirus microarray. 
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Table 3-3: Sequences of the enterovirus probes used for printing the 
experimental enterovirus microarray.  
Adopted from (Abdel-Hakeem, 2010) 
Probe ID Target Sequence ¶-¶ 
ENTC1 ¶875 AGTCCTCCGGCCCCTGAATGCGGCTAATCC 
ENTC2 ¶875 AATCCTCCGGCCCCTGAATGCGGCTAATCC 
ENTC3 ¶875 TCTGTGGCGGAACCGACTACTTTGGGTGTC 
ENTC4 ¶ UTR TCCGTGGCGGAACCGACTACTTTGGGTGTC 
ENTC5 ¶875 TCTGCAGCGGAACCGACTACTTTGGGTGTC 
ENTC6 ¶875 GCGGAACCGACTACTTTGGGTGTCCGTGTT 
 
 
Table 3-4: Sequence of the HPRT probe used as internal positive control in 
the experimental microarrays.  
(Adopted from (Abdel-Hakeem, 2010) 
Probe ID 6HTXHQFH¶-¶ Position on gene 
HPRT AGAATGTCTTGATTGTGGAAGATATAATTG 550 - 579 
 
 
Two µl of each probe was diluted in 3X saline sodium citrate (SSC) and 1.5 M 
betaine to a final working concentration of 20 µM. Betaine was added to 
improve the binding efficiency and maintain the homogeneity of the 
oligonucleotides printed on the microarray slides. Each diluted probes was 
loaded sequentially in to a single well of the first column of a 384 well plate 
(16X24). The plate was located in the plate holder of the BioRobotics 
MicroGrid II 600 robot (Biogem) while the humidity inside the arrayer was 
adjusted to 70% in order to avoid evaporation of the printing buffer from both 
the source plate and the slide surface during the run.  
The desired probes were fabricated on the NHS-coated BSA slides in a 24 
(3x8) repeated grid layout using the robot split pin. Each grid consisted of 6 
rows (one per each enterovirus probe) of 12 spots each plus 34 spots of the 
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HPRT probe printed in columns on both grid sides, the left one with an arrow 
head (figure 3-4).  
 
 
Figure 3-4: Schematic drawing of the experimental enterovirus microarray. 
Figure (A) shows the printing layout of the 24 enterovirus grids on the microarray 
slide. Figure (B) represents a magnified diagram for one of the printed grids showing 
the spot locations represented in circles with a digit inside each one. Numbers from 1 
to 6 refer to the enterovirus probes while number 7 refers to the HPRT probe. 
 
 
 
The printing parameters such as spot numbers, their diameters, space between 
spots and the grid dimensions were defined using the Total Array System 
(TAS) application and saved in a comma-delimited format. Based on the 
comma delimited file, the GenePix array list (GAL) file was generated to be 
used later to determine the spot positions on the microarray slide during the 
scanning process. 
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3.3.5.3 Printing the experimental pTZ18R-enteroviral microarray  
A new experimental microarray containing the six enteroviral probes ENTC 1-
6, HPRT probe, and an additional set of twelve probes specific for pTZ18R 
plasmid was printed on NHS-coated BSA slides. Reverse complement software 
(http://www.bioinformatics.org/sms/rev_comp.html) was used to produce the 
second strand sequence of nucleotides (antisense) from the first strand 
sequence (sense) of the pTZ18R plasmid downloaded from the NCBI. Thus, at 
the end of this step two strands (sense and antisense) of the same size (2861 
nucleotides) were available and used to generate specific probes for the 
pTZ18R plasmid using OligoArray software as described in chapter 2. From 
the few dozens of 30-mer probes generated by the probe design process for 
each strand of the plasmid, twelve specific probes (six per each strand) were 
selected for printing an experimental microarray (table 3-5). The position of the 
selected probes was distributed at the beginning, middle and the end of each 
sequence of the plasmid strands. 
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Table 3-5: Characteristics of designed probes for printing the experimental pTZ18R-enteroviral 
microarray. 
 Probe ID Sequence Position ¶± ¶ Tm oC GC % 
Pl
a
sm
id
 
se
n
se
 
st
ra
n
d 
Plas1 CGAATTCCCTATAGTGAGTCGTATTAAATT 212-241 72.3 33 
Plas2 ATCCGCTCACAATTCCACACAACATACGAG 281-310 79.8 46 
Plas3 TAACTACGATACGGGAGGGCTTACCATCTG 1499-1528 79.6 50 
Plas4 CAGATTTATCAGCAATAAACCAGCCAGCCG 1574-1603 79.1 46 
Plas5 CTCCTTTCGCTTTCTTCCCTTCCTTTCTCG 2323-2352 79.8 50 
Plas6 ATGAGCGGATACATATTTGAATGTATTTAG 2492-2521 79.7 30 
Pl
a
sm
id
 
a
n
ti-
se
n
se
 
st
ra
n
d Plas7 TCCACTATTAAAGAACGTGGACTCCAACGT 156-185 78.7 43 Plas8 CGTAAAGCACTAAATCGGAACCCTAAAGGG 268-297 78.2 46 
Plas9 TATGGATGAACGAAATAGACAGATCGCTGA 1389-1418 76.8 40 
Plas10 CCAAGTTTACTCATATATACTTTAGATTGA 1458-1487 68.7 26 
Plas11 GTATTACCGCCTTTGAGTGAGCTGATACCG 2306-2335 79.4 50 
Plas12 GCGCAACGCAATTAATGTGAGTTAGCTCAC 2484-2513 79.6 46 
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The designed probes were synthesized and provided in a concentration of 100 
µ0E\³(XURILQV0:*2SHURQ´then printed in 24 (3x8) repeated grids using 
the BioRobotics MicroGrid II 600 robot (Biogem) as described in section 
3.3.5.2. The printing layout of the HPRT probes inside each grid was similar to 
that of the experimental enterovirus microarray while the probes of each of the 
enterovirus and pTZ18R were printed in rows of 6 spots in the middle area 
surrounded by the HPRT columns (figure 3-5).  
 
 
 
Figure 3-5: Schematic drawing of the experimental pTZ18R-enterovirus 
microarray. 
Figure (A) shows the printing layout of the 24 pTZ18R-enterovirus grids on the 
microarray slide. Figure (B) represents a magnified diagram for one of the printed 
grids showing the spot locations represented in circles with a digit inside each one. 
Numbers from 1 to 12 refer to the pTZ18R plasmid probes, numbers from 13-18 
represent the enterovirus probes while number 19 refer to the HPRT probe. 
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3.3.5.4 Post-printing slide processing 
The printed slides were subjected to post-printing processing steps included, 
incubation in 80% humidity for 10 minutes in order to maintain the precise 
shape of the spots. Then the slides were baked for 3 hours at 80 oC following a 
quick touch of the back slides to a hot plate at 120 oC.  
 
3.3.6 Manual hybridization of the experimental microarrays  
3.3.6.1 Prehybridization samples preparation  
In order to inhibit any non-specific binding of the labelled oligonucleotides to 
the printed slides, slides were blocked by submersion in a blocking solution 
containing 1% BSA, 5X SSC and 0.2% SDS, with shaking for one hour 
directly before starting the hybridization process. The excess salts were 
removed by washing the slides with ultra-pure water twice followed by dipping 
them in absolute ethanol and drying immediately using the slide centrifuge.  
Labelled nucleic acids as well as the internal positive control (HPRT) were 
precipitated using ethanol precipitation (as described in section 3.3.4.2), and 
resuspended in 60 µl hybridization buffer containing 2.4 M 
tetraethylammonium chloride (TEAC), 2% SDS, 2X SSC and 0.1 mg/ml 
lithium heparin.  
 
3.3.6.2 Hybridization technique 
The blocked printed slide was placed in the metal hybridization cassette 
(ArrayIt Company) such that the slide surface containing the printed probes 
was oriented upside.  
Chapter Three                      Application of MDA for testing the designed viral microarray  
 
114 
  
The cassette lid has a gasket on its inner surface which divides each slide 
surface into 24 (3X8) squares according to their printing layout, which enables 
separation of samples from each other when added to the slide surface (figure 
3-6).  
 
 
Figure 3-6: Metal 24 wells hybridization cassette. 
The microarray slide is placed in the slide holder base and fixed by the in front screw. 
The slide is covered with the slide holder cover and fixed by the 4 upper screws. The 
inner gasket of the slide holder cover will divide the slide into 24 blocks.   
 
 
One hundred µl of pre-warmed prehybridization buffer containing 0.1 mg/ml 
lithium heparin, 5X SSC and 0.2% SDS were loaded to each well of the 
hybridization cassette and sealed with a silicon mat to prevent evaporation. 
After 10 minutes of incubation at 40 oC with shaking, the prehybridization 
buffer was removed and the labelled amplicons suspended in the hybridization 
buffer were immediately loaded into a single well in an indexed way and 
sealed with same silicon mat.  
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The hybridization cassette was incubated at 40 oC for 8 hours or more (up to 
overnight) with shaking. Then, the hybridization cassette was washed 4 times 
with buffer A containing 2X SSC and 0.1% SDS, followed by two washes with 
buffer B containing 1X SSC and 0.1% SDS, and buffer C containing 0.1X SSC 
and 0.1% SDS for 3 minutes each. The final washing step was done once with 
buffer D containing 0.1% SSC only. Reducing the concentrations of the SSC 
during the post-hybridization washing process will increase the stringency of 
the washing buffer, lead to removal of the nucleic acids molecules attached 
loosely to the glass surface. This step helps in reducing the background noise 
which may affect detection of the generated hybridization signals during 
scanning the microarray slide.     
For those hybridization experiments using biotin labelled amplicons, a further 
blocking step of 30 minutes in PBS solution containing 0.01% Tween 20 and 
1% BSA was performed. In order to detect the signals generated from the 
hybridization between the biotin labelled nucleic acids and their 
complementary oligonucleotides, the arrays were incubated for 15 minutes in 
the same above PBS blocking solution containing (1:1000) streptavidin-
peroxidase, and washed 3 times with tris buffered saline 0.01% tween (TBST) 
followed by one time with ultrapure water.  
Two modifications were performed before starting hybridization using the 
experimental plasmid-enterovirus microarray. The first one was represented by 
skipping the purification step after MDA and moving directly to the 
fragmentation process as described in section 3.3.4.1.  
Mixing each one of the fragmented amplicons with one-fifth volume of the 
HPRT amplicon and labelled together in one reaction with the same dye, was 
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the second modification. Thus, each sample had an internal positive control 
during the hybridization process. 
 
3.3.6.3 Slide scanning  
A GenePix 4200AL autoloader scanner (Molecular Devices) was used to scan 
the slides after hybridization in order to detect the generated hybridization 
fluorescence signals. During the scanning process, an appropriate    wavelength 
of laser light (635, 532, 488, or 594 nm) was used to excite the labelling 
fluorescence dye linked to the nucleic acids. The wavelength of the utilized 
laser light was selected according to the optimal wavelength used for the 
excitation of the fluorophores which was determined by the company.  
The photo-multiplier tube (PMT) was calibrated for each array to determine the 
best emitted fluorescent signals of the hybridized viral nucleic acids. The laser 
power and the scan resolution were adjusted to 100% and 5-µm/pixel, 
respectively. The GenePix Pro software was used to determine the fluorescent 
intensities of the foreground and the background of the microarray slide after 
hybridization process. The values of the background intensity were subtracted 
from the mean values of foreground intensity, and the resulted values were 
used for data analysis of the microarray hybridization experiment. 
 
3.3.7 Quantification of the pTZ18R amplicons using 
mLFURSODWHÀXRUHVFHQFHDVVD\ 
For more accurate measurement of the amplified nucleic acid, SYBR Green I 
stain (Invitrogen) was used to quantify the amplified materials generated from 
MDA fluorescently with a microplate reader. One hundred microliters for six 
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different points of the DNA concentration standards ranging from 0-2 ng/µl 
were prepared from calf thymus DNA (Sigma) using double dilution technique 
in TE buffer (10 mM Tris/HCl, 1nM EDTA, pH 8.0) and loaded into the black 
96-well microplate (8X12). An equivalent concentration of the purified 
amplicons were diluted in 100 µl of TE buffer and loaded into another well of 
the same microplate. The final volume in each well of the DNA concentration 
standards and the amplified samples was adjusted to 200 µl/well by adding an 
equal volume (100 µl) of diluted SYBR Green I (1:1250) in TE buffer. After 
10 minutes of incubation in the dark at room temperature, the luminescence 
optic filter attached to the fluorescence microplate reader (Fluostar Omega, 
BMG Labtech) was used to measure the emitted fluorescence in each well. The 
fluorescence values of the DNA concentration standards were plotted against 
the known DNA concentrations in order to generate a standard curve in order 
to provide the actual concentrations of the DNA presented in the amplified 
materials by entering their fluorescence readings into the standard curve 
equation. The resulted value was multiplied by 50 to find the initial 
concentration of the amplified nucleic acid.    
 
3.3.8 Quantitative real time PCR (QPCR) 
The actual representation of the enteroviral nucleic acids in their amplified 
products was quantified using QPCR. Brilliant III Ultra-Fast SYBR Green 
QPCR Master Mix kit (Agilent Technologies, USA) was used for this purpose 
in combination with a set of universal primers designed by Dierssen et al 2008, 
for the detection of any type of human enteroviruses (Table 3-6).   
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Table 3-6: The sequences of the universal enterovirus primes designed by 
Dierssen et al 2008 and their product size 
Primer ID 6HTXHQFHCĺC Tm oC Amplicon Size 
Ent-1-FW ACATGGTGTGAAGAGTCTATTGAGCT 60 141 bp Ent-2-RV CGACCTTGACCATCTTTGGA 60 
FW=Forward primer, RV= Reverse primer   
 
A QPCR standard curve consisting of 6 points of 2 fold diluted concentrations 
of the enterovirus cDNA generated in section 3.3.2.3, starting with 6 ng/µl. 
Five microliters of each one of the diluted standard concentrations as well as 
the serially diluted amplicons generated from MDA process of the cDNA 
synthesized from RNA extracted from clinical sample known to be infected 
with enteroviruses, were added to the QPCR master mix consisting of 10 µl of 
2X SYBR Green QPCR master mix, 600 nM of the reference dye and 200 µM 
of each one of the enterovirus primers mentioned in table 3. Nuclease free 
water was used in order to adjust the final volume of each QPCR reaction to 20 
µl. The prepared QPCR samples were loaded in duplicate into the 
amplification microplate wells together with the no-template control sample 
(NTC: QPCR master mix containing 5 µl of nuclease free water instead of the 
target template) as an indicator for the assay quality as shown in figure 3-7.  
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Figure 3-7: Loading of the standard, unknown and NTC samples into the QPCR 
microplate wells. 
 
 
The microplate was sealed and placed in the Stratagene Mx 3000P machine, 
which was run according to the thermal profile shown in figure 3-8. 
 
 
Figure 3-8: Thermal profile used in QPCR 
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3.4 Results  
3.4.1 MDA results 
Viral cDNA was synthesized from the RNA extract of the Human echovirus 30 
transcript, using the random hexamers of the SuperScript III First-Strand 
Synthesis SuperMix kit. A second cDNA template was also generated from 
RNA extracted from an enterovirus infected stool sample using the Oligo dT 
primers of the µMACS one-step cDNA kit. MDA of the synthesized 
enteroviral cDNA using random primers of the REPLI-g UltraFast mini kit for 
90 minutes, generated an average around 2 micrograms of nucleic acids 
measured by Nanodrop after purifying them using the purification columns of 
the Qiaquick PCR purification kit. Nanodrop readings also revealed that the 
absorbance ratio of the purified products generated from MDA process was 
(1.8-2) at both wavelengths 260/280 and 260/230 nanometre, signifying their 
purity. Visible smeared bands with a variable size ranging between 700 bp and 
20 kb with some fragments which exceeded that size were revealed after 
running the purified MD amplified products on 1% agarose gel. A similar more 
bright smeared band with the same size range was observed with the negative 
control sample which contained nuclease free water instead of the cDNA 
template (figure 3-9). 
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Figure 3-9: Agarose gel electrophoresis of the amplified enteroviral cDNA 
generated by MDA technique for 1.5 hour at 30 oC. 
Viral RNAs extracted from H. echovirus-30 transcript (lane 1) and from a human stool 
sample (lane 2) known to contain an enterovirus were reverse transcribed into cDNA, 
amplified randomly using isothermal MDA at 30 oC for 90 minutes, purified using  
Qiaquick PCR purification columns and loaded into 1% agarose gel. Lane 3 of the 
gel was loaded with the materials generated from MDA of the negative control sample 
which contained nuclease free water rather than the viral cDNA. Smeared bands 
which exceeded 20 kb were revealed after running the gel. M represents the 1 kb plus 
DNA ladder. 
 
 
 
3.4.2 Amplicon fragmentation results 
Different sizes of shorter segments between 200 bp and 1000 bp were 
generated from the fragmentation process of all three of the MD amplicons 
using 3 cycles of ultrasounds emitted from the Soniprep 150 MSE sonicator 
which were visualized as smeared bands when running them on 1% agarose gel 
after purifying them using ethanol precipitation (figure 3-10).  
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Figure 3-10: Agarose gel electrophoresis of the fragmented enteroviral 
amplicons. 
The amplified products generated from MDA of the H. echovirus-30 (lane 1), human 
stool sample (lane 2) and negative control sample (lane 3) were sonicated for 3 cycles 
of 1 minute each, using amplitude 5 of the Soniprep 150 MSE sonicator, purified 
using ethanol precipitation and run in a 1% agarose gel which illustrated smeared 
bands of (200 ± 1000) bp. M represents the 100 bp DNA ladder.    
 
 
 
3.4.3 HPRT-PCR results  
A PCR product of a part of the HPRT gene with the expected target size (160 
bp) was generated from the extracted human DNA, using specific primers 
(table 3-1), in order to be used as an internal positive control through testing 
the experimental enterovirus microarray (figure 3-11). 
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Figure 3-11: Agarose gel electrophoresis of the HPRT PCR products. 
Part of the HPRT gene was amplified in quadruplicate from extracted human DNA 
using PCR. The amplified products were purified and loaded in lanes 1-4 of the 1% 
agarose gel which revealed single specific band with the expected size of 160 bp for 
each product. Lane 5 was loaded with the PCR negative control sample which 
contained nuclease free water instead of the human genome sample. M shows the 
3000 bp DNA ladder.   
     
 
3.4.4 Labelling results 
The fragmented amplicons of the H. echovirus-30, the clinical sample of 
enterovirus, the MDA negative control and the PCR products of the HPRT 
were labelled with dyomics 547 fluorescent dye before starting the 
hybridization experiment. The efficiency of the labelling process was 
determined through calculating the DOL value (amounts of dye per 100 
nucleotides) for each labelled sample using their nanodrop readings (figure 3-
12) and the following equation recommended by the Kreatech Biotechnology 
Company:  
 
Chapter Three                      Application of MDA for testing the designed viral microarray  
 
124 
  
DOL (Labelling %) = 340 x pmol (dye) /ng (nucleic acids) x 1000 x 100 % 
The resultant DOL of the labelled nucleic acids generated from the MDA was 
within the recommended value (<4.5%), also their absorbance ratio at 260/280 
nanometre wavelength was >1.8 as displayed in the nanodrop results.  
 
 
Figure 3-12: Example of the nanodrop plots of the HPRT amplicon labelled 
with dyomics 547 fluorescent dye.   
The peak highlighted with the black arrow refers to the successful labelling process. 
The black rectangle displays the concentration of the labelled nucleic acids in ng/µl, 
and their purification ratio at 260/280 nanometre. The nanodrop also measured the 
fluorescent dye concentration in each microliter which was used for determining the 
labelling efficiency of the labelled nucleic acids. Similar labelling plots were 
generated for other enterovirus amplicons.    
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3.4.5 Hybridization results of the experimental enterovirus 
microarray 
The first trial of nucleic acid hybridization was done by loading the labelled 
amplified products derived from the H. echovirus-30, clinical enterovirus, 
HPRT and the negative control samples separately into the printed grids of the 
enterovirus microarray slide fixed in the hybridization cassette. Scanning the 
microarray slide at the end of the hybridization process using the GenePix 
scanner revealed clear hybridization signals generated only between the 
labelled amplicons of the HPRT and its complementary designed probe, 
displayed as red regular bright spots with an arrow shape on the left side and 
single column on the right side of the printed grid loaded with the HPRT 
amplicons. Neither the labelled amplified enterovirus samples nor the negative 
control loaded into the other three grids of the microarray showed any 
discernible signals for hybridization reaction with their relevant nor any other 
probes during the scan (figure 3-13).  
Given the failure of the above MD amplicons to hybridize with microarray 
probes, the experiment was repeated (4 times) starting from the original viral 
RNA sample, proceeding through cDNA synthesis, MDA, sonication and 
labelling as describe above. In addition, a Human coxsackievirus-A16 RNA 
transcript (also provided by Professor Peter Simmonds) was also prepared by 
the same way and used in hybridization reaction. Each one of the new labelled 
amplicons was mixed with one-fifth volume of the labelled HPRT-PCR 
products. These further trials of hybridization also generated hybridization 
signals with the HPRT probes only.  
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Figure 3-13: Hybridization reaction results of the labelled amplified products 
with the experimental enterovirus microarray as seen on the GenePix laser 
scanner. 
Figures A, B and D represent scanned images of the three grids loaded with the 
labelled MD amplified materials of each of the H. echovirus-30, clinical enterovirus 
and the negative control, respectively, showing no signals with any of the printed 
probes. Figure C: The grid loaded with labelled HPRT amplicons shows fluorescent 
signals generated from hybridization reaction with the printed HPRT probes only, 
which appear as identical red spots arranged in the same shape of the HPRT printing 
layout.  
 
 
3.4.6 Optimizing MDA/hybridization process using pTZ18R 
plasmid 
The low copy number or/and the short length of some of the viral RNA 
segments in both the viral positive controls and the clinical samples would be a 
challenge for the successful of their full length amplification using MDA 
technique. This challenge might be the reason for the failure of acquiring 
visible spots from the hybridization trials using the experimental enterovirus 
microarray.  
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Plasmids became the most ubiquitous instrument used in the molecular biology 
field which can provide a pattern of nucleic acids sequence with a high copy 
number due to their easy cultivation and manipulation. Therefore, it was 
decided to further develop the MDA/hybridization protocols using plasmid 
DNA, which could be produced in large copy number and hopefully act as a 
positive control instead of viral samples for optimizing the microarray 
hybridization reaction.       
    
3.4.6.1 Plasmid digestion results: 
The pTZ18R plasmid is circular dsDNA. Therefore, it was digested using SapI 
enzyme in order to generate a linear template suitable for WGA using MDA 
technique. SapI cut the circular plasmid at the recognition site (470-476 bp) 
and convert the plasmid into linear form (see figure 3-1). This step generated 
0.6 µg of linear DNA which was observed as a clear specific single band with 
the same length (2861 bp) of the circular plasmid when running on 1% agarose 
gel after purification (figure 3-14).   
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Figure 3-14: Agarose gel electrophoresis of the digested pTZ18R plasmid. 
The 2861 nt circular pTZ18R plasmid was digested using SapI restriction enzyme 
which cut the circular plasmid at a specific recognition site and generated linear 
product of DNA with the same length as the undigested plasmid. The circular and the 
digested plasmid were loaded in lanes 1 and 2 of the 1% agarose gel which illustrated 
a smeared band in lane 1, and single band of 2681 bp for lane 2. Lane 3 was loaded 
with negative control sample which contained nuclease free water instead of the 
pTZ18R plasmid. M represents the 1 kb DNA ladder.  
 
 
 
3.4.6.2 Plasmid transcription results: 
Transcription of the digested pTZ18R plasmid started through binding of the 
T7 RNA polymerase to the T7 promoter site located upstream of the 
WUDQVFULSWLRQ LQLWLDWLRQ VLWH QHDU WKH ¶ HQG (see figure 3-1). This process 
generated § 30 micrograms of plasmid RNA. Nanodrop measurement of the 
transcribed RNA at both wavelengths 260/280 and 260/230 nanometre was 2.1, 
signifying an accepted purity.  
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Analysing the pTZ18R RNA generated from the transcription step, using 
Agilent 2100 Bioanalyzer revealed a single band with the expected size 2611 nt 
(figure 3-15-A). The electropherogram of the plasmid RNA also revealed the 
expected size of the transcribed RNA (figure 3-15-B).  
 
 
 
Figure 3-15: Electropherogram generated from analysis of the plasmid RNA 
using Agilent 2100 Bioanalyzer showing the quality of the transcribed RNA.   
The electropherogram of the plasmid RNA (red colour) was aligned to the 
electropherogram of the Agilent RNA 6000 Nano marker (black colour) in order to 
elucidate the expected size of the transcribed RNA.  
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3.4.6.3 MDA results of the pTZ18R:  
A different amplification kit (QuantiTect whole transcriptome kit) was used for 
MDA of the transcribed RNA of the pTZ18R plasmid and 2 other viral RNA 
templates extracted from the H. echovirus-30 transcript and an infected clinical 
sample with enteroviruses, respectively. Three sequential reactions were 
performed using this kit which started with reverse transcription of each one of 
the above RNA templates into first strand cDNA followed by ligating the 
generated fragments of each cDNA together and finished with MDA of the 
ligated cDNA templates. The generated MD amplicons were purified using 
Qiaquick PCR purification kit. According to the Nanodrop results, this process 
generated low concentration of amplicons for each of the above RNA 
templates. Agarose gel electrophoresis showed 3 faint smeared bands with 
variable length starting from 2000 bp to up to more than 20 kb while the 
negative control sample did not show any visible band (figure 3-16).  
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Figure 3-16: Agarose gel electrophoresis of the amplified pTZ18R plasmid and 
enteroviral RNA using Whole transcriptome kit. 
The transcribed pTZ18R RNA (lane 1), enteroviral RNA extracted from the H. 
echovirus-30 transcript (lane 2) and human stool sample known to contain an 
enterovirus (lane 3) were reverse transcribed into cDNA for 30 minutes at 37 oC. The 
cDNA products were ligated together for 2 hours at 22 oC followed by MDA for 2 
hours at 30 oC. The MD amplicons were purified using purification columns of the 
Qiaquick PCR purification kit. Only faint smeared bands exceeding 20 kb were 
seen after running the gel. Lane 4 of the gel was loaded with the materials generated 
from the MDA of the negative control sample contained nuclease free water rather 
than RNA template. M represents the 1 kb plus DNA ladder. 
 
 
 
Running the amplified products generated in section 3.3.3.2 on 1 % Agarose 
gel without a purification step showed high concentrations of nucleic acids 
revealed as 3 bright smeared bands for each one of the amplified RNA 
templates, and for the negative control. The smeared bands were variable in 
size starting from 1500 bp and exceeding 20 kb with additional products which 
did not run through the gel due to their larger size (figure 3-17). 
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Figure 3-17: Agarose gel electrophoresis of the unpurified amplicons generated 
from MDA of the pTZ18R plasmid and enteroviral RNA using Whole 
transcriptome kit. 
The amplified materials generated in section 3.3.3.2 were excluded from the 
purification step after MDA reaction and run directly on 1% agarose gel. The pTZ18R 
amplicons were loaded in lane 1 while viral amplified products of the H. echovirus-30 
and clinical sample were loaded in lanes 2 and 3 of the gel, respectively. Lane 4 of the 
gel was loaded with the materials generated from the MDA of the negative control 
sample containing nuclease free water rather than RNA template. M represents the 1 
kb plus DNA ladder. 
 
 
 
This indicates that MDA of the ligated nucleic acid segments using QuantiTect 
whole transcriptome kit generated long strands of highly branched complicated 
amplicons which GRQ¶W SDVV WKURXJK WKHSXULILFDWLRQFROXPQZLWK WKHHOXWLRQ
solution. Therefore it was decided to skip purifying the amplicons generated 
from MDA technique, and to proceed directly to the sonication step. 
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3.4.6.4 Hybridization results of the experimental plasmid- 
enteroviral microarray using the sonicated amplicons.  
The amplicons of the pTZ18R, H. echovirus-30, clinical stool sample and 
negative control generated from MDA using QuantiTect whole transcriptome 
kit, were fragmented directly using sonication techniques, and then purified 
using ethanol precipitation method. Each one of the above fragmented 
amplicons was mixed with one-fifth volume of the HPRT-PCR products, and 
then labelled with dyomics 547 fluorescent dye in order to be tested in 
hybridization reaction. Each labelled mixture was loaded into a single printed 
grid of the experimental plasmid-enterovirus microarray slide fixed in the 
hybridization cassette. 
Uniform red spots with the same layout of the printed HPRT probes were 
revealed after scanning the experimental plasmid-enteroviral microarray slide 
at the end of the hybridization process. These spots reflect the specific 
hybridization reaction between the HPRT products and their complementary 
probes printed in the grids loaded with above labelled amplicons. No other 
discernible spots were seen with the other printed probes of both of the 
pTZ18R and the enteroviruses, indicating their hybridization failure (figure 3-
18). 
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Figure 3-18: Hybridization reaction results of the labelled amplified products 
with the experimental plasmid-enterovirus microarray as seen on the GenePix 
laser scanner. 
Figures A, B, C and D represent scanned images of the four grids loaded with the 
labelled amplified materials of each of the pTZ18R plasmid, H. echovirus-30, clinical 
enterovirus and the negative control sample, respectively. Each figure shows 
fluorescent red signals generated from hybridization of the HPRT products with their 
complementary printed probes. The other printed probes for both the pTZ18R and the 
enteroviruses did not show any specific hybridization signal against their related 
amplicons loaded into this microarray.  
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3.4.6.5 Fragmentation results using DNase I 
One probable reason for the failure of the hybridization reaction in the previous 
experiments is the random fragmentation of the amplified materials caused by 
using the sonication technique which may leads to generate uneven lengths of 
nucleic acids fragments lacking part or all of the complementary sequence of 
the probes. Therefore, it was decided to fragment the MD amplicons using 
DNase I instead of sonication, and test the fragmented products in a 
hybridization reaction. 
The amplified products of the pTZ18R generated from MDA using QuantiTect 
whole transcriptome kit were sheared directly using DNase I as another method 
for nucleic acid fragmentation. This process was performed through incubating 
1 µg of the amplicons generated from MDA of the pTZ18R, with DNase I 
(0.0004 unit per reaction), at 37 oC for 10, 20, 30 or 40 minutes, in order to set 
the best conditions for the fragmentation. Running the products generated from 
the fragmentation reaction at the above selected times; revealed 4 smeared 
bands with variable length (figure 3-19). Forty minutes of incubation at 37 oC 
was the optimal time for shearing the vast majority of the pTZ18R amplified 
materials generated from MDA, which accumulated between 75-500 bp. The 
amplicons of each of the H. echovirus-30, clinical sample and negative control 
generated from MDA using QuantiTect whole transcriptome kit, were 
fragmented by DNase I using same above conditions. 
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Figure 3-19: Agarose gel electrophoresis of the pTZ18R products generated from 
the fragmentation process using DNase I at different times. 
One µg of the pTZ18R amplicons were treated with 0.0004 unit of DNase I and 
incubated at 37 oC for 10, 20, 30 and 40 minutes. The generated fragmented materials 
at the end of the above times were loaded in lanes 2-5, respectively. Lane 1 was 
loaded with the unfragmented pTZ18R amplicons for a comparison purpose. M 
represents the 1 kb plus DNA ladder. 
 
 
 
3.4.6.6 Blotting results of the biotin labelled amplicons: 
The amplified products of the pTZ18R, H. echovirus-30, clinical sample and 
negative control generated from MDA process using QuantiTect whole 
transcriptome kit were directly fragmented using DNase I. The fragmented 
amplicons were purified using ethanol precipitation and then labelled with the 
universal linkage system attached to a biotin molecule as a marker group 
through a non-enzymatic reaction called biotinylation. Biotinylation is a non-
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fluorescent labelling process which its efficiency cannot be detected using 
nanodrop measurement process.  
In order to evaluate the labelling efficiency with the biotin dye, the biotinylated 
amplicons were run on 1% agarose gel. Scanning the gel at this step using 
ultraviolet light, showed only the segments of the ladder which was used as a 
marker for the size of the labelled amplicons, with no other visible bands. After 
blotting the gel on a nylon membrane, the membrane was treated with 
streptavidin solution. Scanning the nylon membrane containing blot, using 
infrared scanner revealed 4 green smeared bands of biotinylated amplicons 
with variable size ranging from <500 bp up to 3000 bp referring to the  Success 
of the labelling process (figure 3-20). 
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Figure 3-20: Agarose gel electrophoresis of the biotinylated amplicons blotted on 
a nylon membrane as seen under infrared scanner. 
The amplicons generated from MDA of the RNA of each of pTZ18R (lane 1), H. 
echovirus-30 (lane 2), infected clinical sample with enteroviruses (lane 3) and 
negative control (lane 4) using QuantiTect whole transcriptome kit, were 
fragmented using DNase I and run on 1% agarose. The gel was then blotted on a 
nylon membrane followed by treating the membrane with streptavidin. The membrane 
containing the blot was then scanned using infrared scanner. M represents the 1 kb 
DNA ladder. 
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3.4.6.7 Hybridization results of the experimental plasmid- 
enteroviral microarray using the biotinylated amplicons.  
Due to the failure of the sonicated MD amplicons to hybridize with probes of 
the experimental plasmid-enteroviral microarray, another hybridization 
experiment was performed using the fragmented amplicons of the pTZ18R, H. 
echovirus-30, infected clinical sample with enteroviruses and negative control 
amplicons generated from DNase I reaction. The fragmented amplicons were 
purified using ethanol precipitation, mixed with one-fifth volume of the HPRT-
PCR products and then labelled chemically with biotin using the ULS system. 
The biotinylated mixtures were loaded into a new experimental plasmid-
enteroviral microarray slide to start hybridization reaction. The microarray 
slide was treated with the streptavidin-peroxidase diluted in PBS blocking 
solution (1:1000) at the end of the hybridization process and scanned using 
GenePix scanner after washing the slide with TBST. The outcome of this 
hybridization experiment was quite similar to the results of the previous 
hybridization trials generated from using the sonicated amplicons, as the 
hybridization signals were only generated with the HPRT probes which 
displayed as regular red spots arranged in the same printing layout of the 
HPRT probes (as presented previously in figure 3-18).    
     
 
 
 
Chapter Three                      Application of MDA for testing the designed viral microarray  
 
140 
  
3.4.6.8 Amplicon quantification using microplate fluorescence 
assay:    
A microplate fluorescence assay was used to determine the actual 
concentration of the nucleic acids represented in the pTZ18R, H. echovirus-30, 
clinical sample and negative control amplicons generated from MDA using 
QuantiTect whole transcriptome kit in section 3.3.3.2. A standard curve was 
created by linking the 7 known serially diluted concentrations of calf thymus 
DNA against their generated fluorescence values using an excitation/emission 
filter fixed to a fluorescent microplate reader. The fluorescence readings from 
the amplified material emissions were inputted into the standard curve equation 
in order to determine their concentrations (figure 3-21). The concentration of 
the materials generated from the negative control sample amplification was 
half the concentration of the pTZ18R amplicons, and double the amount of 
both of the H. echovirus-30 and the clinical enterovirus amplicons. 
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Figure 3-21: Microplate fluorescence assay calibration results of the products 
generated from MDA. 
Double diluted concentrations ranging from 0-2 ng/µl (blue points) were prepared 
from calf thymus DNA, and used to generate a standard curve (blue linear line). The 
fluorescence emissions of the pTZ18R, H. echovirus-30, clinical sample and negative 
control products generated from MDA using QuantiTect whole transcriptome kit, 
were blotted on the standard curve as red spots numbered from 1-4, respectively, in 
order to determine their DNA concentrations.  
 
 
3.4.7 Target amplification using GenomePlex complete WGA 
kit:  
Given the disappointing results of the experimental hybridization trials using 
MD amplicons it was decided to try a different approach for amplifying target 
nucleic acids. GenomePlex complete WGA kit was used to amplify cDNA 
derived from the pTZ18R, H.echvirus-30 and the clinical enterovirus samples 
through three successive reactions started with fragmenting the cDNA 
templates into shorter products with an average size 400 bp. During the second 
reaction, the generated small fragments will be converted into amplifiable 
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library molecules ending with universal priming sites in a process called library 
preparation. Finally, WGA-DNA polymerase will start extending the universal 
oligonucleotide primers (multiple primers) annealed to the resulted library 
molecules in 14 cycles of denaturation at 94 oC for 15 seconds followed by 
primers annealing and extension for 5 minutes at 65 oC using thermal cycler, 
which generated massive quantities of the amplified materials (figure 3-22). 
 
 
 
Figure 3-22: Schematic diagram showing the amplification steps of the target 
nucleic acids using GenomePlex complete WGA kit. 
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Nanodrop readings revealed that this technique generated 10 times more 
concentrations of amplicons (>20 µg) than the REPLI-g UltraFast mini kit and 
the QuantiTect whole transcriptome kit. The purity ratio of the amplified 
materials generated from the amplification process using GenomePlex 
complete WGA kit was equivalent to that of MD amplicons produced in 
sections 3.3.3.1 and 3.3.3.2. The size of the generated amplified materials 
ranged between 200-1000 bp as illustrated from the Agarose gel 
electrophoresis image which showed 3 bright smeared bands for each one of 
the above samples. No product was generated from the amplification process of 
the negative control sample as it did not show any visible band when it was run 
through the gel (figure 3-23).  
Since the vast majority of the generated amplicons have an average size 
between 200-500 bp, they were excluded from the fragmentation step, purified 
using Qiaquick PCR purification kit, mixed with one-fifth volume of the 
HPRT-PCR products and labelled with the dyomics 547 fluorescent dye. 
Hybridization process of the pTZ18R, H.echvirus-30 and the clinical 
enterovirus labelled amplicons with the experimental plasmid-enteroviral 
microarray also generated hybridization signals with the HPRT probes only 
displayed as red spots while pTZ18R and enteroviral probes did not show any 
discernible hybridization signals (figure 3-18).      
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Figure 3-23: Agarose gel electrophoresis of the amplified materials generated 
from amplification process using GenomePlex complete WGA kit.  
The cDNA template produced from the reverse transcription step of each of the 
pTZ18R, H. echovirus-30 and clinical enterovirus RNA was randomly fragmented 
into small PCR-amplifiable chunks of 100-1000 bp followed by PCR amplification 
using WGA DNA polymerase. The generated amplified materials of the negative 
control, H. echovirus-30, clinical enterovirus and pTZ18R were loaded in lanes 1-4 
respectively. M represents the 1 kb plus DNA ladder. 
 
 
3.4.8 Quantitative real time PCR (QPCR) results: 
The generation of the high molecular weight amplicons during MDA of the 
negative control sample is attributed to the polymerization of the random 
hexamers by Phi 29 DNA polymerase, according to the consultation of the 
amplification kits manufacturer. Primers polymerization may interfere with the 
MDA of the target nucleic acid and generate mixture of amplicon different 
from the original nucleic acid, and lead to hybridization failure. Therefore, it 
was decided to evaluate the efficiency of the MDA to generate specific 
amplicons representing the original target. 
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QPCR was used for this purpose through determining either the concentration 
or the copy number of a part of the enterovirus genome before and after MDA. 
Specific primers targeting a particular sequence (142 bp) of the enterovirus 
genome were used for this purpose. Therefore, the enterovirus amplicons 
generated from the MDA were re-amplified in parallel with 6 double diluted 
concentrations of the original enterovirus cDNA, following the PCR principles. 
The fluorescence emission generated from the excited nonspecific fluorescent 
dye (Sybrgreen) which binds to any dsDNA, was measured using a sensor 
fixed to the PCR machine. The fluorescence readings were analysed using the 
MxPro-Mx3005P software which calculates the concentration of the selected 
part of the enterovirus genome in both the cDNA template and the amplified 
materials generated from the MDA reaction. 
The software generated a linear amplification curve between the 6 standard 
concentrations prepared from the enterovirus cDNA, and their threshold cycle 
(Ct) values. The software also plotted the Ct values generated from 2 of the 
serially diluted enterovirus MDA products on the QPCR standard curve which 
illustrated that the absolute concentration of the enterovirus nucleic acids 
presented in the MDA products was one twenty fifth the total concentration of 
these MDA products. Both of the efficiency factor and the R square (R2) values 
were within the recommended level indicating the satisfactory performance of 
the QPCR (figure 3-24).  
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Figure 3-24: Standard curve of the enterovirus QPCR used for determining the 
copy number of the enterovirus nucleic acids in their amplified materials 
generated from MDA.  
A QPCR standard curve was created from 6 double diluted standard concentrations 
(St1-St6) of the enterovirus cDNA starting from (6 ng/µl) using MxPro-Mx3005P 
software which linked each concentration versus its relevant Ct value. The resulted 
standard curve was used to quantify the enterovirus nucleic acids concentration in the 
serially diluted MDA products (MDA1-MDA4) starting from 1000 ng/µl. The 
enterovirus   nucleic acids were only detected in the second and third dilutions (100 & 
10 ng/µl) of the MDA products with a quantity representing one twenty fifth the 
quantity of the amplified materials generated from MDA process. The first and fourth 
dilutions of the enteroviruses nucleic acid were not quantified by the QPCR due to 
their very high and very low concentrations, respectively.   
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The QPCR amplification plots shows the logical inversely correlation between 
the standard concentrations (St1-St6) and their Ct values which increased with 
the diminution of these concentrations. The QPCR amplification plots of the 
enterovirus MDA products revealed that their Ct values were similar to the Ct 
value of the enterovirus cDNA template before MDA process which is 
opposite the expected (figure 3-25).  
This QPCR experiment indicates that the enterovirus cDNA was not amplified 
during MDA, and the high molecular weight product generated from this 
process was resulted from the random hexamers polymerisation which can 
predominate on the MDA of the target enterovirus cDNA.  
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Figure 3-25: Amplification plots of the enterovirus QPCR. 
The first 6 figures represent the amplification plots of the 2-fold standard 
concentrations (St1-St6) prepared from the enterovirus cDNA synthesized in section 
3.3.2.3, showing an increasing in the amplification Ct value associated with 
decreasing the quantities of the enterovirus cDNA template required to start the 
QPCR. The last 2 figures in the bottom represent the amplification plots of only 2 
serially diluted concentrations prepared from the enterovirus MDA products (MDA2, 
MDA3) which were detected by the QPCR, showing that their Ct values were similar 
to the Ct value of the unamplified enterovirus cDNA template.    
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3.5 Discussion:  
Nucleic acid microarray hybridization is a sequential multistep technique. Any 
defect in the preparation of the target samples during each step may affect the 
next step and lead to hybridization failure (Majtan et al., 2004, Kumar, 2009). 
It was necessary to evaluate the performance of sample preparation at the end 
of each step before starting the following one in order to avoid wasting time, 
efforts and costs, and to get reliable results. Therefore, an optimization process 
was done for all of the proposed steps required for sample preparation prior to 
use the main virochip designed in chapter 2, using experimental microarrays 
printed in the laboratory. 
Manufacturing the viral nucleic acids microarray starts with the spotting of the 
viral oligonucleotides or probes which were designed particularly for the 
diagnosis of the target viruses which suspected to be the causative of the viral 
infections. Since the six enterovirus probes designed by Abdel-Hakeem, 2010 
have the same length (30-mer) and GC ratio ( 50 %) of the viral probes 
designed in chapter 2, they were selected for fabricating the experimental 
enterovirus microarray in order to be used for optimizing the microarray 
hybridization process of the virochip. 
 
3.5.1 Sample preparation: 
Microarray-based assays for the diagnosis of viral infections depend on the 
detection of viral nucleic acid in infected clinical samples (Hadidi et al., 2004, 
Liu et al., 2006, O'Connell et al., 2006, Guan et al., 2008, Yoo et al., 2009). 
Enteroviral RNA was extracted from a clinical sample known to be infected 
with enteroviruses in order to be used in addition to other two enterovirus RNA 
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transcripts (H.echo-30 and H. coxsackievirus-A16) for optimizing the 
hybridization process using the experimental enterovirus microarray. There are 
many obstacles preventing using RNA extracts directly for nucleic acid 
microarrays including their low concentration especially when using low 
biomass samples, and their susceptibility for degradation due to their fragile 
structure (single strand of nucleic acids, (Watson et al., 1998, Puskas et al., 
2002, Wu et al., 2006).  
Amplification of the nucleic acid has therefore now become a widespread 
method used to provide adequate amounts of nucleic acid required for different 
types of genetic analysis including microarray (Bowtell, 1999, Geiss et al., 
2000, Hughes et al., 2001, Mori et al., 2002, Nygaard et al., 2003). 
 
3.5.2 cDNA synthesis: 
The extracted viral RNA was reverse transcribed into cDNA in order to 
provide the required template for DNA polymerase to start the amplification 
process. Both of the Oligo dT and random primers were used to synthesize the 
cDNA template from the mRNA and the total RNA, respectively. 
The fragile structure of extracted RNA makes it vulnerable for degradation and 
depletion during this process which may generate short fragments of cDNA 
(Wang, 2005). Reverse transcription reaction generates single strand of DNA 
complementary to the extracted RNA, which is also susceptible for degradation 
during any further step. The expected short lengths and the little quantities of 
the synthesized cDNA which is equivalent to the RNA template, led to exclude 
the cDNA products from the purification step in order to avoid its degradation 
and losing it (according to the personal communication with Invitrogen 
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technical services). For the above reasons, it was not possible to evaluate the 
quality or quantify the synthesized cDNA in the existence of the reaction 
components (primers, dNTPs, cations and the reverse transcriptase).     
  
3.5.3 Amplification of the viral cDNA: 
Use of MDA for amplifying the nucleic acids is a debatable issue. Many 
studies described it as an optimal alternative technique to all conventional 
methods used for genetic profile analysis of different organisms as it can 
provide the required amounts of nucleic acids for many genome projects, from 
its tiny initial concentrations (Dean et al., 2001, Dean et al., 2002, Hosono et 
al., 2003, Luthra and Medeiros, 2004, Bergen et al., 2005, Monstein et al., 
2005, Maragh et al., 2008). Therefore, MDA technique using DNA polymerase 
derived from Bacillus subtilis bacteriophage Phi 29, and the random primers, 
were selected for amplifying the viral genome in order to provide adequate 
amounts of desired viral nucleic acids for the microarray-hybridization 
experiment.  
REPLI-g Ultrafast mini kit was used to amplify the enteroviral cDNA based on 
the MDA principle, which was efficient in generating high molecular weight 
amplicons for the target enterovirus nucleic acids. High molecular weight 
products were also generated from MDA of the negative control sample using 
the above kit, which displayed as a smeared band having the same size of the 
enteroviral amplicons on the agarose gel.  
This high molecular weight product was generated in all trials of the MDA of 
the negative control sample prepared from different sources of nuclease free 
water, using different lots of the Repli-g amplification kit in different 
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laboratories which is attributed to the polymerization of the random hexamers 
during MDA of the negative control sample. The low numbers of the priming 
sites available in the tiny concentrations of the target template, which can be 
used for random primers annealing allows forming the primer dimers which 
can serve as a template for Phi 29 DNA polymerase and leads to a nonspecific 
amplification with high rate of bias causing hybridization failure (Uda et al., 
2007, Abdel-Hakeem, 2010) .  
Barber and his colleague (Barber and Foran, 2006) indicated that MDA of 
short fragments of nucleic acids using Phi 29 DNA polymerase will generate 
shorter forks of nucleic acids along these short fragments with less priming 
sites end with a complicated branched amplicon not representing the entire 
genome. Shoaib and his colleagues (Shoaib et al., 2008) suggested that ligation 
of the short fragments of nucleic acids will generate long linear template with 
lots of priming sites, which may generate more specific amplicons.  
QuantiTect whole transcriptome kit was used as an alternative method for 
MDA of the desired viral genomes starting from their RNA which was reverse 
transcribed into cDNA followed by ligation of the generated cDNA segments 
in order to generate long linear template to provide more priming sites ready 
for annealing with the random hexamers to be amplified by Phi 29 DNA 
polymerase. High molecular weight products were generated from both of viral 
genomes and negative control samples.  
Due to the high molecular weight (> 20 kb) of the complex MDA product 
generated from MDA using QuantiTect whole transcriptome kit, the vast 
majority of the amplicons were retained in the purification column and did not 
pass through the elution step. Therefore, these amplified materials were not 
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purified, but were fragmented directly in order to overcome this problem. 
Random ligation of the generated cDNA fragments prior to MDA may 
generate linear product with chunks of sequence different from the sequence of 
the original template, which may enhance the representational bias in the 
amplified materials (Ho-Pun-Cheung et al., 2009).  
GenomePlex complete WGA kit was used as a third technique for amplifying 
viral genome based on fragmenting and converting viral nucleic acids into 
amplifiable molecules before starting amplifying them using WGA-DNA 
polymerase. This kit was efficient in generating amplicons with an average size 
of 500 bp ready for hybridization experiment without need for sonication step 
or endonuclease treatment.  
 
3.5.4 Fragmenting viral amplicons 
Adoption of the MDA principle for amplifying viral genomes using either 
REPLI-UltraFast mini kit or QuantiTect whole transcriptome kit generated 
high molecular weight products. These bulky amplicon molecules will either 
fail to hybridize to oligonucleotides on the solid surface due to spatial and 
steric limitations, or may generate noisy background that may conceal the weak 
signals of the specific hybridization (Shchepinov et al., 1997, Southern et al., 
1999, Vora et al., 2004). Therefore, it was necessary to fragment the amplicons 
generated from MDA before going ahead with the hybridization experiment, 
which may facilitate their access to the target probes and enhance successful 
hybridization opportunities (Dai et al., 2002, Mehlmann et al., 2005).  
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3.5.5 Labelling viral amplicons 
Labelling nucleic acids with detectable molecules is the most common way 
used for the detection of the successful microarray hybridization with their 
complementary printed oligonucleotides. Chemical labelling technique using 
Platinum based ULS was selected for this purpose due to its easy application 
within short time (40 minutes), low cost, no modification in the target 
structure, indefinite stability of the labelled materials and no interference or 
variation in the hybridization results (Alers et al., 1999, Hagedoorn et al., 2003, 
Majtan et al., 2004, Abdel-Hakeem, 2010).   
 
3.5.6 Hybridizing viral amplicons:  
All hybridization experiments revealed that HPRT-PCR products hybridized 
with its complementary probe and generated specific hybridization signals, 
while viral amplicons failed to hybridize with their target probes printed on the 
experimental microarrays. The probable reason for this failure could be 
attributed to the low concentration of the viral nucleic acids which allow 
polymerisation of the random primers by Phi 29 DNA polymerase during 
MDA of the viral genomes and generate high molecular weight of amplicons 
containing non-viral sequences. The ligation step which preceded MDA of the 
viral cDNA using QuantiTect whole transcriptome kit exacerbated this 
problem as it generated sequences of amplicons different from the original                 
viral sequences. Amplifying viral genome using GenomePlex complete WGA 
kit was not improved due to the random fragmentation reaction that preceded 
their amplification (Singh et al., 2005, Jahn et al., 2008). Figure 3-26 
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summarises all the steps used for optimizing hybridization process using the 
experimental microarrays.    
 
 
Figure 3-26: Schematic diagram showing the steps used for optimizing 
hybridization process using the experimental microarrays. 
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4 Application of the Polymerase Chain Reaction for 
testing the specificity of the designed viral 
microarray 
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4.1 Introduction 
The probes of the enteroviruses, (HMPV), (HRSV) and human influenza virus 
A printed on the microarray chip were designed in order to be used for 
diagnosing viral infections caused by these viruses through detecting their 
nucleic acids in clinical samples. These probes need to be tested in a 
hybridization reaction using positive control and clinical samples in order to 
explore their performance and determine the specificity and sensitivity of the 
probes which can hybridize to the related viral nucleic acids exist in these 
samples, and select the best performing probes for generating a diagnostic 
microarray chip. These probes were designed along the whole genomes of the 
selected RNA viruses in order to detect any part of the viral nucleic acids 
which may be existed in a clinical sample suspected to be infected with one or 
more of the above viruses. Therefore, amplifying the entire genomes of the 
desired viruses at this stage is necessary in order to provide nucleic acid 
templates with an adequate concentration able to hybridize with the 
complementary probes printed on the virochip. PCR has been widely utilized 
for in vitro unlimited amplification of nucleic acids which can generate 
millions copies of a target genome starting from a single copy (Hernandez-
Rodriguez et al., 2011, Waters and Shapter, 2014). Many researchers have 
exploited the low detection limits of the PCR technique for the detection of 
viral nucleic acids in environmental and infected clinical samples, which leads 
to the diagnosis of the viral infections, identifies their causative agents and 
determines the appropriate treatment regimen (Clementi, 2000, Mackay, 2004). 
Kleinschmidt and his colleagues (Kleinschmidt-DeMasters et al., 2001) were 
able to diagnose viral nervous system infections when they detected human 
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herpesviruses in cerebrospinal fluid samples using the PCR method. Other 
researchers cited that two types of influenza viruses (A and B) were detected 
VLPXOWDQHRXVO\ LQ SDWLHQWV¶ VDPSOHV ZKR KDG V\PSWRPV RI UHVSLUDWRU\
infections, using a PCR based method (van Elden et al., 2001). Therefore, PCR 
technique was adopted for amplifying the entire genomes of the pTZ18R 
plasmid, enteroviruses, HMPV, HRSV and human influenza virus A, after the 
failure of the hybridization experiments between the probes printed on the 
experimental microarrays and the amplified materials generated from MDA 
process in chapter 3. 
 
4.2 Aims 
The aims of this chapter were:  1) Generate full length amplified DNA 
covering human enteroviruses, human influenza virus A, HMPV and HRSV in 
order to explore the efficiency of most of the probes designed using the 
microarray. 2) Hybridize the microarray to full length viral sequences in order 
to describe the performance characteristics of the designed probes especially 
their sensitivity and specificity.   
 
4.3 Materials and methods    
4.3.1 Samples  
Several nucleic acids samples were used for completing optimizing the 
microarray hybridization conditions and validating the performance of the 
microarray chip containing viral probes designed in chapter 2. These samples 
included:  
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1- Enteroviral RNA including i) RNA transcripts consisted of 10^6 copies/µl 
for each of the Human echovirus 7 and Human coxsackievirus A-21 which 
were provided kindly by Professor Peter Simmonds, Centre of Infectious 
Diseases, University of Edinburgh, Summerhall, Edinburgh, UK, ii) an 
extracted RNA from a clinical stool sample infected with enteroviruses 
which was provided by the clinical Virology laboratory, QMC, 
Nottingham, UK.  
2- RNA extracts for each of i) HMPV, ii) HRSV, iii) human influenza virus 
A, which were extracted from clinical samples (nasopharyngeal aspirate) 
and provided by clinical Virology laboratory, QMC, Nottingham, UK. 
3- pTZ18R plasmid RNA generated from its transcription reaction in section 
3.3.2.5.5. 
4- HPRT product generated from PCR amplification of the human DNA 
extracted from the human peripheral blood in section 3.3.2.6.1. 
5- Varicella zoster virus (VZV) DNA extracted from live attenuated vaccine 
for this virus (GlaxoSmithKline, UK) using QIAamp DNA mini extraction 
kit as described in section 3.3.2.6.1. 
 
4.3.2 Amplification of the samples nucleic acids using PCR 
technique 
4.3.2.1 Designing specific primers  
PCR amplification reaction requires the use of specific primers for the desired 
template to be amplified. Primer 3 software version 0.4.0 
(http://bioinfo.ut.ee/primer3-0.4.0/) was used for designing the required 
primers for PCR amplification of the entire genome of the pTZ18R, 
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enteroviruses, HMPV and HRSV in addition to the entire HA and NA genetic 
segments of the human influenza virus A, and part of the VZV genome. Primer 
picking conditions of the software were set as follow: primer size was 15-28 
bases, primer Tm was 50 oC to 61 oC and primer GC% was 20-50 %. Loading 
the sequence of the pTZ18R plasmid into the Primer 3 software generated one 
set of primers (forward and reverse) for amplifying the whole genome (2686 
bp) of the pTZ18R. Similarly, one set of primers targeting part of the VZV 
genome (5514 bp) was generated after loading the sequence of that part into 
the software (table 4-1).  
Designing one pair of primers for each viral group capable of amplifying the 
whole genome of all subtypes within each viral group is almost impossible. 
Therefore, it was decided to design several sets of primers for each group of 
the selected RNA viruses through several repeated trials, covering their whole 
genomes.  
 
4.3.2.1.1 Human enterovirus primers design  
Due to the high genetic diversity among the 87 serotypes of the human 
enterovirus, several trials of primer design were implemented in order to 
generate the required primers for amplifying their entire genomes, by loading 
different sequences of them as a template into the Primer 3 software. In the 
first trial, the sequence of the Human coxsackievirus A-2 was loaded into the 
Primer 3 software. Aligning the sequences of the primers generated from this 
trial to the sequences of the enterovirus serotypes revealed that the Ent-FW1 
primer showed high degree of homology with the most serotypes (89 %) except 
Human coxsackievirus A-5 and 11, Human coxsackievirus B-4, Human 
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echovirus 12 and 18-19 and Human enterovirus 81, and 90 which they showed 
1 base mismatch with the above primer sequence, which is acceptable as long 
DV LW¶V QRW DW WKH ¶ HQG RI WKH SULPHU (Thweatt et al., 1990, Kolmodin and 
Birch, 2002). Alignment results also showed that the Ent-FW1 primer has 
several noncomplementarities DW LWV¶HQGZLWK WKHHuman echovirus 30 and 
therefore another forward primer (Ent-FW2) was designed specifically for this 
enterovirus serotype.  
The sequence of the Ent-FW1 primer was used as a conserved forward primer 
during designing the revers primers which were designed specifically for each 
enterovirus subtype by loading the sequences of the Human coxsackievirus A-
2, Human coxsackievirus A-9, Human coxsackievirus A-11, and human 
enterovirus 70 as representative templates for the human enterovirus A, B, C 
and D, respectively into the software. Accordingly, the alignment results 
showed that the reverse primers Ent-RV1, 3, 4 and 6 generated from further 
primer design trials, were conserved with most serotypes of the human 
enterovirus A, B, C and D, respectively, therefore they were selected for 
amplifying their entire genomes. The alignment results also revealed that the 
Ent-RV1 primers and the Ent-RV4 primer showed many nucleotide 
PLVPDWFKHV HVSHFLDOO\ DW WKHLU¶ HQG ZLWK VRPHRI the human enterovirus A 
and C serotypes, respectively, therefore the reverse primers Ent-RV2 and 5 
were designed for amplifying the above mismatched serotypes, respectively 
(table 4-1). 
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4.3.2.1.2 HMPV primers design      
One of the HMPV sequences was used as a template for designing the required 
primers for amplifying the entire genome of the HMPV. In order to simplify 
the process of the primers design and the subsequent PCR amplification step, 
the template sequence of the HMPV was separated into three smaller segments 
(Seg-1, 2 and 3); each segment was loaded separately into the Primer 3 
software. This primer design process generated one set of primers for each 
segment of the HMPV. Alignment results of the generated primers sequences 
with the sequences of the HMPV strains revealed that the reverse primer of the 
second segment (HMPV-RV2) showed one base mismatch, and the forward 
primer of the third segment (HMPV-FW3) showed two base mismatches with 
some of the HMPV strains, while other primers were conserved in most strains.  
Use of the degenerate nucleotides at the mismatch positions of the above 
primers can make them conserved in all of the HMPV strains through 
providing several unique sequences of each primer differ at the mismatch 
positions only such that each primer sequence contains one of the four possible 
nucleotides (A, T, G or C) at each mismatch position (Linhart and Shamir, 
2002). Accordingly, one degenerate nucleotides symbolized by R (which 
represents either A or G) was used at the mismatch position of the primer 
HMPV-RV2, while two degenerate nucleotides symbolized by R and Y (which 
represents either C or T) were used at the two mismatch positions of the primer 
HMPV-FW3 (see table 4-1). 
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4.3.2.1.3 HRSV primers design      
The same primer design process of the HMPV was used for designing the 
required primers for amplifying the entire genome of the HRSV through 
selecting one of the HRSV sequences as a template and chopping it into three 
parts which were loaded separately into the Primer 3 software. One set of 
primers for each part of the HRSV genome was generated after running the 
software. The sequences of the generated primers were aligned with the 
sequences of the HRSV strains and the results revealed that the forward primer 
HRSV-FW1, and the reverse primers HRSV-RV1 and HRSV-RV2 were 
conserved in all sequences, while the forward primer HRSV-FW2 and the 
revers primer HRSV-RV3 showed two base mismatches with only two of the 
HRSV strains (HRSV-strain B1 and HRSV-cp52). Two degenerate nucleotides 
symbolized by W (which represents either A or T), and R were used at the 
mismatch positions of the HRSV-FW2 primer, while other two degenerate 
nucleotides represented by R were used at the mismatch positions of the 
HRSV-RV3 primer in order to provide the required sequences of them for 
amplifying all the strains belong to the HRSV. The alignment results also 
showed that the HRSV-FW3 primer has four noncomplementarities with the 
above two strains (see table 4-1).  
 
4.3.2.1.4 Human influenza virus A primers design      
One set of specific primers for each of the HA and NA genomic segments 
belong to H1N1 and H3N2; the most common subtypes of human influenza 
virus A, was generated after loading one of each segment sequences as a 
template into the Primer 3 software. Alignment results of the generated primers 
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sequences with the sequences of the HA and NA segments of the viral strains 
belong to the above viral subtypes revealed 100 % homology with most strains. 
However, the alignment results also showed variable degree of 
noncomplementarity with some viral strains (see table 4-1). 
All primers generated from Primer 3 software for amplifying all the above 
samples were synthesized and provided as a lyophilized form by Eurofins 
MWG Operon, resuspended in nuclease free water at a concentration of 100 
µM and stored at -80 oC. 
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Table 4-1: Characteristics of the primers used for PCR amplification of the viral groups. 
 Primer ID 6HTXHQFH¶ĺ¶ Tm oC GC% Amplicon size 
pTZ18R Plas-FW AAGGCGATTAAGTTGGGTAAC 55.9 42.9 2686 bp Plas-RV ATCGGCAAAATCCCTTATAAAT 52.8 31.8 
VZV VZV-FW AACCTCCAAAAGCATCAATAAC 54.7 36.4 5514 bp VZV-RV AGTTCAACCCTTATCAAACTCG 56.5 40.9 
Enterovirus 
Ent-FW1 ACTACTTTGGGTGTCCGTGTTT 58.4 45.5 
§6.9 kb 
Ent-FW2 ACTACTTTGGGTGTTTTTCCTT 54.7 36.4 
Ent-RV1 TTATAACAAATTTACCCCCACCA 57.9 47.6 
Ent-RV2 ATCTTTGGTGACTTTGTCAAGC 55.3 34.8 
Ent-RV3 ATGCGGAGAATTTACCCCTAC 56.5 40.9 
Ent-RV4 AATCCAATTCGACTGAGGTAGG 58.4 45.5 
Ent-RV5 AAGCCAATTCGGGTGAGGTA 57.3 50 
Ent-RV6 CCCAATTAACCAAAATTTACCT 52.8 31.8 
H
u
m
a
n
 
m
et
ap
n
eu
m
o
 
v
ir
u
s 
Seg-1 HMPV-FW1 AAAATGTCTCTTCAAGGGATTCA 55.3 34.8 §4.1 kb HMPV-RV1 GTGCTGACTTTGCATGGGTA 57.3 50 
Seg-2 HMPV-FW2 CTAAGCAAAGTTGAGGGTGAAC 58.4 45.5 §4.2 kb HMPV-RV2 GCTTTRTCATTTAATACCATCTCA 55 31.3 
Seg-3 HMPV-FW3 CCRGAAACYTTAACAAAGTATGGTGA 60.1 38.5 §3.3 kb HMPV-RV3 CCTGCTCCTTCTCCAATAAAG 57.9 47.6 
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 Primer ID 6HTXHQFH¶ĺ¶ Tm oC GC% Amplicon size 
H
u
m
a
n
 
re
sp
ir
a
to
ry
 
sy
nc
yt
ia
l v
ir
u
s Seg-1 HRSV-FW1 GGGGCAAATAAGAATTTGATAAG 55.3 34.8 §3.2 kb HRSV-RV1 TTGTTCACGTATGTTTCCATATTT 54.2 29.2 
Seg-2 HRSV-FW2 CAGCWGCTGTTCARTACAATG 55.9 42.9 §5.8 kb HRSV-RV2 TGTATTAACCATGATGGAGGATG 57.1 39.1 
Seg-3 HRSV-FW3 CTTGACATGGAAAGATATTAGCC 57.1 39.1 §5.3 kb HRSV-RV3 GGCATRATGAAATTTTTRGTT 52 33.3 
Flu-A 
HA 
(H1N1) FW CAATTCAACAGACACTGTAGACACA 59.7 40 §1.5 kb (H1N1) RV ATCTGGTAAATCCTTGTTGATTCC 57.6 37.5 
(H3N2) FW TCCCGGAAATGACAACAG 52.2 46.3 §1.6 kb (H3N2) RV TGCAAATGTTGCACCTAAT 50.2 36.8 
NA 
(H1N1) FW CCATTGGTTCGGTCTGTATG 57.3 50 §1.3 kb (H1N1) RV AAGACCAACCCACAGTGTCA 57.3 50 
(H3N2) FW CCTTATGTGTCATGCGATCC 57.3 50 §1 kb (H3N2) RV ATGTACCTGAGGTGCCACAA 57.3 50 
Abbreviation; FW: Forward, RV: Reverse, HMPV: Human metapneumovirus, RSV: Respiratory syncytial virus, 
HA: Hemagglutinin, NA: Neuraminidase, R: A or G, Y: C or T, W: A or T. 
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4.3.2.2 Long range cDNA synthesis 
Maxima H Minus First Strand cDNA Synthesis kit (provided by Thermo 
Scientific) was used for efficient synthesis of the full length cDNA templates 
(up to 20 kb) from the selected viral RNAs as well as pTZ18R plasmid RNA. 
Oligo-dT primers were used to synthesize cDNA strand from the enterovirus 
RNA containing poly-$WDLODWLWV¶HQGZKLOHUDQGRPKH[DPHUSULPHUVZHUH
used to generate cDNA from total RNA of each of the of the pTZ18R, human 
influenza virus A, HMPV and HRSV RNAs.   
$FFRUGLQJWRWKHPDQXIDFWXUHU¶VJXLGHOLQHµl of the viral RNA were mixed 
with 1 µl of either oligo-dT or random hexamer primers (100 µM), and 1 µl of 
dNTP mix (10 mM). The reaction volume was adjusted to 15 µl by adding 3 µl 
of nuclease free water. The reaction mixture was incubated at 65 oC for 5 
minutes in thermal cycler and chilled immediately on ice for 1 minute and spun 
briefly. Generation of the viral cDNA was initiated by adding 4 µl of 5X RT 
buffer and 1 µl of Maxima H Enzyme mix containing the reverse transcriptase. 
The reaction mixture was incubated in thermal cycler at 50 oC for 30 minutes, 
preceded by 10 minutes at 25 oC when using random hexamers. The reaction 
was terminated by heating the mixture for 5 minutes at 85 oC. The generated 
cDNA was stored at -80 oC for further use. 
 
4.3.2.3 Long-range PCR amplification 
LongAmp Hot Start Taq DNA polymerase kit (New England, Biolabs) was 
used for PCR amplification of the viral nucleic acids. This enzyme is able to 
generate long PCR products (up to 30 kb) in one reaction.  
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$FFRUGLQJ WR WKHPDQXIDFWXUHU¶VSURWRFROµl of each of the desired nucleic 
acid templates (pTZ18R cDNA generated in section 3.3.2.5.5, viral cDNAs 
generated in section 4.3.2.2 and VZV DNA extracted from live attenuated 
vaccine for VZV) were added to 23 µl of reaction mixture containing 1X PCR 
LongAmp Taq Reaction Buffer, 300 µM of each dNTP, 0.4 µM of each primer 
and 2.5 units of LongAmp Hot Start Taq DNA polymerase. The PCR reaction 
was incubated in a thermal cycler (Techne TC-3000) with the following 
thermal profile: 30 seconds of initial denaturation at 94 oC followed by 40 
cycles composed of denaturation for 30 seconds at 94 oC, primer annealing for 
60 seconds at the Tm temperature specific for each set of primers (clarified in 
table 4-1) and primer extension at 65 oC for 50 seconds/ kb, with a final 
extension step for 10 minutes at 65 oC.   
PCR amplicons were purified using Qiaquick PCR purification kit as described 
in section 3.3.2.5.2 followed by measuring their concentration and purity using 
the NanoDrop ND 1000 as described in section 3.3.2.5.4 and finally run on a 
1% agarose gel as described in section 3.3.2.5.3 in order to detect their 
expected size.  
 
4.3.3 Fragmenting and Labelling the PCR products 
The purified amplicons generated from PCR amplification of samples under 
study in this chapter were fragmented by sonication using the same conditions 
described in section 3.3.4.1.1 followed by ethanol precipitation as described in 
section 3.3.4.2. Finally, the clean fragmented amplicons were mixed with one-
fifth volume of the HPRT-PCR product and labelled with dyomics 547 and 495 
fluorescent dyes as described in section 3.3.4.3. The DOL was calculated using 
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the Nanodrop results in order to determine the efficiency of the nucleic acid 
labelling process. 
 
4.3.4 Manual hybridization experiments 
A hybridization trial was performed using an experimental microarray in order 
to optimize the hybridization process and evaluate the efficiency of the PCR 
amplification process and validate the appropriateness of the generated 
amplicons for hybridization before starting any hybridization experiments 
using the virochip microarray designed in chapter 2. One of the NHS-coated 
BSA slides prepared in section 3.3.5.1 was used for fabricating a new 
experimental microarray in order to be used for testing some of the amplicons 
generated from long-range PCR including enterovirus, pTZ18R and VZV in a 
hybridization experiment. Accordingly, two dozen of probes specific for VZV 
and herpes simplex virus type 1 (HSV1), and eight probes for HSV2 designed 
by Abdel-Hakim, 2010 (table-4-2), in addition to HPRT, enterovirus and 
pTZ18R probes described in tables 3-3, 3-4 and 3-5 were used for printing the 
experimental microarray (HHVs-pTZ18R-enterovirus microarray) following 
the same printing protocol described in section 3.3.5.2. Each probe was printed 
in duplicate according to the printing layout illustrated in figure 4-1. Then the 
labelled amplicons of the enterovirus, pTZ18R and VZV generated from long-
range PCR amplification process were tested in a hybridization experiment 
using the experimental HHVs-pTZ18R-enterovirus microarray following the 
hybridization technique described in section 3.3.6.2.  
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Table 4-2: Sequences of the HHVs probes used for printing the experimental microarray. 
Adopted from (Abdel-Hakeem, 2010) 
 Probe ID 6HTXHQFH¶-¶ Position on gene 
H
SV
1 
HSV1-5 GAAATTACCTTCCTCTTCGGACTCGATATC 24958-24987 
HSV1-7 AATCCCATAAACATACGACACACAGGCATA 34978-35007 
HSV1-12 TACCGCAGAATCTGGTTTGCCATGTAGTAC 59350-59379 
HSV1-13 GATTATAACCGACAAGATCAAGCTCTCGAG 64391-64420 
HSV1-18 TTTGAGCAGAAGGACATTCTCCACTACTAC 90251-90280 
HSV1-21 TGTTGGTGCTTTATTGTCTGGGTACGGAAG 105458-105487 
HSV1-22b AGAGTCCCTTCTGGTTTCTTAGCAAATTCG 109729-109758 
HSV1-22a CAATCACAAACATCATCCTGGATCTCGACA 110914-110943 
HSV1-24 AAAGTTGTTCCTAAAGCGAGGATACGGAGG 119871-119900 
HSV1-25 CCCATTAATGAGTTTCTAATTACCATACCG 124779-124808 
HSV1-27 GTTGGTATATTACAGGCCCGTGTCCGATTT 134934-134963 
HSV1-28 CTTCTCGGTGTTTGTGTTGTATCGTGCTTG 141275-141304 
H
SV
2 
HSV2-2 AGACGGAATATTTCTTCGCTATCACTGCCC 9630 ± 9652 
HSV2-5 CATTTCTGTCTTTATTCGCTATCAGAGAGT 24803 ± 24832 
HSV2-6 AACAAACCTAGGATCTTGTGTACTCACGCC 28761 ± 28790 
HSV2-12 TACCTCAAGATCTGGTTGGCCATGTAGTAC 59744 ± 59773 
HSV2-17 AACAGGCCCTTTAAACATTTGCGTATGCAC 84871 ± 84900 
HSV2-20 GGTAAGCGTCGCGTTAATTATATACTGGGC 100559 ± 100588 
HSV2-21 AATAACGATCTCGAGAGGCGAATGAGACGT 105790 ± 105810 
HSV2-23 TATGCTAATCGACCTAGGATTGGACCTGTC 114610 ± 114640 
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 Probe ID 6HTXHQFH¶-¶ Position on gene 
V
ZV
 
VZV-1 TTGTAAATACATACCATATACAAACCATGC 4870 ± 4899 
VZV-2 ATATGTTTGTAGGTTAAGGGAACATCGATA 9985 ± 10014 
VZV-7 AAATTTAAACCAACTGTAGACGTGCCGGAT 35203 ± 35232 
VZV-9 GATGGTTGACTGTTCATCATCGGAACATCG 45334 ± 45363 
VZV-10 AAGTAATAACGGTACCAAGCGGTCGTGTTG 50196 ± 50225 
VZV-12 ATCTGATTTGCAAACATATCGGCGTCGTCT 60344 ± 60373 
VZV-15 GTTCTACCGAAATGACACAGGATCCGTGTG 75557 ± 75586 
VZV-16 GTTGTTGTAGCCACAATTTACATCACGCGC 80586 ± 80615 
VZV-17 AATAGACCTACAATGGCAAATCTACGGGAC 85607 ± 85636 
VZV-19 CTTGTCCATCGGTATATCCAAAGTCACCGG 95718 ± 95747 
VZV-20 TATGGATCTTGACCAATAATTACAACGCGA 100776 ± 100805 
VZV-23 CAGAGCATCCGTCTTGCGATACGATGATTT 115896 ± 115925 
HHVs: Human herpesviruses 
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Figure 4-1: Schematic drawing of the experimental HHVs-pTZ18R-enterovirus 
microarray. 
Figure (A) shows the printing layout of the 24 HHVs-pTZ18R-enterovirus grids on the 
microarray slide that was used during optimization steps. Figure (B) represents a 
magnified diagram for one of the printed grids showing the spot locations represented 
in circles with a digit inside each one. Numbers from 1 to 12 refer to the VZV probes, 
13-24 represent HSV1 probes, 25-32 refer to HSV2 probes, 33-44 represent the 
pTZ18R plasmid probes, 45-50 represent the enterovirus probes while number 51 
refers to the HPRT probe. 
 
 
4.3.4.1 Hybridization experiment using virochip  
An Agilent Microarray Hybridization Chamber Kit (Agilent Technologies) was 
used for holding the virochip containing the specific probes designed for the 
selected RNA viruses in chapter 2, during the hybridization process. An 
Agilent gasket slide enclosing 8 chambers (2x4) matching the format of the 
virochip grids was used in order to separate the grids and prevent samples 
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intermixing during the hybridization reaction. Therefore, and according to the 
hybridization chamber user guide, the prehybridization buffer as well as the 
labelled viral amplicons suspended in the hybridization buffer, were loaded 
into the Agilent gasket slide surface fixed in the slide chamber base, rather than 
the microarray slide. After that, the microarray slide surface containing the 
printed viral probes was carefully lowered on the top of the Agilent gasket 
slide surface. The chamber cover was placed onto the chamber base holding 
both the microarray and the Agilent gasket slides, and fixed using the clamp 
assembly located in the centre of the chamber cover (figure 4-2). The 
hybridization reaction was performed following the same hybridization 
technique described in section 3.3.6.2.  
 
 
Figure 4-2: Agilent Microarray Hybridization Chamber Kit used for holding the 
virochip during hybridization with the labelled viral amplicons. 
Adopted from (Berger and Bulyk, 2009). 
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4.4 Results 
4.4.1.1 Long-range PCR amplification results 
Long-range PCR amplification of the selected viral RNAs was preceded by 
reverse transcribing them into cDNA templates using Maxima H Minus First 
Strand cDNA synthesis kit. Poly-A tail RNA extracts including these derived 
from Human echovirus 7, Human coxsackievirus A-21 and a clinical sample 
known to contain an enterovirus were reverse transcribed into cDNA using 
Oligo-dT primers. First strand cDNA was also synthesised from three RNAs of 
each of HMPV, HRSV and human influenza virus A (two for H1N1 and one 
for H3N2) extracted from clinical samples containing these viruses, in addition 
to the pTZ18R plasmid using random primers.  
The cDNA templates generated from reverse transcription reaction of the 
human enteroviruses, HMPV, HRSV, H1N1, H3N2 and pTZ18R plasmid 
RNAs in section 4.3.2.2, in addition to the VZV DNA extracted from a VZV 
vaccine were amplified using LongAmp Hot Start Taq DNA polymerase kit 
following the PCR principles. The Qiaquick PCR purification kit was used for 
purifying the amplicons generated from long-range PCR amplification reaction 
of the above viral and plasmid nucleic acids. The PCR products generated from 
Long-range PCR amplification reaction of the pTZ18R genome and part of the 
VZV genome using their specific designed primers were revealed as a clear 
single bands for each one with the expected target size (2610 and 5514 bp, 
respectively) after running them on 1% agarose gel as shown in figure 4-3.  
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Figure 4-3: Agarose gel electrophoresis of the pTZ18R cDNA and VZV DNA 
generated from Long-range PCR amplification reaction.   
pTZ18R plasmid RNA was reverse transcribed into cDNA and then amplified in 
parallel with the VZV DNA extracted from a VZV vaccine using PCR. Lane 1 was 
loaded with PCR amplicon of the VZV while PCR amplicon of the pTZ18R plasmid 
was loaded into lane 2. PCR negative control sample containing nuclease free water 
was loaded into lane 3. M refers to 1 kb ladder.  
 
 
Long-range PCR amplification reaction of the Human echovirus 7 and Human 
coxsackievirus A-21 cDNA using Ent-FW1 as a forward primer, and Ent-RV1 
and Ent-RV4 as a reverse primer for each one, respectively, generated 
approximately 9 µg of nucleic acids. Agarose gel electrophoresis of the 
generated amplicons revealed single bright bands of the expected size (§7 kb) 
for the entire genome of each of the above mentioned enterovirus serotypes. 
The gel also showed some less bright bands related to shorter fragments of the 
amplified enteroviral cDNA (figure 4-4). 
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Figure 4-4: Agarose gel electrophoresis of Long-range PCR amplification of 
enteroviral cDNA.   
Ent-FW1 and Ent-RV1, and Ent-FW1 and Ent-RV4 primers were tested for 
amplifying the whole genome of Human echovirus 7 and Human coxsackievirus A-21, 
respectively, using their cDNA preparations in Long-range PCR amplification 
reaction. Lane 1 was loaded with PCR amplicon of Human echovirus 7 while PCR 
amplicon of Human coxsackievirus A-21 was loaded into lane 2. PCR negative control 
sample containing nuclease free water instead of enteroviral cDNA template was 
loaded into lane 3. M refers to 1 kb ladder.  
 
 
As the enterovirus serotype isolated from the clinical sample was not known, 
all enterovirus primers were loaded together into one PCR reaction for 
amplifying the cDNA generated from this sample. A temperature gradient was 
used for optimizing the primer annealing temperature during the above PCR 
reaction. Running the amplified products generated from the temperature 
gradient step revealed that 56 oC was the optimal temperature for annealing the 
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relevant enterovirus primers to their complementary nucleic acid sequences 
available in the clinical enterovirus cDNA template, as shown in figure 4-5.  
 
 
 
Figure 4-5: Agarose gel electrophoresis of the clinical enterovirus amplicons 
generated from Long-range PCR reaction using temperature gradient.   
Enterovirus RNA extracted from a clinical sample was reverse transcribed into cDNA 
and then amplified using PCR. Three different temperatures (56 oC, 58 oC and 60 oC) 
were used. M represents the 1 kb plus ladder while B refers to the gel well loaded with 
the negative control sample containing nuclease free water instead of enteroviral 
cDNA template.  
 
 
Amplifying the three segments of each of HMPV or HRSV genomes using 
their specific three sets of primers described in table 4-1, together in one Long-
range PCR amplification reaction was failed. Therefore, three Long-range PCR 
amplification reactions were performed; each reaction was dedicated for 
amplifying part of the viral genome using one set of the related primers.   
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Three PCR products with a concentration ranging from 5-9 µg, were generated 
from long-range PCR amplification process of each of the HPMV and HRSV 
cDNAs derived from clinical samples. A bright main band with the expected 
size was observed after running each PCR product of HMPV or HRSV on 1% 
agarose gel (figures 4-6 and 4-7).   
 
 
Figure 4-6: Agarose gel electrophoresis of HMPV amplicons generated from 
Long-range PCR amplification process.  
Three different sets of specific primers were designed and used in Long-range PCR 
amplification reactions, for amplifying the entire genome of HMPV. Each set of 
primers was used for amplifying part (1/3) of the entire viral genome using cDNA 
template generated from a reverse transcription reaction of HMPV RNA isolated from 
a known positive clinical sample. PCR product of first segment of the above viral 
genome was loaded in lane 1 (expected size is 4.1 kb), middle segment in lane 2 
(expected size is 4.2 kb) and last segment in Lane 3 (expected size is 3.3 kb). Lane 4 
was loaded with PCR negative control. M represents 1 kb DNA ladder. 
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Figure 4-7: Agarose gel electrophoresis of HRSV amplicons generated from 
Long-range PCR amplification process.  
Three different sets of specific primers were designed and used in Long-range PCR 
amplification reactions, for amplifying the entire genome of HRSV. Each set of 
primers was used for amplifying part (1/3) of the entire viral genome using cDNA 
template generated from a reverse transcription reaction of HRSV RNA isolated from 
a known positive clinical sample. PCR product of first segment of the above viral 
genome was loaded in lane 1 (expected size is 3.2 kb), middle segment in lane 2 
(expected size is 5.8 kb) and last segment in Lane 3 (expected size is 5.3 kb). Lane 4 
was loaded with PCR negative control. M represents 1 kb plus DNA ladder. 
 
 
The total size of the three amplified segments generated from long-range PCR 
amplification process of HMPV and HRSV was § 11.6 kb and 14.3 kb, 
respectively, which represent most of their entire genomes (§ 90 %). The rest 
of the HMPV and HRSV genomes (1.7 kb and 0.9 kb, respectively) were not 
targeted by the designed primers due to their high sequence diversity among 
the HMPV and HRSV strains, therefore they were not amplified (figure 4-8).
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Figure 4-8: Schematic diagram shows the size and position of the amplified and the unamplified parts of the HMPV and HRSV genomes generated 
from long-range PCR amplification process. 
Three segments (1, 2 and 3 shown as brown bars) of each of the HMPV and HRSV genomes were amplified using three sets of primers. The red bars above 
the amplified segments refer to the forward primers and the pink bars below the amplified segments refer to the reverse primes, used for amplifying the 
genome segments. The blue bars represent the unamplified sequences of the above genomes.  
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HA and NA genomic segments of H1N1 and H3N2 subtypes of human 
influenza A virus were amplified individually in four different PCR reactions 
using their respective specific set of primers (table 4-1), in order to avoid the 
difficulties that accompanied their amplification process when using all 
primers sets in one PCR reaction. PCR amplification process generated 
abundant quantities of amplified materials representing most length of the 
above genomic segments for each H1N1 and H3N2 subtypes. The amplified 
materials of each segment appeared as a single bright band having the expected 
amplicon size as mentioned in table 4-1, after running on an agarose gel (figure 
4-9).   
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Figure 4-9: Agarose gel electrophoresis of the products of HA and NA genomic 
segments of H1N1 and H3N2 subtypes generated from Long-range PCR 
amplification process.  
Four different sets of specific primers were designed and used in Long-range PCR 
amplification reaction, for amplifying two genomic segments (HA and NA) of two 
subtypes (H1N1 and H3N2) of human influenza virus A. Each set of primers was used 
for amplifying most of the desired segment using cDNA template generated from 
reverse transcription reaction of human influenza virus A RNA isolated from known 
positive clinical sample.  
 
 
The size of the amplified products generated from long-range PCR 
amplification process of the HA and NA of the H1N1 subtype was §1.5 kb and 
1.3 kb, respectively, which represent 90 % of the full length of the above 
segments. In contrast, the size of the same segments of the H3N2  subtype was 
§ 1.6 kb and 1 kb, respectively, which represent 96 % of the full length of the 
HA segment and 71 % of the NA segment. The rest sequence of each segment 
was not amplified as it was not targeted by the designed primers due to the 
genetic diversity among the strains of each subtype (figure 4-10). 
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Figure 4-10: Schematic diagram shows the size of the amplified and unamplified products generated from long-range PCR amplification process of 
the HA and NA segments of the H1N1 and H3N2 subtypes of the human influenza virus A.   
The brown bars represent the amplified parts of the HA and NA segments generated from long-range PCR amplification process. The red bars above the 
amplified segments refer to the forward primers and the pink bars below the amplified segments refer to the reverse primes, used for amplifying the above 
segments. The blue bars represent the unamplified sequences. 
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4.4.2 Experimental hybridization results of the VZV, pTZ18R 
and enterovirus long-PCR products  
The amplicons of the clinical enterovirus, pTZ18R and VZV generated from 
Long-range PCR amplification process using LongAmp Hot Start Taq DNA 
polymerase kit in section 4.3.3.2, were applied into a hybridization reaction 
with the experimental HHVs-pTZ18R-enterovirus microarray in order to test 
their behaviour after fragmenting them; the step which was omitted from the 
hybridization experiment of the enterovirus QPCR products. The amplicons 
were purified using Qiaquick PCR purification kit, sonicated using Soniprep 
150 MSE sonicator and precipitated using ethanol precipitation. Each one of 
the above fragmented amplicons were mixed with one-fifth volume of the 
HPRT-PCR product and then labelled with the dyomics 547 fluorescent dye 
using ULS system. Each labelled mixture was loaded separately into a single 
printed grid of the experimental HHVs-pTZ18R-enterovirus microarray slide 
fixed in the hybridization cassette in order to start their hybridization reaction. 
Scanning the HHVs-pTZ18R-enterovirus microarray slide at the end of 
hybridization process revealed hybridization signals generated between the 
above labelled amplicons and their complementary probes displayed as clear 
red bright spots. Since all the probes used for fabricating the above microarray 
were printed in duplicate, two hybridization signals were generated for each 
probe hybridized to its complementary target amplicon. Therefore, VZV 
amplicon generated four hybridization signals as it hybridized with only the 
first two probes (VZV-1 and VZV-2) of the twelve VZV probes described in 
table 4-2 (figure 4-11-A). However, the pTZ18R amplicon generated 24 
hybridization signals as it hybridized with all of the twelve probes described in 
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table 3-5 (figure 4-11-B). In contrast the enterovirus amplicons generated eight 
hybridization signals as they hybridized with the last four probes (ENTC3-4) of 
the six enteroviral probes described in table 3-3 (figure 4-11-C). As each one of 
the above amplicons was mixed with one-fifth volume of the HPRT-PCR 
product, their grids showed 36 fluorescent hybridization signals generated from 
hybridization of the HPRT product with its complementary probe printed on 
the HHVs-pTZ18R-enterovirus microarray.  
 
 
Figure 4-11: Hybridization reaction results of the labelled VZV, pTZ18R and 
enterovirus amplicons generated from Long-range PCR amplification process  
with the experimental HHVs-pTZ18R-enterovirus microarray as seen on the 
GenePix laser scanner. 
Figures A, B and C represent scanned images of the three grids loaded with the 
labelled fragmented products generated from Long-range PCR amplification process 
of each of the VZV, pTZ18R and clinical enterovirus, respectively, showing the 
fluorescent hybridization signals generated with their complementary printed probes. 
Each figure also shows fluorescent red signals generated from hybridization of the 
HPRT products with their complementary printed probes.  
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4.4.3 Hybridization results using virochip  
Having optimized all the steps and conditions used for preparing the pTZ18R 
plasmid, VZV and enteroviral nucleic acids starting from their extraction and 
reverse transcription steps, passing through their amplification and 
fragmentation methods, and ending with their labelling reaction down to the 
hybridization reaction which led to successful hybridization between them and 
their complementary probe, it was decided to apply the amplicons of the 
selected RNA viruses generated from the Long-range PCR amplification 
process in a hybridization process with the virochip containing the viral probes 
designed in chapter 2, in order to test its performance. Since the viral 
amplicons generated from the MDA process in chapter 3 had not been used in a 
hybridization reaction with the virochip, it was decided to use a MD amplicon 
for only one sample of each of the selected RNA viral groups, in parallel with 
the viral amplicons generated from Long-range PCR amplification for testing 
the virochip and studying the performance of the probes on the chip.            
Three different RNA extracts for each of the HMPV, HRSV and human 
influenza virus A, and one enterovirus RNA extracted from clinical samples, in 
addition to the echovirus 7 and coxsackievirus A-21 transcripts were reverse 
transcribed into cDNA using Maxima H Minus First Strand cDNA synthesis 
kit. The generated viral cDNAs were amplified using LongAmp Hot Start Taq 
DNA polymerase kit following the PCR principles, and then purified using 
Qiaquick PCR purification kit. At the same time, one cDNA of each of the 
above viral groups was amplified using REPLI-g UltraFast mini kit following 
MDA principle. Thus, twelve viral amplicons were generated from Long-range 
PCR, and four amplicons were generated from MDA process (table 4-3).  
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Table 4-3: Shows the amplification methods and fluorescent dyes used 
for amplifying and labelling the viral samples used for validating the 
designed viral probes.  
Amplification  
method Viral sample 
Labelling 
dye 
Lo
n
g-
ra
n
ge
 
PC
R
 
Echovirus 7  Dyomics 547 
Coxsackievirus A-21  Dyomics 495 
Clinical enterovirus Dyomics 547 
HMPV-1 Dyomics 547 
HMPV-2 Dyomics 547 
HMPV-3 Dyomics 495 
HRSV-1 Dyomics 547 
HRSV-2 Dyomics 495 
HRSV-3 Dyomics 495 
H1N1-1 Dyomics 547 
H1N1-2 Dyomics 495 
H3N2 Dyomics 495 
M
D
A
 
Clinical enterovirus Dyomics 547 
HMPV-1 Dyomics 547 
HRSV-1 Dyomics 495 
H1N1-1 Dyomics 495 
 
 
All of the purified products generated from Long-range PCR, and the 
amplicons generated by MDA were sonicated using a Soniprep 150 MSE 
sonicator. Then the sonicated viral amplicons were ethanol precipitated and 
each was mixed with one-fifth volume of the HPRT-PCR product. Then, the 
viral amplicon-HPRT mixtures were labelled with dyomics 547 and dyomics 
495 fluorescent dye (table 4-3). The labelled amplicons were ethanol 
precipitated and resuspended in the prehybridization buffer, then each two of 
the above amplicon mixtures labelled with the two different dyes were loaded 
together into one of the eight chambers of the Agilent gasket slide surface fixed 
in the slide chamber base (figure 4-12). This process enabled using three 
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different PCR products and one MD amplicon for each group of the selected 
RNA viruses for validating the behaviour of the virochip probes.   
 
 
Figure 4-12: Schematic diagram shows the loading sequence of the labelled 
amplicons into the chambers of the Agilent gasket slide. 
The amplicons of the enteroviruses, HMPV, HRSV and human influenza virus A 
generated from Long-range PCR amplification reaction and MDA process were mixed 
with one-fifth volume of HPRT-PCR product and labelled with the dyomics 547 (red 
colour) and 495 (green colour) fluorescent dyes. Then two amplicons labelled with 
each of the above two dyes were loaded into one of the Agilent gasket chambers.   
 
 
The surface of the microarray slide containing viral probes was lowered down 
on the Agilent gasket containing the labelled viral amplicon samples to start the 
hybridization process. The hybridization signals were displayed as regular 
spots during scanning of the microarray slide using the appropriate filter of 
GenePix 4200AL autoloader scanner for each fluorescent dye used. 
Hybridization signals, whose fluorescent intensities exceeded the mean of the 
negative control by more than two times standard deviation, were considered as 
positive signals, and those positive signals showing high fluorescent intensities 
were adopted for evaluating the sensitivity and specificity of the designed viral 
probes.  
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Figure 4-13: Scanned image of the virochip after hybridization reactions with the 
labelled amplicons of the enteroviruses, HMPV, HRSV and human influenza 
virus A, showing the fluorescent hybridization signals generated with their 
complementary printed probes.   
 
 
4.4.4 Description of the virochip 
 The designed virochip consists of eight repeated grids; each grid contained 
several thousands of probes designed specifically for each of the human 
enterovirus, HMPV, HRSV and human influenza virus A, B and C using 
OligoArray and Agilent technologies eArray software, in addition to the HHVs 
probes designed by a previous PhD student (Abdel-Hakeem, 2010) table 4-4.  
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Table 4-4: Shows the number of the probes designed for each species or subtype of the selected RNA viruses, using OligoArray 
and Agilent eArray software 
Family Genus Species Subtype Probe No. OligoArray Agilent eArray 
Picornaviridae Enterovirus 
Human enterovirus-A 
------------ 
703 142 
Human enterovirus-B 1081 439 
Human enterovirus-C 858 126 
Human enterovirus-D 310 30 
Human rhinovirus A and B 108 170 
Paramyxoviridae Pneumovirus Human respiratory syncytial virus  649 42 Metapneumovirus Human metapneumovirus 473 66 
Orthomyxoviridae Influenzavirus A Influenza A virus 
HA-H1N1 63 302 
HA-H1N2 61 21 
HA-H2N2 66 25 
HA-H3N2 61 165 
HA-H7N7 93 20 
NA-H1N1 52 375 
NA-H1N2 57 11 
NA-H2N2 57 22 
NA-H3N2 57 212 
NA-H7N7 62 10 
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Family Genus Species Subtype Probe No. OligoArray Agilent eArray 
Orthomyxoviridae 
Influenzavirus A Influenza A virus 
MP-H1N1 28 143 
MP-H1N2 26 7 
MP-H2N2 27 19 
MP-H3N2 26 97 
MP-H7N7 42 15 
Influenzavirus B Influenza B virus 
HA 57 77 
NA 50 123 
MP 31 61 
Influenzavirus C Influenza C virus HEF 71 22 MP 44 12 
Herpesviridae 
Simplexvirus  Human herpesvirus 1 
------------ 
12 ------------ 
Human herpesvirus 2 9 ------------ 
Varicellovirus  Human herpesvirus 3 12 ------------ 
Lymphocryptovirus Human herpesvirus 4 11 ------------ 
Cytomegalovirus Human herpesvirus 5 12 ------------ 
Roseolovirus Human herpesvirus 6 17 ------------ Human herpesvirus 7 7 ------------ 
Total 5293 2754 8047 
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4.4.4.1 Hybridization results of the human enterovirus amplicons  
The amplicons of the echovirus 7 and coxsackievirus A-21 transcripts, and 
clinical enterovirus generated by long-range PCR amplification reaction and 
MDA process were sonicated and labelled with dyomics 547 and 495 
fluorescent dyes (table 4-3). The labelled enterovirus amplicons were loaded 
into hybridization reactions with the probes designed for the selected RNA 
virus groups using four different grids of the virochip.  
 
4.4.4.1.1 Sensitivity of the human enterovirus probes designed using 
OligoArray software 
Echovirus 7 and coxsackievirus A-21 belong to human enterovirus B and C, 
respectively. Analysing the positive signals generated from the hybridization 
reactions of the human enterovirus amplicons revealed that 50 probes out of 
1081of the OligoArray probes designed specifically for human enterovirus B, 
and one probe out of 858 of the OligoArray probes designed specifically for 
human enterovirus C generated positive specific hybridization signals of high 
intensities with the amplicons of the echovirus 7 and coxsackievirus A-21, 
respectively (see table 4-4). On the other hand, several of the OligoArray 
probes designed specifically for of the human enterovirus A ¶875showed 
cross hybridization with the echovirus 7 amplicon (figure 4-14).  
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Figure 4-14: Signals generated from the hybridization reactions of four of the human enterovirus amplicons with the probes designed specifically 
for the human enteroviruses using OligoArray software. 
RNA extracts of the echovirus 7, coxsackievirus A-21 and clinical enterovirus were reverse transcribed into cDNA and amplified using long-range PCR 
amplification. The cDNA of the clinical enterovirus was also amplified using MDA. The generated amplicons were sonicated, labelled and loaded into 
hybridization reactions with the designed probes of the selected RNA viruses and HHVs. The red, blue, green and purple columns represent the positive 
hybridization signals generated from the human enterovirus OligoArray probes after hybridization to the PCR products of the echovirus 7, coxsackievirus A-
21 and clinical enterovirus, and the MD amplicon of the clinical enterovirus, respectively.     
Chapter Four                         Application of PCR for testing the designed viral microarray  
 
194 
  
For the amplicons of the clinical enterovirus, they showed different behaviour 
during their hybridization reactions with the human enterovirus OligoArray 
probes as only one of the human enterovirus A OligoArray probes generated a 
positive hybridization signal of high fluorescent intensity with the amplicon 
generated by long-range PCR, while five of the human enterovirus B and one 
of the human enterovirus D OligoArray probes showed high fluorescent 
intensities from the hybridization reaction with the MD amplicon of the clinical 
enterovirus (figure 4-14). The outcome of the hybridization reactions with 
clinical enterovirus amplicons revealed that this enterovirus can be identified as 
one of the human enterovirus B strains since the positive hybridization signals 
generated from the human enterovirus B OligoArray probes were more than 
the positive signals generated from other human enterovirus OligoArray 
probes. The possible explanation for the hybridization results of the 
coxsackievirus A-21 is that the PCR product of this virus was either 
contaminated with another amplicon of other viruses during the preparation 
steps (sonication, labelling and ethanol precipitation) or replaced with an 
amplicon of the other viruses, which will be illustrated later.  
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4.4.4.1.2 Sensitivity of the human enterovirus probes designed using 
Agilent eArray software 
Analysing the positive signals generated from the hybridization reactions of the 
human enterovirus amplicons revealed that 30 probes out of 439 of the Agilent 
eArray probes designed specifically for the human enterovirus B generated 
positive specific signals of high fluorescent intensities with the echovirus 7 
PCR amplicon (See table 4-4). On the other hand, several other Agilent eArray 
probes designed specifically for the human enterovirus A, C and D (CDS) 
showed cross hybridization with the above enterovirus amplicon. The 
fluorescent intensities of the positive signals generated from the hybridization 
reactions of the human enterovirus Agilent eArray probes with the amplicons 
of the coxsackievirus A-21 and clinical enterovirus were very low (figure 4-
15). 
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Figure 4-15: Signals generated from the hybridization reactions of four of the enterovirus amplicons with the probes designed specifically for the 
human enteroviruses using Agilent eArray software. 
RNA extracts of the echovirus 7, coxsackievirus A-21 and clinical enterovirus were reverse transcribed into cDNA and amplified using long-range PCR. The 
cDNA of the clinical enterovirus was also amplified by MDA. The generated amplicons were sonicated, labelled and loaded into hybridization reactions with 
the designed probes of the selected RNA viruses and HHVs. The red, blue, green and purple columns represent the positive hybridization signals generated 
from the human enterovirus Agilent eArray probes after hybridization to the PCR products of the echovirus 7, coxsackievirus A-21 and clinical enterovirus, 
and the MD amplicon of the clinical enterovirus, respectively.  
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Those human enterovirus OligoArray and Agilent eArray probes showing 
higher fluorescent intensities with the above human enterovirus amplicons are 
listed in table 4-5. Tracking the position of these probes revealed that they are 
targeting different genes of the human enterovirus genome as shown in table 4-
5. The table shows that the OligoArray probe EB3-0013 and the Agilent 
eArray probe AGV-0376 had the same sequence and generated a positive 
hybridization signal of high fluorescent intensity with echovirus 7 amplicon.  
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Table 4-5: Characteristics of the human enterovirus OligoArray and Agilent eArray probes which showed higher fluorescent intensities with the amplicons 
of the echovirus 7, coxsackievirus A-21, clinical enterovirus, and cross hybridization with the amplicons of the HMPV, HRSV and human influenza virus A, 
during their hybridization reactions.    
Sample Probe ID Probe Sequence Position Cross hybridization HMPV HRSV Flu-A 
Echovirus 7 (PCR product) 
O
lig
oA
rr
a
y 
pr
o
be
s 
EA5-0013 AAATTGTTACCATATAGCTATTGGATTGGC ¶875 ¥ ¥ ¥ 
EA5-0030 TTGTTACCATATAGCTATTGGATTGGCCAT ¶875 - - - 
EA5-0032 AATTGAGAGATTGTTACCATATAGCTATTG ¶875 - - - 
EA5-0038 CTATTGGATTGGCCATCCGGTGACAAACAG ¶875 - - - 
EA5-0039 CTGGCTGCTTATGGTGACAATTGAGAGATT ¶875 ¥ ¥ ¥ 
EA5-0050 TGTTACCATATAGCTATTGGATTGGCCATC ¶875 ¥ ¥ ¥ 
EA5-0064 ATATAGCTATTGGATTGGCCATCCGGTGAA ¶875 ¥ - ¥ 
EA5-0094 ATATAGCTATTGGATTGGCCATCCGGTGAC ¶875 ¥ ¥ ¥ 
EA3-0002 TGACAAAGTCACCAAAGATTAATTACCCTA ¶875 - ¥ - 
EB5-0018 AATTGAGAGATTGTTACCATATAGCTATTG ¶875 - - ¥ 
EB5-0021 TTGTTACCATATAGCTATTGGATTGGCCAT ¶875 ¥ ¥ ¥ 
EB5-0023 TTGGCTGCTTATGGTGACAATTGAGAGATT ¶875 ¥ ¥ ¥ 
EBC-0040 CCTGAAAGAGTCACTAGTGGGTCAAGACTC VP1  - - - 
EBC-0134 ATACAGTTCAAGTCCAAATGCCGTATTGAG VP1 ¥ ¥ ¥ 
EBC-0248 CGGTGGCTCAAACAGAAAGTGTCACAATAT VP1 - ¥ ¥ 
EBC-0132 CAATGGATGGCTTAAGAAGTTCACTGAGAT VP1-2A - - ¥ 
EBC-0133 GCCGTATTGAGCCTGTATGTTTGCTCCTAC 2A - ¥ - 
EBC-0254 GATGACAAACGCCTGCAAGGGTATGGAATG 2A - - - 
EBC-0257 AAGTCCAAATGCCGTATTGAACCTGTATGT 2A - - - 
EBC-0258 CATACAGTTCAAGTCCAAATGCCGTATTGA 2A - ¥ ¥ 
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Sample Probe ID Probe Sequence Position Cross hybridization HMPV HRSV Flu-A 
Echovirus 7 (PCR product) 
O
lig
oA
rr
a
y 
pr
o
be
s 
EBC-0529 TTCAAGTCCAAATGCCGTATTGAACCTGTA 2A - - - 
EBC-0655 AGCAACTACATACAGTTCAAGTCCAAATGC 2A - - - 
EBC-0656 AAGTCCAAATGCCGTATTGAACCTGTATGT 2A - -  
EBC-0942 TTCAAGTCCAAATGCCGTATTGAACCTGTA 2A ¥ - ¥ 
EBC-0154 AAGTCACAGATTACGGCTTCCTAAACCTGG 2C - - - 
EBC-0160 GACCAACCATCCTGATGAATGACCAGGAAG 2C - - - 
EBC-0161 GAAGTTCAGAGACATCAGAGGCTTCTTAGC 2C - - - 
EBC-0375 GAAGTTCAGAGACATCAGAGGCTTCTTGGC 2C - - ¥ 
EBC-0376 AAACCGGAATGAGAAGTTCAGAGACATCAG 2C - ¥ ¥ 
EBC-0764 GGAGTGTTGCCCGGTCAATTTCAAGAAATG 2C - - - 
EBC-0169 TCAAAGGAAGCAGGGTTCCCAATCATCAAC 3A - - - 
EBC-0280 CAGGACAATTGGCCACCCTAGATATCAGCA 3C - - ¥ 
EBC-0283 CACCCTAGATATCAGCACTGAACCAATGAA 3C - - - 
EBC-0291 GTTGACCATTATGCAGGACAATTGGCCACC 3C - - ¥ 
EBC-0377 GATGGTCATCTCATAGCCTTTGATTACTCT 3C - - - 
EBC-0386 AGTGATGTTGGATGGTCATCTCATAGCCTT 3C - - - 
EBC-0387 TCATAGCCTTTGATTACTCTGGGTATGATG 3C - - - 
EBC-0480 TATGGCTTGAACCTGCCAATGGTGACTTAT 3C - - - 
EBC-0199 CTTAGTGCACCCTGTTATGCCCATGAAAGA 3D - - - 
EBC-0300 CACGAGTATGAGGAGTTCATCCGTAAGATC 3D - ¥ ¥ 
EBC-0302 AAGGGAATTGACTTGGACCAGTTCAGGATG 3D - - - 
EBC-0308 ACTTGGACCAGTTCAGGATGATTGCATATG 3D - - ¥ 
EBC-0310 CATATGGTGACGATGTGATTGCGTCATACC 3D - - ¥ 
EBC-0312 AGGATGATTGCATATGGTGACGATGTGATT 3D - - ¥ 
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Sample Probe ID Probe Sequence Position Cross hybridization HMPV HRSV Flu-A 
Echovirus 7 (PCR product) 
O
lig
oA
rr
a
y 
pr
o
be
s 
EBC-0379 GGATACACGCACAAGGAGACAAATTACATT 3D - - - 
EBC-0597 GACCAATTCAGGATGATTGCATATGGTGAT 3D - - - 
EB3-0004 GCACTAACCGAACTAGATAACGGTGCAGTA ¶875 ¥ ¥ ¥ 
EB3-0005 TTGAAATTGGCTTAACCCTACTGCACTAAC ¶875 ¥ ¥ ¥ 
EB3-0006 TAACCCTACTGCACTAACCGAACTAGATAA ¶875 ¥ ¥ ¥ 
EB3-0009 AACCCTACTGCGCTAACCGAACTAGATAAC ¶875 - - - 
EB3-0010 TAAATTGGCTTAACCCTACTGCGCTAACCG ¶875 ¥ - ¥ 
EB3-0012 TTGATATAATTTGAATTGGCTTAACCCTAC ¶875 ¥ - ¥ 
EB3-0013 TTGAATTGGCTTAACCCTACTGCACTAACC ¶875 ¥ ¥ ¥ 
EB3-0014 CCCTACTGCACTAACCGAACTAGATAACGG ¶875 ¥ ¥ ¥ 
EB3-0016 TTGAAATAATTTGAATTGGCTTAACCCTAC ¶875 ¥ - ¥ 
EB3-0017 CCCTACTGTACTAACCGAACTAGATAACGG ¶875 - - - 
EB3-0018 ATTGGCTTAACCCTACTGTACTAACCGAAC ¶875 ¥ - ¥ 
EB3-0019 ATTTGAATTGGCTTAACCCTACTGCATTAA ¶875 ¥ - ¥ 
EB3-0020 CAATTTGAAATAATTTGAATTGGCTTAACC ¶875 - - - 
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s AGV-0205 TGATTGCATATGGTGACGATGTGATTGCGT 3D - - ¥ 
AGV-0220 CCTTTCTAAAGAGGTATTTTAGAGCAGATG 3D - - ¥ 
AGV-0256 CTCTCATGCTAAAAGTGTATAAGGGAATTG 3D - - ¥ 
AGV-0343 AATATGAGGAGTTCATCCGCAAGATCAGGA 3D ¥ ¥ ¥ 
AGV-0448 TGTATAAGGGAATTGACCTGGACCAGTTCA 3D - - - 
AGV-0449 TGCATATGGTGACGATGTGATTGCGTCATA 3D - - - 
AGV-0451 TGGACCAATGTCACATTTCTAAAGAGGTAT 3D - - - 
AGV-0452 TTTAGAGCAGATGAGCAATATCCCTTCCTG 3D - - ¥ 
AGV-0454 GGAAGTGGTTGGACTCTTTTTAAATTAGAG 3D ¥ - - 
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Sample Probe ID Probe Sequence Position Cross hybridization HMPV HRSV Flu-A 
Echovirus 7 (PCR product) 
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s AGV-0455 AACTAGATAACGGCGCAGTAGGGGTAAATT ¶875 - - ¥ 
AGV-0462 ATTGGCTTAACCTTACTGCACTAACCGAAC ¶875 - - ¥ 
AGV-0529 TTGGCTTAACCCTACTGTACTAACCGAACT 3D - - ¥ 
AGV-0607 AATTGGCTTAACCCTACTGCACTAACCGAA 3D - ¥ - 
AGV-2711 TAGTAACCCTACCTCAGTCGAATTGGATTG 3D-3¶875 - - ¥ 
AGV-0243 TTTGAATTGGCTTAACCCTACTGCGCTAAC 3D-3¶875 - - ¥ 
AGV-0261 AATTGGCTTAACCCTACTGCACTTACCGAA 3D-3¶875 - - ¥ 
AGV-0376 TTGAATTGGCTTAACCCTACTGCACTAACC 3D-3¶875 - ¥ - 
AGV-0424 TGAATTGGCTTAACCCTACTGTACTAACCG 3D - - ¥ 
Coxsackievirus A-21(PCR product) 
O
lig
oA
rr
a
y 
pr
o
be
s ECC-0507 ACTCACTTACCGACTCAAATTCATGAGACC 3D - ¥ - 
Clinical enterovirus (PCR product) EAC-0483 ACAAAATAGCAAGATGCAAGTGCAAAACTGG VP1 ¥ ¥ - 
Clinical enterovirus (MDA) 
EBC-0722 CAGGTAGCAGTGAGAGCCAACAATTCAAGC VP2 ¥ ¥ ¥ 
EBC-0327 ATGACCTAATCACAGTAACTGCCACACTAG VP1 ¥ - - 
EBC-0874 ATACATCATTTACAAGTTGTTTGCAGGCTT 2C ¥ - - 
EBC-0802 TAACACACACGTGGATGAGTACATGCAAGA 3B ¥ ¥ ¥ 
EBC-0914 CCAAGATCATGTGCGATCCTTGTGCCTATT 3D ¥ - ¥ 
EDC-0152 TACCAGACTAATGTACTTCTAGCAGCTGGC VP1 - ¥ - 
Abbreviations; EA: human enterovirus A probes, EB: human enterovirus B probes, EC: human enterovirus C probes, ED: human enterovirus D probes,  
$*9$JLOHQWH$UUD\SUREHV¥K\EULGL]DWLRQVLJQDO-: no hybridization. 
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4.4.4.1.3 Specificity of the human enterovirus probes  
Many of the human enterovirus OligoArray and Agilent eArray probes shown 
in table 4-5 showed cross hybridization with the amplicons of the HMPV, 
HRSV, H1N1 and H3N2 revealed as nonspecific signals of various fluorescent 
intensities (figures 4-16 to 4-18).   
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Figure 4-16: Signals of cross hybridization generated between the human 
enterovirus probes and the HMPV amplicons.  
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4.4.4.2 Hybridization results of the HMPV amplicons  
RNA extracts of three HMPV clinical samples (HMPV-1, 2 and 3) were 
reverse transcribed into cDNA and then amplified using long-range PCR. The 
cDNA of HMPV-1 was also amplified by MDA. The amplicons were 
fragmented by sonication. The fragmented PCR amplicons of the HMPV-1 and 
2 in addition to the MDA of the HMPV-1 were labelled with dyomics 547 
fluorescent dye, while the fragmented PCR amplicon of the HMPV-3 was 
labelled with dyomics 495 fluorescent dye (see table 4-3). The labelled HMPV 
amplicons were loaded into hybridization reactions with the probes designed 
for the selected RNA virus groups using four different grids of the virochip. 
None of the HMPV probes designed using Agilent eArray software generated 
positive hybridization signals during the hybridization reactions of the HMPV 
amplicons. This might be due to the use of whole viral genome sequences of 
the HMPV rather than using their consensus sequence during the probe design 
stage.  
 
4.4.4.2.1 Sensitivity of the HMPV probes designed using OligoArray 
software 
Hybridization reactions of the HMPV amplicons showed that 347 probes out of 
473 of the OligoArray probes designed specifically for the HMPV generated 
positive specific hybridization signals (see table 4-4). Analysing these positive 
hybridization signals revealed that more than 120 of these positive HMPV 
OligoArray probes showed high fluorescent intensities with the HMPV-2 
amplicon generated by long-range PCR (figure 4-19). For the HMPV-1, all the 
positive signals generated from the HMPV OligoArray probes showed low 
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fluorescent intensities when the hybridization reaction was carried out with the 
HMPV-1 amplicon generated by long-range PCR. This might be due to the 
extensive processing of the samples which might affect the resultant 
hybridization signals. In contrast, the hybridization reactions of the HMPV-1 
and HMPV-3 amplicons generated by MDA and long-range PCR, respectively, 
revealed positive signals of various fluorescent intensities generated from 
several of the HMPV OligoArray probes which most of them showed positive 
hybridization signals with the amplicon of the HMPV-2 (figure 4-19).  
Those HMPV OligoArray probes showing higher fluorescent intensities with 
the HMPV amplicons are listed in table 4-6. Tracking the position of these 
probes revealed that they are targeting different genes of the HMPV genome as 
shown in table 4-6.  
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Figure 4-19: Signals generated from the hybridization reactions of four of the HMPV amplicons with the probes designed specifically for the HMPV 
using OligoArray software. 
RNA extracts of three HMPV clinical samples (HMPV1-3) were reverse transcribed into cDNA and amplified using long-range PCR. The cDNA of the 
HMPV-1was also amplified using MDA. The generated amplicons were sonicated, labelled and loaded into hybridization reactions with the designed probes 
of the selected RNA viruses and HHVs. The red, green, blue and brown columns represent the positive hybridization signals generated from the HMPV 
OligoArray probes after hybridization to the PCR products of the HMPV-1, 2 and 3, and the MD amplicon of the HMPV-1, respectively. 
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Table 4-6: Characteristics of the HMPV OligoArray probes which showed higher fluorescent intensities with the HMPV 
amplicons, and cross hybridization with the amplicons of the human enteroviruses, HRSV and human influenza virus A, 
during their hybridization reactions.    
Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0003 GAGAGAGTACAGCAGATTCTAAGAAACTCA N ¥ ¥ - 
HMPV-0006 ATTCTAAGAAACTCAGGCAGTGAAGTTCAA N - - - 
HMPV-0011 TACAAATATGCTGCAGAAATAGGAATACAA N - - - 
HMPV-0014 GACACCCTCATCATTGCAACAAGAAATAAC N - - - 
HMPV-0017 TCTCTTCAAGGGATTCACCTGAGTGATCTA N - - - 
HMPV-0022 GAGGCTGCAGAACACTTCTTAAATGTGAGT N - - ¥ 
HMPV-0024 TATCGAGGGAGAGTGCCAAACACAGAACTA N - ¥ - 
HMPV-0026 CAACTTTGCTAGTGTTGTTCTCGGCAATGC N - ¥ - 
HMPV-0027 GCTGGACTGTTATCATTAGCCAATTGTCCC N - ¥ - 
HMPV-0225 GTTTGTTCATTGAGTATGGCAAAGCATTAG N ¥ ¥ ¥ 
HMPV-0226 TAGGATGGACATACCAAAGATTGCTAGATC N ¥ ¥ - 
HMPV-0227 AATCTTATTATGTGTAGGTGCCTTAATATT N ¥ ¥ - 
HMPV-0228 CAGTCAGAAGAGCTAACCGTGTGCTAAGTG N ¥ ¥ - 
HMPV-0229 TTAGAGACCACAGTCAGAAGAGCTAACCGT N - ¥ - 
HMPV-0237 TGTTAATATATTCATGCAAGCTTATGGAGC N - - - 
HMPV-0239 CTTCTACAGGCAGCAAAGCAGAAAGTTTAT N - ¥ - 
HMPV-0241 TATTACAGAAGTTTGTTCATTGAGTATGGC N ¥ ¥ - 
HMPV-0029 GGCTATTAAGAACACTCAACATTGCAACAG P - - - 
HMPV-0039 TCATCATTAAGCATTGAGGCCAGACTAGAA P - ¥ - 
HMPV-0040 GAAGATGCAGAATCCTCAATCTTAACCTTT P - ¥ - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0253 GAAGATGACATTTACCAGTTAATTATGTAG P - ¥ - 
HMPV-0256 AATGATGGAAGAGGAAATGAATCAACGGTC P ¥ ¥ ¥ 
HMPV-0053 AGAACTAGGAGCATATGTCCAGGCTGAAAG M ¥ ¥ - 
HMPV-0057 TATGCAAGACTTGGAGCCATCAAGGAACAA M - - - 
HMPV-0252 GTTACCTGCAAGCCTAACAATATGGTTTCC M ¥ ¥ - 
HMPV-0263 ACACAGCAGCTGTTCAAGTTGATCTAGTAG M - ¥ ¥ 
HMPV-0272 TAAGCAGTGAAGCAGACCAAGCTCTAACAC M ¥ ¥ - 
HMPV-0273 ATCAAAGAGAGTGAATCAGCCACTGTTGAA M ¥ ¥ ¥ 
HMPV-0276 ACAATACCAGCATTTATCAAATCAGTTTCA M - ¥ - 
HMPV-0278 GAATCAGCCACTGTTGAAGCTGCAATAAGC M ¥ ¥ ¥ 
HMPV-0050 GCTAATAACACCTCAACACGGTCTTAAAGA F - ¥ - 
HMPV-0060 ATCATGTAGCACTATAACTGAGGGATATCT F - - - 
HMPV-0062 GTGTTATAGATACGCCTTGCTGGATAGTAA F ¥ ¥ ¥ 
HMPV-0063 GTGCAGCTGCCAATCTTTGGTGTTATAGAT F ¥ ¥ - 
HMPV-0064 TAATTTACATGGTGCAGCTGCCAATCTTTG F - ¥ - 
HMPV-0067 AATTACCCATGCAAAGTCAGCACAGGAAGA F ¥ ¥ ¥ 
HMPV-0068 ATCTACTACAAATTACCCATGCAAAGTCAG F ¥ ¥ ¥ 
HMPV-0070 AAGGAGTGCAACATCAACATATCTACTACA F - - - 
HMPV-0071 ATCAATGTTGCTGAGCAATCAAAGGAGTGC F ¥ ¥ ¥ 
HMPV-0072 CTATGCTTGCCTCCTAAGAGAAGACCAAGG F - ¥ - 
HMPV-0279 AGTGAAGTTACAGCAATTAAGAATGCCCTC F ¥ ¥ - 
HMPV-0280 ACGGCTTGAGAGTGAAGTTACAGCAATTAA F ¥ ¥ - 
HMPV-0281 ACTTAATGACAGATGCTGAACTAGCCAGAG F ¥ ¥ - 
HMPV-0283 TTGTTCTAGGAGCAATAGCACTCGGTGTTG F ¥ ¥ - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0285 ATGCTGAACTAGCCAGAGCTGTTTCAAACA F - ¥ - 
HMPV-0288 AACAGAAGGTTTCTAAATGTTGTGCGGCAA F ¥ ¥ ¥ 
HMPV-0289 CAGTCAATTCAACAGAAGGTTTCTAAATGT F - - - 
HMPV-0318 TATCAGCTAAGCAAAGTTGAGGGTGAACAG F ¥ ¥ ¥ 
HMPV-0076 ATTGATGATAACCAAAGCATAACAAAGGCT M2 - - - 
HMPV-0337 AGTGGAGAACATTCGAGCAATAGACATGCT G - - - 
HMPV-0114 GTAAACATGCAACATGAAATAATGAAGAAT L ¥ ¥ ¥ 
HMPV-0115 AGTAGAACCAGTAAACATGCAACATGAAAT L - ¥ ¥ 
HMPV-0116 ATTACAAGGTAGTAGAACCAGTAAACATGC L - - - 
HMPV-0117 AAATAACAATGGATCCTCTTAATGAATCCA L ¥ ¥ - 
HMPV-0119 TCCAAGAGACAAATAACAATGGATCCTCTT L - ¥ - 
HMPV-0120 GAGAATCCTGTTATTGAGCATGTTAGACTC L ¥ ¥ ¥ 
HMPV-0121 TCCTCTTAATGAATCCACTGTTAATGTCTA L - ¥ - 
HMPV-0123 AAATAATGAAGAATGTACACAGTTGTGAGC L - ¥  
HMPV-0131 GAGAATGCTGCAGAATTATACTATATATTC L ¥ ¥ ¥ 
HMPV-0132 TGAAGTTGTACTTAAATTATTAGGAGATAC L ¥ ¥ - 
HMPV-0133 TGATTATCCAATGTATGAAGTTGTACTTAA L ¥ ¥ - 
HMPV-0135 CTCAATTCAGTACTAGATTTAGAAATACTT L ¥ ¥ - 
HMPV-0136 TCTTAGGATTACTGAACATGCTCAATTCAG L - ¥ - 
HMPV-0137 TGAGTGAAATTCTTAGGATTACTGAACATG L - - - 
HMPV-0138 GGTTTTATTATGAGTGAAATTCTTAGGATT L - ¥ - 
HMPV-0139 GTTGGAGAGCTTGACAGAACTAAGAGGAGC L - ¥ - 
HMPV-0141 ACTGAACATGCTCAATTCAGTACTAGATTT L - ¥ ¥ 
HMPV-0142 AGAGTTCGAAGGTTTTATTATGAGTGAAAT L ¥ ¥ ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0143 CACCCAATGGTAGATGAGAGAGATGCAATG L - - - 
HMPV-0154 AACTTATACATGCATGAATCAAAGCAACAT L - - - 
HMPV-0157 CTGGCTGTATAACTTATACATGCATGAATC L - - - 
HMPV-0167 AATGACATCTTTATTAAACGGTGACAACCA L - - - 
HMPV-0169 AGAACCTAGGATTATTATCTAGAATATTGT L - ¥ - 
HMPV-0170 TGACAGAACTACAAGAGGTCAAAGAGGTCC L ¥ ¥ - 
HMPV-0173 GGAGTAACATCTCCTAGCATCACTACATGT L - ¥ ¥ 
HMPV-0178 GTCAGTAGTTGTTGATAGTATAGAAATTCC L ¥ ¥ - 
HMPV-0179 CTAGAATATTGTCAGTAGTTGTTGATAGTA L - ¥ - 
HMPV-0180 ATGATGTTGGAGAACCTAGGATTATTATCT L - ¥ ¥ 
HMPV-0181 GGAAATAGTTGGAGTAACATCTCCTAGCAT L - ¥ - 
HMPV-0184 CTAGTTCTCATTTGAAAGGGATAATTATTG L - ¥ - 
HMPV-0186 AGCTGTATCTATGATGTTGGAGAACCTAGG L - ¥ - 
HMPV-0189 ATCTGCTATTAATGGTGAAGATATTGACAG L - ¥ ¥ 
HMPV-0190 TACAGAGAACATCTGCTATTAATGGTGAAG L - ¥ - 
HMPV-0192 AATCTTATTGAGTCTTTATCAGCAGCATTA L - ¥ - 
HMPV-0193 CCATGGAAATAATCTTATTGAGTCTTTATC L - - - 
HMPV-0194 GATGAAGATATAATAGATGAATCAATAGAC L - ¥ - 
HMPV-0195 TCTTTATCAGCAGCATTAGCATGTCATTGG L - ¥ - 
HMPV-0199 GGTGTGGGATATTAACAGAACAATGCATAG L - ¥ - 
HMPV-0200 GCATGTCATTGGTGTGGGATATTAACAGAA L - - - 
HMPV-0201 ACTTCTGATCAACATATCTTCAGTCCTGAC L - ¥ - 
HMPV-0202 AGATAAGATAACTTCTGATCAACATATCTT L ¥ ¥ - 
HMPV-0220 GTTCTGTACTTTATTGGAGAAGGAGCAGGA L ¥ ¥ ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0342 TCATCATATGGATGTATAGTCAAGAGCAAC L - - - 
HMPV-0343 TAGAATTTATACCTAGTTGGGTAAGCAATT L - ¥ - 
HMPV-0344 AAATTAAATATGATATGTGATTGGCTGCAG L - ¥ ¥ 
HMPV-0346 GTGAGCTTCTTCACATACAACCAACTGTTA L - - - 
HMPV-0348 GTAATCTGCAAGGTATGTTAACTAATAAAT L ¥ ¥ ¥ 
HMPV-0349 GGGTTTAGAAGTAATCTGCAAGGTATGTTA L - ¥ - 
HMPV-0354 AACCAACTGTTAACATGGAAAGATGTGATG L ¥ ¥ ¥ 
HMPV-0356 GGAAGTAATAAGAACTGGTTCAATCTTATG L ¥ ¥ ¥ 
HMPV-0357 GGTAAGCAATTGGTTTAGTAATTGGTACAA L - ¥ - 
HMPV-0358 GAGCTTGCTGCAATACAATTTGAACAAGAG L ¥ ¥ - 
HMPV-0361 CCAATCTTGAGATGGTATTAAATGATAAAG L ¥ ¥ ¥ 
HMPV-0398 GTAGTAGATCTATGGATGAACATACCAATG L - - - 
HMPV-0400 GGAGGAGATCCAGTAGTCTTCTATAGATCT L ¥ ¥ - 
HMPV-0405 ATGAGAGATCCTCAGGCTGTTGGATCAGAA L ¥ ¥ ¥ 
HMPV-0406 GACAACACTAATGAGAGATCCTCAGGCTGT L - ¥ - 
HMPV-0407 GTGCTACACTGACAACACTAATGAGAGATC L - - - 
HMPV-0412 CACCAGTGTTTCAAGGGAAATTCAATTATA L ¥ ¥ - 
HMPV-0414 TAGCATAATGAGTGTAGTAGAACAATTAAC L - ¥ - 
HMPV-0415 CAATTAATCAAGCACTAAGTGAGAGATTTG L ¥ ¥ ¥ 
HMPV-0419 TGTAGTAGAACAATTAACTGGTAGAAGCCC L ¥ ¥ ¥ 
HMPV-0420 GCTGTGGAATTAGCATAATGAGTGTAGTAG L ¥ ¥ - 
HMPV-0421 TAAGTGAGAGATTTGGGAATGAAGATATTA L ¥ ¥ ¥ 
HMPV-0423 GACCTATGGAATTCCCAGCATCAGTTCCAG L ¥ ¥ - 
HMPV-0424 TGTCAGTAGTAGACCTATGGAATTCCCAGC L ¥ ¥ ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HRSV Flu-A 
HMPV-0432 AGTTCCAGCTTATAGAACAACAAATTACCA L ¥ ¥ ¥ 
HMPV-0433 TCCCAGCATCAGTTCCAGCTTATAGAACAA L ¥ ¥ - 
HMPV-0434 GATATAACTTTGTCTTTAGTTCTACTGGAT L ¥ ¥ - 
HMPV-0435 GCATGTTAATAGATATAACTTTGTCTTTAG L ¥ ¥ - 
HMPV-0436 AGCTAACAAGAAATTACATGATACTATTGC L ¥ ¥ - 
HMPV-0437 TTATGCTAAAGGGAAGCTAACAAGAAATTA L ¥ ¥ - 
HMPV-0438 CAAGTTCAAATTATGCTAAAGGGAAGCTAA L ¥ ¥ - 
HMPV-0443 GCTGAAGGTGATTTGGTTGAGATCAAATCA L ¥ ¥ - 
HMPV-0445 GATTGTCAATGCTGAAGGTGATTTGGTTGA L ¥ ¥ ¥ 
HMPV-0449 TCTCACACGATTAATTAGAAAGAAGTTGAT L - - - 
HMPV-0450 ATTGCCATGGCAGCATGTTAATAGATATAA L ¥ ¥ - 
HMPV-0452 AAGTTGATGTGTGATAATGCACTTTTAACT L - ¥ - 
HMPV-0453 AATTAGAAAGAAGTTGATGTGTGATAATGC L ¥ ¥ - 
HMPV-0454 TGGCACATGCTCTCACACGATTAATTAGAA L ¥ ¥ - 
HMPV-0455 AAGTACCTTGGATTGTCAATGCTGAAGGTG L ¥ ¥ ¥ 
HMPV-0457 TAGGGTTTAAGAACTGGTTTATAGAGCAGT L ¥ ¥ - 
HMPV-0458 GTAGGTTATATAGGGTTTAAGAACTGGTTT L ¥ ¥ - 
Abbreviations; ¥K\EULGL]DWLRQVLJQDO-: no hybridization. 
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4.4.4.2.2 Specificity of the HMPV probes  
Many of the HMPV OligoArray probes shown in table 4-6 showed cross 
hybridization with the amplicons of the human enterovirus, HRSV, H1N1 and 
H3N2 revealed as nonspecific signals of various fluorescent intensities (figures 
4-20 to 4-22).  
 
H
M
P
V
-
0
0
0
3
H
M
P
V
-
0
0
5
3
H
M
P
V
-
0
0
6
2
H
M
P
V
-
0
0
6
3
H
M
P
V
-
0
0
6
7
H
M
P
V
-
0
0
6
8
H
M
P
V
-
0
0
7
1
H
M
P
V
-
0
1
1
4
H
M
P
V
-
0
1
1
7
H
M
P
V
-
0
1
2
0
H
M
P
V
-
0
1
3
1
H
M
P
V
-
0
1
3
2
H
M
P
V
-
0
1
3
3
H
M
P
V
-
0
1
3
5
H
M
P
V
-
0
1
4
2
H
M
P
V
-
0
1
7
0
H
M
P
V
-
0
1
7
8
H
M
P
V
-
0
2
0
2
H
M
P
V
-
0
2
2
0
H
M
P
V
-
0
2
2
5
H
M
P
V
-
0
2
2
6
H
M
P
V
-
0
2
2
7
H
M
P
V
-
0
2
2
8
H
M
P
V
-
0
2
4
1
H
M
P
V
-
0
2
5
2
H
M
P
V
-
0
2
5
6
H
M
P
V
-
0
2
7
2
H
M
P
V
-
0
2
7
3
H
M
P
V
-
0
2
7
8
H
M
P
V
-
0
2
7
9
H
M
P
V
-
0
2
8
0
H
M
P
V
-
0
2
8
1
H
M
P
V
-
0
2
8
3
H
M
P
V
-
0
2
8
8
H
M
P
V
-
0
3
1
8
H
M
P
V
-
0
3
4
8
H
M
P
V
-
0
3
5
4
H
M
P
V
-
0
3
5
6
H
M
P
V
-
0
3
5
8
H
M
P
V
-
0
3
6
1
H
M
P
V
-
0
4
0
0
H
M
P
V
-
0
4
0
5
H
M
P
V
-
0
4
1
2
H
M
P
V
-
0
4
1
5
H
M
P
V
-
0
4
1
9
H
M
P
V
-
0
4
2
0
H
M
P
V
-
0
4
2
1
H
M
P
V
-
0
4
2
3
H
M
P
V
-
0
4
2
4
H
M
P
V
-
0
4
3
2
H
M
P
V
-
0
4
3
3
H
M
P
V
-
0
4
3
4
H
M
P
V
-
0
4
3
5
H
M
P
V
-
0
4
3
6
H
M
P
V
-
0
4
3
7
H
M
P
V
-
0
4
3
8
H
M
P
V
-
0
4
4
3
H
M
P
V
-
0
4
4
5
H
M
P
V
-
0
4
5
0
H
M
P
V
-
0
4
5
3
H
M
P
V
-
0
4
5
4
H
M
P
V
-
0
4
5
5
H
M
P
V
-
0
4
5
7
H
M
P
V
-
0
4
5
8
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
3 0 0 0 0
3 5 0 0 0
4 0 0 0 0
4 5 0 0 0
5 0 0 0 0
5 5 0 0 0
6 0 0 0 0
F
lo
u
r
e
s
c
e
n
c
e
 
in
te
n
c
it
y
A
r
b
it
r
a
r
y 
u
n
it
e
E c h o v ir u s  7  (P C R  p r o d u c t )
C o x s a c k iv ir u u s  A - 2 1  (P C R  p r o d u c t )
C l in ic a l  e n t e r o v ir u s  ( P C R  p r o d u c t )
C lin ic a lE n t e r o v ir u s  ( M D A - p r o d u c t )
Figure 4-20: Signals of cross hybridization generated between the HMPV probes 
and the human enterovirus amplicons. 
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4.4.4.3 Hybridization results of the HRSV amplicons  
RNA extracts of three HRSV clinical samples (HRSV-1, 2 and 3) were reverse 
transcribed into cDNA and then amplified using long-range PCR. The cDNA 
of the HRSV-1 was also amplified by MDA. The generated HRSV amplicons 
were fragmented by sonication. The fragmented PCR amplicon of the HRSV-1 
was labelled with dyomics 547 fluorescent dye, while the fragmented PCR 
amplicons of the HRSV-2 and HRSV-3 in addition to the fragmented MD 
amplicon of the HRSV-1 were labelled with dyomics 495 fluorescent dye (see 
table 4-3). The labelled HRSV amplicons were loaded into hybridization 
reactions with the probes designed for the selected RNA virus groups using 
four different grids of the virochip.  
 
4.4.4.3.1 Sensitivity of the HRSV probes designed using OligoArray 
software  
Hybridization reactions of the HRSV amplicons showed that 498 probes out of 
649 of the OligoArray probes designed specifically for the HRSV generated 
positive specific hybridization signals (see table 4-4). Analysing these positive 
hybridization signals revealed that more than 200 of these positive HRSV 
OligoArray probes showed high fluorescent intensities with the HRSV-1 
amplicon generated by long-range PCR (figure 4-23). For the HRSV-2, all the 
positive signals generated from the HRSV OligoArray probes showed low 
fluorescent intensities when the hybridization reaction was carried out with the 
HRSV-2 amplicon generated by long-range PCR. In contrast, the hybridization 
reactions of the HRSV-1 and HRSV-3 amplicons generated by MDA and long-
range PCR, respectively, revealed positive signals of various fluorescent 
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intensities generated from several of the HRSV OligoArray probes which most 
of them showed positive hybridization signals with the amplicon of the HRSV-
1 (figure 4-23).  
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Figure 4-23: Signals generated from the hybridization reactions of four of the HRSV amplicons with the probes designed specifically for the HRSV 
using OligoArray software. 
RNA extracts of three HRSV clinical samples (HRSV1-3) were reverse transcribed into cDNA and amplified using long-range PCR. The cDNA of the 
HRSV-1 was also amplified by MDA. The generated amplicons were sonicated, labelled and loaded into hybridization reactions with the designed probes of 
the selected RNA viruses and HHVs. The green, blue, red and brown columns represent the positive hybridization signals generated from the HRSV 
OligoArray probes after hybridization to the PCR products of the HRSV-1, 2 and 3, and the MD amplicon of the HRSV-1, respectively.     
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4.4.4.3.2 Sensitivity of the HRSV probes designed using Agilent eArray 
software  
Analysing the positive signals generated from the hybridization reactions of the 
HRSV amplicons revealed that only 14 probes out of 42 of the Agilent eArray 
probes designed specifically for the HRSV generated positive specific signals 
when the hybridization reaction was carried out with the HRSV-1 amplicon 
generated by long-range PCR; eight of them showed high fluorescent 
intensities. None of the HRSV Agilent eArray probes generated positive 
hybridization signals during the hybridization reactions of other HRSV 
amplicons (figure 4-24). 
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Figure 4-24: Signals generated from the hybridization reactions of the HRSV-1 
amplicon with the probes designed specifically for the HRSV using Agilent 
eArray software. 
RNA extract of the HRSV clinical sample (HRSV-1) were reverse transcribed into 
cDNA and amplified using long-range PCR. The generated amplicon was sonicated, 
labelled and loaded into hybridization reaction with the designed probes of the selected 
RNA viruses and HHVs. The green columns represent the positive hybridization 
signals generated from the HRSV Agilent eArray probes after hybridization to the 
PCR products of the HRSV-1.  
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Those HRSV OligoArray and Agilent eArray probes showing higher 
fluorescent intensities with the HRSV amplicons are listed in table 4-7. 
Tracking the position of these probes revealed that they are targeting different 
genes of the HRSV genome as shown in table 4-7. The table shows that the 
OligoArray probe HRSV-0300 and the Agilent eArray probe AGV-2736 had 
the same sequence and generated a positive hybridization signal of high 
fluorescent intensity with PCR product of the HRSV-1. 
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Table 4-7: Characteristics of the HRSV OligoArray and Agilent eArray probes which showed higher fluorescent intensities with 
the HRSV amplicons, and cross hybridization with the amplicons of the human enteroviruses, HMPV and human influenza 
virus A, during their hybridization reactions.   
Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
o
be
s 
HRSV-0330 CAACTAGCAAATCAATGTCACTAACACCAT NS1 - - - 
HRSV-0314 TATTTATCAATCATGATGGGTTCTTAGAAT NS2 - - - 
HRSV-0315 CCTATGCCAATATTTATCAATCATGATGGG NS2 - - - 
HRSV-0020 TGTTATTAATCACAGAAGATGCTAATCATA N ¥ - - 
HRSV-0021 AGTTATGTGGCATGTTATTAATCACAGAAG N ¥ ¥ ¥ 
HRSV-0024 GAATGATACACTCAACAAAGATCAACTTCT N ¥ ¥ - 
HRSV-0025 AAGTCAAGTTGAATGATACACTCAACAAAG N ¥ ¥ - 
HRSV-0030 ATTCACTGGGTTAATAGGTATGTTATATGC N ¥ ¥ ¥ 
HRSV-0031 CTAATCATAAATTCACTGGGTTAATAGGTA N ¥ ¥ - 
HRSV-0032 ACAGAAGATGCTAATCATAAATTCACTGGG N ¥ ¥ ¥ 
HRSV-0034 TACTCCTAATTATGATGTGCAGAAACACAT N ¥ ¥ - 
HRSV-0038 GCTCTTAGCAAAGTCAAGTTGAATGATACA N ¥ ¥ ¥ 
HRSV-0335 CTTCTACCAGAGGTGGCAGTAGAGTTGAAG N ¥ ¥ - 
HRSV-0336 TATAGCACAATCTTCTACCAGAGGTGGCAG N ¥ ¥ ¥ 
HRSV-0340 CCTGATTGTGGGATGATAATATTATGTATA N - - - 
HRSV-0341 AATTCAAATCAACATTGAGATAGAATCTAG N ¥ - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
o
be
s 
HRSV-0342 TAACAACTGAAATTCAAATCAACATTGAGA N ¥ - ¥ 
HRSV-0343 TTGGCAAGCTTAACAACTGAAATTCAAATC N ¥ - - 
HRSV-0345 ATGTAACAACACATCGTCAAGACATTAATG N - - - 
HRSV-0346 AGCAGTGATTAGGAGAGCTAATAATGTCCT N - - - 
HRSV-0348 GCAGCATTAGTAATAACCAAATTAGCAGCA N ¥ - ¥ 
HRSV-0349 ATTATGTATAGCAGCATTAGTAATAACCAA N - - - 
HRSV-0350 GGATGATAATATTATGTATAGCAGCATTAG N ¥ ¥ ¥ 
HRSV-0351 GCATGACTCTCCTGATTGTGGGATGATAAT N ¥ ¥ ¥ 
HRSV-0352 CAGAATACAGGCATGACTCTCCTGATTGTG N ¥ ¥ ¥ 
HRSV-0354 TGAAATTTGAAGTGTTAACATTGGCAAGCT N - - - 
HRSV-0356 ACTAGAGGCTATCAAACATCAGCTTAATCC N ¥ ¥ ¥ 
HRSV-0357 CAGCAGAAGAACTAGAGGCTATCAAACATC N ¥ ¥ ¥ 
HRSV-0361 TCTTTGACTCAATTTCCTCACTTCTCCAGT N - - - 
HRSV-0364 TTAGACTTGACAGCAGAAGAACTAGAGGCT N - - - 
HRSV-0367 GAGTACAGAGGTACACCAAGGAATCAAGAT N - - - 
HRSV-0369 AGCAGGATTCTACCATATATTGAACAACCC N ¥ ¥ ¥ 
HRSV-0370 TGGGTGGAGAAGCAGGATTCTACCATATAT N ¥ ¥ ¥ 
HRSV-0373 GCAGAAATGGAACAAGTTGTGGAGGTTTAT N ¥ ¥ ¥ 
HRSV-0044 ACGATAATATAACAGCAAGATTAGATAGGA P - ¥ ¥ 
HRSV-0045 GAAGAAATAAATGATCAGACAAACGATAAT P ¥ ¥ ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
o
be
s 
HRSV-0046 CTAAACTATACAAAGAAACCATAGAAACAT P ¥ ¥ ¥ 
HRSV-0048 AGTAAGTTTCAAAGAAGACCCTACACCAAG P ¥ ¥ ¥ 
HRSV-0053 AGAAAGCCCTATAACATCAAATTCAACCAT P - ¥ ¥ 
HRSV-0054 TATCATATCTGTCAACTCAATAGATATAGA P ¥ - - 
HRSV-0055 ACTAGGAATGCTTCACACATTAGTAGTTGC P - - - 
HRSV-0056 TAAGTGAAATACTAGGAATGCTTCACACAT P ¥ ¥ ¥ 
HRSV-0057 GATCAGACAAACGATAATATAACAGCAAGA P ¥ ¥ ¥ 
HRSV-0059 GAAGAATCTAGCTATTCATATGAAGAAATA P - - ¥ 
HRSV-0060 CATAGAAACATTTGATAACAATGAAGAAGA P ¥ ¥ ¥ 
HRSV-0061 AAGTAACCAAAGAAAGCCCTATAACATCAA P ¥ ¥ ¥ 
HRSV-0062 ATAGATATAGAAGTAACCAAAGAAAGCCCT P ¥ ¥ ¥ 
HRSV-0063 GGCAAATTCACATCACCCAAAGATCCCAAG P ¥ ¥ ¥ 
HRSV-0064 ATCAATAAAGGGCAAATTCACATCACCCAA P ¥ ¥ ¥ 
HRSV-0065 AATTCCTAGAATCAATAAAGGGCAAATTCA P ¥ ¥ ¥ 
HRSV-0067 TGCAAACAACAGAGCTACCAAATTCCTAGA P - - - 
HRSV-0068 ATGGAGAAGATGCAAACAACAGAGCTACCA P ¥ ¥ ¥ 
HRSV-0069 CCTGAATTCCATGGAGAAGATGCAAACAAC P ¥ ¥ ¥ 
HRSV-0070 TACTGCAGGGAACAAGCCCAATTATCAAAG P - - - 
HRSV-0113 AAATCCAGAACACACAAGTCAAAAGGAAAC P - ¥ - 
HRSV-0375 AACACACAACACCAACAGAAGACCAACAAA P - ¥ - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
o
be
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HRSV-0378 CAAACAAACCAACTCAACCATCCAACCAAA P ¥ ¥ - 
HRSV-0382 ATCACTTGAAGATTTCTGATTAGTTACCAA P - - - 
HRSV-0385 TGACAGATTAGAAGCTATGGCAAGACTCAG P - - - 
HRSV-0387 AGAACTGAAGCATTAATGACCAATGACAGA P ¥ ¥ ¥ 
HRSV-0388 CCTACATCTGCTCGGGATGGTATAAGAGAT P ¥ ¥ ¥ 
HRSV-0389 ACAATGATCTATCACTTGAAGATTTCTGAT P ¥ ¥ ¥ 
HRSV-0390 AATGATAGTGACAATGATCTATCACTTGAA P ¥ - ¥ 
HRSV-0391 GTTGGAAGGGAATGATAGTGACAATGATCT P ¥ ¥ ¥ 
HRSV-0392 AGATGAAGTGTCTCTCAATCCAACATCAGA P ¥ ¥ ¥ 
HRSV-0393 CCATGGTTGGTTTAAGAGAAGAAATGATAG P ¥ ¥ ¥ 
HRSV-0394 GTATAAGAGATGCCATGGTTGGTTTAAGAG P - ¥ ¥ 
HRSV-0096 ACACAGCTGCTGTTCAATACAATGTCCTAG M ¥ - - 
HRSV-0414 CAGCTACACGATTTGCAATCAAACCCATGG M - - - 
HRSV-0431 ACTAACAACTGCAATCATACAAGATGCAAC G - - - 
HRSV-0432 ACAAAGTCACACTAACAACTGCAATCATAC G - - - 
HRSV-0433 TCGGCAAACCACAAAGTCACACTAACAACT G - - - 
HRSV-0434 TATTCATAGCCTCGGCAAACCACAAAGTCA G - ¥ - 
HRSV-0435 TAATTGCAGCCATCATATTCATAGCCTCGG G - ¥ - 
HRSV-0439 GTTAAATCTTAAATCTATAGCACAAATCAC G - - - 
HRSV-0123 AGCATATCAAACATTGAAACTGTGATAGAG F ¥ - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
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HRSV-0127 CAAATAGTTAGACAGCAAAGTTACTCTATC F ¥ - ¥ 
HRSV-0128 CAACAATGTTCAAATAGTTAGACAGCAAAG F ¥ - - 
HRSV-0131 GCAAAGCTGCAGCATATCAAACATTGAAAC F ¥ - ¥ 
HRSV-0135 GCTCTACTATCCACAAACAAGGCTGTAGTC F ¥ - - 
HRSV-0136 ATCAATGATATGCCTATAACAAATGATCAG F ¥ - - 
HRSV-0139 AATTTAGTGTTAATGCAGGTGTAACTACAC F - - - 
HRSV-0145 CTGAGTGGTATAAATAATATTGCATTTAGT F - - ¥ 
HRSV-0148 CTGGTAAATCCACCACAAATATCATGATAA F - - - 
HRSV-0157 AATGTAAATGCTGGTAAATCCACCACAAAT F ¥ - - 
HRSV-0160 GAATTTGATGCATCAATATCTCAAGTCAAT F - - - 
HRSV-0450 GGCTATCTTAGTGCTCTAAGAACTGGTTGG F ¥ - ¥ 
HRSV-0451 AGTTAGCAAAGGCTATCTTAGTGCTCTAAG F ¥ - ¥ 
HRSV-0452 CATGCAGTGCAGTTAGCAAAGGCTATCTTA F ¥ - ¥ 
HRSV-0461 TATCACATCTCTAGGAGCCATTGTGTCATG F ¥ - - 
HRSV-0462 TAAGCAGCTCCGTTATCACATCTCTAGGAG F ¥ - - 
HRSV-0463 AGTAAATCTCTGCAACATTGACATATTCAA F - - - 
HRSV-0467 CCCACAAGCTGAAACATGTAAAGTTCAATC F ¥ - - 
HRSV-0470 CACAATGAACAGTTTAACATTACCAAGTGA F - - - 
HRSV-0473 GAGGATGGTACTGTGACAATGCAGGATCAG M2 ¥ ¥ ¥ 
HRSV-0481 ATGTTAAACAGAATACTTAAGTCTATGGAT M2 - - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
o
be
s 
HRSV-0482 ATCCTTGCAAATTTGAAATTCGAGGTCATT M2 - - - 
HRSV-0485 AATATAACTAAACAATCAGCATGTGTTGCC M2 ¥ ¥ ¥ 
HRSV-0486 AGTTGGAGTGCTAGAGAGTTATATAGGATC M2 ¥ - - 
HRSV-0487 CTCTTGGTGTAGTTGGAGTGCTAGAGAGTT M2 - - - 
HRSV-0488 AGAGTTGGACAGAACAGAAGAGTATGCTCT M2 ¥ - ¥ 
HRSV-0489 AATAAGTGGAGCTGCAGAGTTGGACAGAAC M2 ¥ ¥ ¥ 
HRSV-0490 AGGTCATTGCTTGAATGGTAAGAGGTGTCA M2 ¥ - - 
HRSV-0491 TTGAAATTCGAGGTCATTGCTTGAATGGTA M2 - ¥ ¥ 
HRSV-0494 GGACCTCTCAAGACTTGATTGATGCAATTC M2 ¥ - ¥ 
HRSV-0495 GAAATCCATTGGACCTCTCAAGACTTGATT M2 ¥ ¥ ¥ 
HRSV-0496 AACATTCAATGAAATCCATTGGACCTCTCA M2 ¥ - ¥ 
HRSV-0504 AATGATACTACCTGACAAATATCCTTGTAG M2 ¥ - ¥ 
HRSV-0507 ACTGTCATATCATATATTGAAAGCAACAGG M2 ¥ - ¥ 
HRSV-0165 AGTGATGTCAAAGTCTATGCTATATTGAAT L ¥ - ¥ 
HRSV-0166 TATAGAAATAAGTGATGTCAAAGTCTATGC L ¥ - - 
HRSV-0167 ACAAGAGTATGACCTCGTCAGAACAGATTG L - - - 
HRSV-0168 CCTTAATATCTAAGTATCATAAAGGTGAAA L ¥ - - 
HRSV-0169 ATAACACAGTCCTTAATATCTAAGTATCAT L ¥ - - 
HRSV-0170 GAAACTAAATATAACACAGTCCTTAATATC L ¥ - ¥ 
HRSV-0172 GGAAGTTACATATTCAATGGTCCTTATCTC L ¥ - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
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HRSV-0173 TAATGCTTTAGGAAGTTACATATTCAATGG L ¥ - ¥ 
HRSV-0177 CAGTCATTACTTATGACATACAAGAGTATG L - - - 
HRSV-0196 ACCCAATGGTAGATGAAAGACAAGCCATGG L - - - 
HRSV-0199 TACATTTAACTATTCCTCATGTCACAATAA L - - - 
HRSV-0200 ATTTGTAGTGATGTACTGGATGAACTGCAT L - - - 
HRSV-0201 GTGCTCTATCATCACAGATCTCAGCAAATT L - - - 
HRSV-0202 ACATTAGTAAGTGCTCTATCATCACAGATC L - - - 
HRSV-0206 AATGTTCAGACAAGTTCAAATATTAGCAGA L - - - 
HRSV-0207 TTGACAGGCAAAGAAAGAGAACTCAGTGTA L - - - 
HRSV-0208 GTCACAATAATATGCACATATAGGCATGCA L - - - 
HRSV-0209 CTGGATGAACTGCATGGTGTACAATCTCTA L - - ¥ 
HRSV-0211 AAGCATTTCGATATGAAACATCATGTATTT L - - - 
HRSV-0212 CTCAGCAAATTCAATCAAGCATTTCGATAT L - - ¥ 
HRSV-0213 GAATAAGTAACAAATCAAATCGTTACAATG L - - - 
HRSV-0214 TTGAAAGCAGGAATAAGTAACAAATCAAAT L - - - 
HRSV-0215 TGCAACCAGGAATGTTCAGACAAGTTCAAA L - - ¥ 
HRSV-0216 TGTGGTATCATTGACAGGCAAAGAAAGAGA L - - - 
HRSV-0220 ATGTTTGCAATGCAACCAGGAATGTTCAGA L - - - 
HRSV-0223 AAGTTCTTAACATGCATAATCACGTTTGAC L ¥ - ¥ 
HRSV-0224 GATAGATTGAATAAGTTCTTAACATGCATA L ¥ - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
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o
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HRSV-0225 TCTGTCAGATGATAGATTGAATAAGTTCTT L ¥ - ¥ 
HRSV-0226 AACTTCAAGATCTGTCAGATGATAGATTGA L - - - 
HRSV-0227 GTTCATACTTAGTTATTATACAAACCATGA L - - - 
HRSV-0229 GAGGCTATAGTTCACTCTGTGTTCATACTT L - - - 
HRSV-0230 TATCGAAGTTTCTATAGAAGAACTCCTGAC L - - - 
HRSV-0231 CAACTTGTTATATCGAAGTTTCTATAGAAG L - - - 
HRSV-0236 GGTGAAAGTCTATTATGCAGTTTAATATTT L - - - 
HRSV-0240 GTGGTGATCCCAACTTGTTATATCGAAGTT L ¥ - ¥ 
HRSV-0244 ATACTAGCCCTATTAATCGCATATTAACAG L - - - 
HRSV-0250 CTAGTGGCATAATTATAGAGAAATATAATG L - - - 
HRSV-0251 TATCACTTTGATACTAGCCCTATTAATCGC L ¥ - ¥ 
HRSV-0253 GTAGTAGACCATGTGAATTCCCTGCATCAA L ¥ - ¥ 
HRSV-0254 CTTACAGTCAGTAGTAGACCATGTGAATTC L ¥ - ¥ 
HRSV-0258 GGGTGTATGCATCTATAGATAACAAGGATG L - - ¥ 
HRSV-0261 AGCACTATAGCTAGTGGCATAATTATAGAG L - - - 
HRSV-0262 ATATACAACAAGCACTATAGCTAGTGGCAT L - - - 
HRSV-0264 AACAACAAATTATCACTTTGATACTAGCCC L - - - 
HRSV-0267 CATCTATTAACTAAACATATAAGGATTGCT L - - ¥ 
HRSV-0269 CTCAGATAATACTCATCTATTAACTAAACA L - - - 
HRSV-0270 ATAGATCTTGTTAGAATGGGATTGATAAAT L - - - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
y 
pr
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HRSV-0273 TAAACGTCTTAATGTAGCAGAATTCACAGT L - - - 
HRSV-0279 CCAACACATATGAAAGCAATATTAACTTAT L - - - 
HRSV-0280 AGATTATCATCCAACACATATGAAAGCAAT L ¥ - ¥ 
HRSV-0281 TTGTTAACATAGATTATCATCCAACACATA L - - - 
HRSV-0282 TGCCCTTGGGTTGTTAACATAGATTATCAT L ¥ - ¥ 
HRSV-0284 AGTAGTTATTGGAAGTCTATGTCTAAGGTA L - - ¥ 
HRSV-0285 ATTAATAGACAGTAGTTATTGGAAGTCTAT L - - - 
HRSV-0286 GTGTATTGGAATTAATAGACAGTAGTTATT L - - - 
HRSV-0291 TACAATGGACATATCAACATTGATTATGGT L - - ¥ 
HRSV-0292 ATATTTACAGAAGTCTGAAAGATTGCAATG L ¥ ¥ ¥ 
HRSV-0294 GGAATTTATTATTGCGTACAGTAGTGGAAC L ¥ ¥ ¥ 
HRSV-0295 GCTGAATTGCCTGTAACAGTCAACTGGAGT L ¥ ¥ ¥ 
HRSV-0296 AGTCTGAAAGATTGCAATGATCATAGTTTA L ¥ ¥ ¥ 
HRSV-0297 GATCTGAAGTTTACTTAGTCCTTACAATAG L - - ¥ 
HRSV-0298 AAGTTAAAGGGATCTGAAGTTTACTTAGTC L ¥ - ¥ 
HRSV-0299 CTTAGGCAGTAAGTTAAAGGGATCTGAAGT L ¥ - - 
HRSV-0300 CTTATGTATGCTTAGGCAGTAAGTTAAAGG L ¥ - - 
HRSV-0303 GGAGCAAGCATGTAAGAAAGTGCAAGTACT L - - - 
HRSV-0305 TACATATAAAGTTTGCTGAACCTATCAGTC L ¥ - ¥ 
HRSV-0306 TGGTCTTATTTACATATAAAGTTTGCTGAA L ¥ - ¥ 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
oA
rr
a
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HRSV-0307 CAACAACATTCATTGGTCTTATTTACATAT L - - ¥ 
HRSV-0308 CTACAGATGCAACCAACAACATTCATTGGT L ¥ - ¥ 
HRSV-0309 TTTGACCATTCCTGCTACAGATGCAACCAA L ¥ - ¥ 
HRSV-0516 AAAGATAATCAATCTCATCTTAAAGCAGAC L ¥ - ¥ 
HRSV-0520 TGGACAAGATGAAGACAACTCAGTTATTAC L - - - 
HRSV-0524 GACATGGAAAGATATTAGCCTTAGTAGATT L ¥ ¥ ¥ 
HRSV-0525 ATCAATTCTTGACATGGAAAGATATTAGCC L ¥ ¥ ¥ 
HRSV-0528 GCAACATCCTCCATCATGGTTAATACATTG L ¥ ¥ ¥ 
HRSV-0529 ATGTGTTCAATGCAACATCCTCCATCATGG L ¥ - ¥ 
HRSV-0534 TGTTGGAACTTACAGAAAGAGATTTGATTG L - - - 
HRSV-0550 TCAAAGTGAGTCTAGAATCTATAGGTAGTT L - - - 
HRSV-0553 GTATATTACCCAGCTAGTATAAAGAAAGTC L - - - 
HRSV-0555 GTCAGACTCATGGAAGGTCAAACTCATGCT L ¥ - ¥ 
HRSV-0556 TAAGTAAACCAGTCAGACTCATGGAAGGTC L - - ¥ 
HRSV-0557 GCTTTAATTAATGGTGACAATCAATCAATA L - - - 
HRSV-0558 CTCAATTACTGCTTTAATTAATGGTGACAA L - - - 
HRSV-0559 AAGGGAAATTCTCAATTACTGCTTTAATTA L - - - 
HRSV-0565 GTATAAAGAAAGTCCTAAGAGTGGGACCGT L ¥ - ¥ 
HRSV-0571 TCAAACTCATGCTCAAGCAGATTATTTGCT L - - ¥ 
HRSV-0573 ATATCTCTCAAAGGGAAATTCTCAATTACT L - - - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
O
lig
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rr
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HRSV-0576 CTAAGAGTGGGACCGTGGATAAACACTATA L - - - 
HRSV-0577 TATAGATATCATATGGGTGGTATCGAAGGG L - - - 
HRSV-0580 AGTTGGTGTTACATCACCCAGTATCATGTA L - - - 
HRSV-0581 TATCCAATATAGTTGGTGTTACATCACCCA L - - - 
HRSV-0583 AGATATTGATAGAGCCACTGAGATGATGAG L ¥ - ¥ 
HRSV-0584 TAGACTTAACAGATATTGATAGAGCCACTG L - - ¥ 
HRSV-0587 TCTTGGTCTTTATCCAATATAGTTGGTGTT L - - - 
HRSV-0590 GGGCTAAGAGTTGTTTATGAAAGTTTACCC L ¥ - ¥ 
HRSV-0595 ATTCACAGGTGATGTTGATATTCACAAGTT L ¥ - ¥ 
HRSV-0597 ACTAATGTATGTCCTAACAGAATTATTCTC L - - - 
HRSV-0598 GTAGTAGAACAATTTACTAATGTATGTCCT L - - ¥ 
HRSV-0601 TGTATAAGCTTTGGCCTTAGCTTAATGTCA L ¥ - ¥ 
HRSV-0602 GGGATATATAACTGATCATATGTTCATTAA L - - - 
HRSV-0606 AAGTACTAATTTAGCTGGACATTGGATTCT L ¥ - ¥ 
HRSV-0607 GACTCAATATGTGGAATTATTCTTAAGTAA L - - ¥ 
HRSV-0608 AACCTCCCATATTCACAGGTGATGTTGATA L ¥ - ¥ 
HRSV-0609 CATTTGATGAAACCTCCCATATTCACAGGT L ¥ - ¥ 
HRSV-0610 TAATGAGATACATTTGATGAAACCTCCCAT L ¥ - ¥ 
HRSV-0620 ATAAGAAGCTTATTAAATCGTCTACAATGA L ¥ - ¥ 
HRSV-0626 GCTTCCTTGGCATCATATTAATAGATTCAA L ¥ - - 
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Probe ID Probe sequence Position Cross hybridization H. enteroviruses HMPV Flu-A 
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HRSV-0627 CACATCACTTTATTGCATGCTTCCTTGGCA L ¥ ¥ ¥ 
HRSV-0628 TGCACAATAGCACATCACTTTATTGCATGC L ¥ - ¥ 
HRSV-0629 GCCAAATCTAACCAACTTTACACTACTACT L ¥ - ¥ 
HRSV-0630 AGGTAATACAGCCAAATCTAACCAACTTTA L ¥ - ¥ 
HRSV-0631 TAGATCATTCAGGTAATACAGCCAAATCTA L ¥ - ¥ 
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s 
AGV-2729 ATGTATGCTTAGGCAGTAAGTTAAAGGGAT L ¥ - - 
AGV-2736 CTTATGTATGCTTAGGCAGTAAGTTAAAGG L ¥ - - 
AGV-2745 CTATCAGTCTTTTTGTCTGTGATGCTGAAT L ¥ - ¥ 
AGV-2748 ATGTATGCTTAGGCAGTAAGTTAAAGGGGT L - - - 
AGV-2749 CTGAAGTTTACTTAGTCCTTACAATAGGTC L ¥ - - 
AGV-2750 CTGCAAATGTGTTCCCAGTATTTAATGTAG L ¥ - - 
$EEUHYLDWLRQV$*9$JLOHQWH$UUD\SUREHV¥K\EULGL]DWLRQVLJQDO-: no hybridization. 
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4.4.4.3.3 Specificity of the HRSV probes  
Many of the HRSV OligoArray and Agilent eArray probes shown in table 4-7 
showed cross hybridization with the amplicons of the human enterovirus 
HMPV, H1N1 and H3N2 revealed as nonspecific signals of various fluorescent 
intensities (figures 4-25 to 4-27). 
C
hapter F
o
u
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A
pplicatio
n
 of
 PC
R
 fo
r testing
 the desig
n
ed viral m
icro
a
rray
 
 
 
233 
 
 
 
H R SV - 0 0 2 0
H R SV - 0 0 2 1
H R SV - 0 0 2 4
H R SV - 0 0 2 5
H R SV - 0 0 3 0
H R SV - 0 0 3 1
H R SV - 0 0 3 2
H R SV - 0 0 3 4
H R SV - 0 0 3 8
H R SV - 0 0 4 5
H R SV - 0 0 4 6
H R SV - 0 0 4 8
H R SV - 0 0 5 4
H R SV - 0 0 5 6
H R SV - 0 0 5 7
H R SV - 0 0 6 0
H R SV - 0 0 6 1
H R SV - 0 0 6 2
H R SV - 0 0 6 3
H R SV - 0 0 6 4
H R SV - 0 0 6 5
H R SV - 0 0 6 8
H R SV - 0 0 6 9
H R SV - 0 0 9 6
H R SV - 0 1 2 3
H R SV - 0 1 2 7
H R SV - 0 1 2 8
H R SV - 0 1 3 1
H R SV - 0 1 3 5
H R SV - 0 1 3 6
H R SV - 0 1 5 7
H R SV - 0 1 6 5
H R SV - 0 1 6 6
H R SV - 0 1 6 8
H R SV - 0 1 6 9
H R SV - 0 1 7 0
H R SV - 0 1 7 2
H R SV - 0 1 7 3
H R SV - 0 2 2 3
H R SV - 0 2 2 4
H R SV - 0 2 2 5
H R SV - 0 2 4 0
H R SV - 0 2 5 1
H R SV - 0 2 5 3
H R SV - 0 2 5 4
H R SV - 0 2 8 0
H R SV - 0 2 8 2
H R SV - 0 2 9 2
H R SV - 0 2 9 4
H R SV - 0 2 9 5
H R SV - 0 2 9 6
H R SV - 0 2 9 8
H R SV - 0 2 9 9
H R SV - 0 3 0 0
H R SV - 0 3 0 5
H R SV - 0 3 0 6
H R SV - 0 3 0 8
H R SV - 0 3 0 9
H R SV - 0 3 3 5
H R SV - 0 3 3 6
H R SV - 0 3 4 1
H R SV - 0 3 4 2
H R SV - 0 3 4 3
H R SV - 0 3 4 8
H R SV - 0 3 5 0
H R SV - 0 3 5 1
H R SV - 0 3 5 2
H R SV - 0 3 5 6
H R SV - 0 3 5 7
H R SV - 0 3 6 9
H R SV - 0 3 7 0
H R SV - 0 3 7 3
H R SV - 0 3 7 8
H R SV - 0 3 8 7
H R SV - 0 3 8 8
H R SV - 0 3 8 9
H R SV - 0 3 9 0
H R SV - 0 3 9 1
H R SV - 0 3 9 2
H R SV - 0 3 9 3
H R SV - 0 4 5 0
H R SV - 0 4 5 1
H R SV - 0 4 5 2
H R SV - 0 4 6 1
H R SV - 0 4 6 2
H R SV - 0 4 6 7
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H R SV - 0 4 9 5
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H R SV - 0 5 0 7
H R SV - 0 5 1 6
H R SV - 0 5 2 4
H R SV - 0 5 2 5
H R SV - 0 5 2 8
H R SV - 0 5 2 9
H R SV - 0 5 5 5
H R SV - 0 5 6 5
H R SV - 0 5 8 3
H R SV - 0 5 9 0
H R SV - 0 5 9 5
H R SV - 0 6 0 1
H R SV - 0 6 0 6
H R SV - 0 6 0 8
H R SV - 0 6 0 9
H R SV - 0 6 1 0
H R SV - 0 6 2 0
H R SV - 0 6 2 6
H R SV - 0 6 2 7
H R SV - 0 6 2 8
H R SV - 0 6 2 9
H R SV - 0 6 3 0
H R SV - 0 6 3 1
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H R S V - 0 0 2 1
H R S V - 0 0 2 4
H R S V - 0 0 2 5
H R S V - 0 0 3 0
H R S V - 0 0 3 1
H R S V - 0 0 3 2
H R S V - 0 0 3 4
H R S V - 0 0 3 8
H R S V - 0 0 4 4
H R S V - 0 0 4 5
H R S V - 0 0 4 6
H R S V - 0 0 4 8
H R S V - 0 0 5 3
H R S V - 0 0 5 6
H R S V - 0 0 5 7
H R S V - 0 0 6 0
H R S V - 0 0 6 1
H R S V - 0 0 6 2
H R S V - 0 0 6 3
H R S V - 0 0 6 4
H R S V - 0 0 6 5
H R S V - 0 0 6 8
H R S V - 0 0 6 9
H R S V - 0 1 1 3
H R S V - 0 2 9 2
H R S V - 0 2 9 4
H R S V - 0 2 9 5
H R S V - 0 2 9 6
H R S V - 0 3 3 5
H R S V - 0 3 3 6
H R S V - 0 3 5 0
H R S V - 0 3 5 1
H R S V - 0 3 5 2
H R S V - 0 3 5 6
H R S V - 0 3 5 7
H R S V - 0 3 6 9
H R S V - 0 3 7 0
H R S V - 0 3 7 3
H R S V - 0 3 7 5
H R S V - 0 3 7 8
H R S V - 0 3 8 7
H R S V - 0 3 8 8
H R S V - 0 3 8 9
H R S V - 0 3 9 1
H R S V - 0 3 9 2
H R S V - 0 3 9 3
H R S V - 0 3 9 4
H R S V - 0 4 3 4
H R S V - 0 4 3 5
H R S V - 0 4 7 3
H R S V - 0 4 8 5
H R S V - 0 4 8 9
H R S V - 0 4 9 1
H R S V - 0 4 9 5
H R S V - 0 5 2 4
H R S V - 0 5 2 5
H R S V - 0 5 2 8
H R S V - 0 6 2 7
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H R S V -0 0 2 1
H R S V -0 0 3 0
H R S V -0 0 3 2
H R S V -0 0 3 8
H R S V -0 0 4 4
H R S V -0 0 4 5
H R S V -0 0 4 6
H R S V -0 0 4 8
H R S V -0 0 5 3
H R S V -0 0 5 6
H R S V -0 0 5 7
H R S V -0 0 5 9
H R S V -0 0 6 0
H R S V -0 0 6 1
H R S V -0 0 6 2
H R S V -0 0 6 3
H R S V -0 0 6 4
H R S V -0 0 6 5
H R S V -0 0 6 8
H R S V -0 0 6 9
H R S V -0 1 2 3
H R S V -0 1 2 7
H R S V -0 1 3 1
H R S V -0 1 4 5
H R S V -0 1 6 5
H R S V -0 1 7 0
H R S V -0 1 7 2
H R S V -0 1 7 3
H R S V -0 2 0 9
H R S V -0 2 1 2
H R S V -0 2 1 5
H R S V -0 2 2 3
H R S V -0 2 2 4
H R S V -0 2 2 5
H R S V -0 2 4 0
H R S V -0 2 5 1
H R S V -0 2 5 3
H R S V -0 2 5 4
H R S V -0 2 5 8
H R S V -0 2 6 7
H R S V -0 2 8 0
H R S V -0 2 8 2
H R S V -0 2 8 4
H R S V -0 2 9 1
H R S V -0 2 9 2
H R S V -0 2 9 4
H R S V -0 2 9 5
H R S V -0 2 9 6
H R S V -0 2 9 7
H R S V -0 2 9 8
H R S V -0 3 0 5
H R S V -0 3 0 6
H R S V -0 3 0 7
H R S V -0 3 0 8
H R S V -0 3 0 9
H R S V -0 3 3 6
H R S V -0 3 4 1
H R S V -0 3 4 2
H R S V -0 3 4 8
H R S V -0 3 5 0
H R S V -0 3 5 1
H R S V -0 3 5 2
H R S V -0 3 5 6
H R S V -0 3 5 7
H R S V -0 3 6 9
H R S V -0 3 7 0
H R S V -0 3 7 3
H R S V -0 3 8 7
H R S V -0 3 8 8
H R S V -0 3 8 9
H R S V -0 3 9 0
H R S V -0 3 9 1
H R S V -0 3 9 2
H R S V -0 3 9 3
H R S V -0 3 9 4
H R S V -0 4 5 0
H R S V -0 4 5 1
H R S V -0 4 5 2
H R S V -0 4 7 3
H R S V -0 4 8 1
H R S V -0 4 8 5
H R S V -0 4 8 8
H R S V -0 4 8 9
H R S V -0 4 9 1
H R S V -0 4 9 4
H R S V -0 4 9 5
H R S V -0 4 9 6
H R S V -0 5 0 4
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H R S V -0 5 1 6
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4.4.4.4 Hybridization results of the human influenza virus A 
amplicons  
RNA extracts of three clinical samples infected with human influenza virus A 
(H1N1-1, H1N1-2 and H3N2) were reverse transcribed into cDNA and then 
amplified using long-range PCR. The cDNA of the H3N2 was also amplified 
by MDA. The generated amplicons were fragmented by sonication. The 
fragmented PCR amplicon of the H1N1-1 was labelled with dyomics 547 
fluorescent dye, while the fragmented PCR amplicons of the H1N1-2 and 
H3N2 in addition to the fragmented MD amplicon of the H3N2 were labelled 
with dyomics 495 fluorescent dye (see table 4-3). The labelled amplicons were 
loaded into hybridization reactions with the probes designed for the selected 
RNA virus groups using four different grids of the virochip.  
 
4.4.4.4.1 Sensitivity of the human influenza virus A probes designed using 
OligoArray software  
Analysing the positive signals generated from the hybridization reactions of the 
human influenza virus A amplicons revealed that the vast majority of the 
OligoArray probes designed specifically for the HA and NA genomic segments 
of the H1N1 generated positive specific signals of high fluorescent intensities 
with the HA and NA PCR products of the H1N1 (see table 4-4) . Most of these 
H1N1 OligoArray probes showed signals of cross hybridization with the HA 
and NA PCR products of the H3N2. In contrast, all the positive hybridization 
signals generated from the OligoArray probes designed specifically for the HA 
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amplicons of the H1N1-1, H1N1-2 and H3N2. Many of the OligoArray probes 
designed specifically for the NA genomic segment of the H3N2 generated 
positive specific hybridization signals with their target H3N2 amplicons, and 
also showed cross hybridization signals with the H1N1-1 and H1N1-2 
amplicons. All other OligoArray probes designed specifically for other 
subtypes of the human influenza virus A, and human influenza B and C did not 
generate any positive hybridization signals with the amplicons of the H1N1 
and H3N2 (figure 4-28). 
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Figure 4-28: Signals generated from the hybridization reactions of four of the human influenza virus A amplicons with the probes designed 
specifically for the HA and NA genomic segments of the H1N1 and H3N2 using OligoArray software. 
RNA extracts of two H1N1 (H1N1-1 and 2) and one H3N2 clinical samples were reverse transcribed into cDNA and amplified using long-range PCR. The 
cDNA of the H3N2 was also amplified by MDA. The generated amplicons were sonicated, labelled and loaded into hybridization reactions with the 
designed probes of the selected RNA viruses and HHVs. The green, brown, red and blue columns represent the positive hybridization signals generated from 
the human influenza virus A OligoArray probes after hybridization to the PCR products of the H1N1-1, H1N1-2 and H3N2, and the MD amplicon of the 
H3N2, respectively.  
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4.4.4.4.2 Sensitivity of the human influenza virus A probes designed using 
Agilent eArray software  
Analysing the positive signals generated from the hybridization reactions of the 
human influenza virus A amplicons revealed that 126 probes out of 302 of the 
Agilent eArray probes designed specifically for the HA genomic segment, and 
170 probes out of 375 of the Agilent eArray probes designed specifically for 
NA genomic segment of H1N1 generated positive specific signals of high 
fluorescent intensities with the HA and NA PCR products of the H1N1 (see 
table 4-4). Most of these H1N1 Agilent eArray probes showed signals of cross 
hybridization with the HA and NA PCR products of the H3N2. In contrast, all 
the positive hybridization signals generated from the Agilent eArray probes 
designed specifically for the HA genomic segment of the H3N2 showed very 
low fluorescent intensities with all amplicons of the H1N1-1, H1N1-2 and 
H3N2. Many of the Agilent eArray probes designed specifically for the NA 
genomic segment of the H3N2 generated positive specific hybridization signals 
of various fluorescent intensities with their target H3N2 amplicons, and also 
showed cross hybridization signals with the H1N1-1 and H1N1-2 amplicons. 
All other Agilent eArray probes designed specifically for other subtypes of the 
human influenza virus A, B and C did not generate any positive hybridization 
signals with the amplicons of the H1N1 and H3N2 (figure 4-29). 
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Figure 4-29: Signals generated from the hybridization reactions of four of the human influenza virus A amplicons with the probes designed 
specifically for the HA and NA genomic segments of the H1N1 and H3N2 using Agilent eArray software. 
RNA extracts of two H1N1 (H1N1-1 and 2) and one H3N2 clinical samples were reverse transcribed into cDNA and amplified using long-range PCR. The 
cDNA of the H3N2 was also amplified by MDA. The generated amplicons were sonicated, labelled and loaded into hybridization reactions with the 
designed probes of the selected RNA viruses and HHVs. The green, brown, red and blue columns represent the positive hybridization signals generated from 
the human influenza virus A Agilent eArray probes after hybridization to the PCR products of the H1N1-1, H1N1-2 and H3N2, and the MD amplicon of the 
H3N2, respectively.  
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Those OligoArray and Agilent eArray probes designed for the HA and NA 
genomic segments of the human influenza virus A which showed higher 
fluorescent intensities with the H1N1 and H3N2 amplicons are listed in table 4-
8. The table shows that the OligoArray probe INF-A-H1N1-HA-0063 and the 
Agilent eArray probe AGV-1007 had the same sequence and generated a 
positive hybridization signal of high fluorescent intensity with PCR product of 
the HA genomic segment of the H1N1-1.  
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Table 4-8: Characteristics of the OligoArray and Agilent eArray probes of the HA and NA genomic segments of the human influenza 
virus A which showed higher fluorescent intensities with the H1N1 and H3N2 amplicons, and cross hybridization with the amplicons 
of the human enteroviruses, HMPV and HRSV, during their hybridization reactions.   
Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
O
lig
oA
rr
a
y 
pr
o
be
s 
INF-A-H1N1-HA-0005 CATACCCAAAGCTCAGCAAATCCTACATTA - ¥ - 
INF-A-H1N1-HA-0006 ATCATGACTCGAACAAAGGTGTAACGGCAG ¥ - - 
INF-A-H1N1-HA-0007 GTTCATGGCCCAATCATGACTCGAACAAAG - - - 
INF-A-H1N1-HA-0008 CATCTAGTTCAGACAATGGAACGTGTTACC - - - 
INF-A-H1N1-HA-0009 ATTGTGGAAACATCTAGTTCAGACAATGGA - - - 
INF-A-H1N1-HA-0010 TCTGTTAACCTTCTAGAAGACAAGCATAAC - - - 
INF-A-H1N1-HA-0012 TTCTAGAAGACAAGCATAACGGGAAACTAT - - - 
INF-A-H1N1-HA-0014 TAAATGTAACATTGCTGGCTGGATCCTGGG - - - 
INF-A-H1N1-HA-0015 AAGCATAACGGGAAACTATGCAAACTAAGA - ¥ ¥ 
INF-A-H1N1-HA-0017 TGCATTTGGGTAAATGTAACATTGCTGGCT - ¥ - 
INF-A-H1N1-HA-0018 AGTAACACACTCTGTTAACCTTCTAGAAGA - - - 
INF-A-H1N1-HA-0019 AGTGTCATCATTTGAAAGGTTTGAGATATT - - - 
INF-A-H1N1-HA-0020 AATTGAGCTCAGTGTCATCATTTGAAAGGT - - - 
INF-A-H1N1-HA-0021 AGACAATGGAACGTGTTACCCAGGAGATTT - - - 
INF-A-H1N1-HA-0022 ATTATGAGGAGCTAAGAGAGCAATTGAGCT - - - 
INF-A-H1N1-HA-0023 ATTTCAGAATATACATCCGATCACAATTGG ¥ ¥ - 
INF-A-H1N1-HA-0024 CCAGCCTCCCATTTCAGAATATACATCCGA - - - 
INF-A-H1N1-HA-0025 ATTGCAATACAACTTGTCAGACACCCAAGG - - ¥ 
INF-A-H1N1-HA-0026 CCAGTCCACGATTGCAATACAACTTGTCAG - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
O
lig
oA
rr
a
y 
pr
o
be
s 
INF-A-H1N1-HA-0027 TTCAGATACACCAGTCCACGATTGCAATAC ¥ - - 
INF-A-H1N1-HA-0028 GTATTATCATTTCAGATACACCAGTCCACG ¥ - - 
INF-A-H1N1-HA-0029 GCTGGATCTGGTATTATCATTTCAGATACA - - - 
INF-A-H1N1-HA-0030 GGAAAGAAATGCTGGATCTGGTATTATCAT - - - 
INF-A-H1N1-HA-0031 CATTCGCAATGGAAAGAAATGCTGGATCTG - - - 
INF-A-H1N1-HA-0032 CCGAGATATGCATTCGCAATGGAAAGAAAT - - - 
INF-A-H1N1-HA-0033 TCTAGTGGTACCGAGATATGCATTCGCAAT - - - 
INF-A-H1N1-HA-0034 CAACTGGAAATCTAGTGGTACCGAGATATG ¥ - - 
INF-A-H1N1-HA-0035 ACATTCGAAGCAACTGGAAATCTAGTGGTA ¥ - - 
INF-A-H1N1-HA-0038 GAAGTTCAAGCCGGAAATAGCAATAAGACC ¥ ¥ ¥ 
INF-A-H1N1-HA-0039 GATACAGCAAGAAGTTCAAGCCGGAAATAG ¥ ¥ ¥ 
INF-A-H1N1-HA-0040 CAACAAAGTCTCTATCAGAATGCAGATGCA - - - 
INF-A-H1N1-HA-0043 GTCCCGTCTATTCAATCTAGAGGCCTATTT ¥ - ¥ 
INF-A-H1N1-HA-0044 ATTGAGGAATGTCCCGTCTATTCAATCTAG - - - 
INF-A-H1N1-HA-0045 GCTATAAACACCAGCCTCCCATTTCAGAAT ¥ ¥ - 
INF-A-H1N1-HA-0046 GAGGGATCAAGAAGGGAGAATGAACTATTA ¥ ¥ ¥ 
INF-A-H1N1-HA-0047 CCGGAAATAGCAATAAGACCCAAAGTGAGG - - - 
INF-A-H1N1-HA-0049 ATGGTCCTACATTGTGGAAACATCTAGTTC - - - 
INF-A-H1N1-HA-0051 ACAGGGATGGTAGATGGATGGTACGGTTAT - - - 
INF-A-H1N1-HA-0052 AAAGAACTTTGGACTACCACGATTCAAATG - ¥ - 
INF-A-H1N1-HA-0053 CTGGACATTTGGACTTACAATGCCGAACTG - - - 
INF-A-H1N1-HA-0054 CGAGATTACTAACAAAGTAAATTCTGTTAT - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
O
lig
oA
rr
a
y 
pr
o
be
s 
INF-A-H1N1-HA-0055 TGATGGTTTCCTGGACATTTGGACTTACAA - - - 
INF-A-H1N1-HA-0056 GGACTACCACGATTCAAATGTGAAGAACTT - - - 
INF-A-H1N1-HA-0057 CAGCAGTAGGTAAAGAGTTCAACCACCTGG - - - 
INF-A-H1N1-HA-0060 ACTTACAATGCCGAACTGTTGGTTCTATTG - - - 
INF-A-H1N1-HA-0062 AAATGCGATAACACGTGCATGGAAAGTGTC - - - 
INF-A-H1N1-HA-0063 TAAAGCTGGAATCAACAAGGATTTACCAGA ¥ ¥ - 
H
1N
1-
H
A
-
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s 
AGV-0946 GGCTGCTTTGAATTTTACCATAAATGCGAT - - - 
AGV-0954 TTGGAAACGGCTGCTTTGAATTTTACCACA ¥ - - 
AGV-0955 AATGCGATAACACGTGCATGGAAAGTGTCA ¥ - - 
AGV-0957 ATGGTTTCCTGGACATTTGGACTTACAATG ¥ - - 
AGV-0958 CCGAACTGTTGGTTCTATTGGAAAATGAAA - - - 
AGV-0960 GGCTGCTTTGAATTTTACCACAAATGCAAT - - - 
AGV-0961 CTGTTGGTTCTATTGGAAAACGAAAGAACT - - - 
AGV-0969 TGAATTTTACCACAAGTGCGATAACACGTG - - - 
AGV-0972 TCAACAAGGATTTACCAGATTTTGGCGATT ¥ - - 
AGV-0974 GGCTGCTTTGAATTTTATCACAAATGCGAT - - - 
AGV-0976 CCAAGGAAATTGGAAACGGCTGCTTTGAAT - - - 
AGV-0977 TTTACCACAAATGCGATAACACGTGCATGG - - - 
AGV-0978 AAAGTGTCAAAAATGGGACTTATGACTACC - - - 
AGV-0981 CCAGCTAAAAAACAATGCCAAGGAAATTGG ¥ ¥ - 
AGV-0982 GACTATCCAAAATACTCAGAGGAAGCAAAA - ¥ ¥ 
AGV-0985 TTTCCTGGACATTTGGACTTACAATGCCGA - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
H
1N
1-
H
A
-
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s 
AGV-0986 GCTGTTGGTTCTATTGGAAAATGAAAGAAC - - - 
AGV-0991 GGACTATCACGATTCAAATGTGAAGAACTT - - - 
AGV-0992 TGGTTTCCTGGACATTTGGACTTATAATGC - - - 
AGV-0998 TTCCTGGACATTTGGACTTACAATGCCGAA - - - 
AGV-0999 CTGTTGGTTCTGTTGGAAAATGAAAGAACT - - - 
AGV-1007 CAATGCCAAGGAAATTGGAAATGGCTGCTT - - - 
AGV-1077 CCAAAATACTCAGAGGAAGCAAAATTGAAC - - ¥ 
AGV-1078 GCCGAACTGTTGGTTTTATTGGAAAATGAA - - - 
AGV-1095 GAGTTCAACCACCTGGAAAAAAGAATAGAG ¥ ¥ ¥ 
AGV-1096 GACATTTGGACTTACAATGCCGAACTGTTG - - - 
AGV-1396 CAGTTAAAAAACAATGCCAAGGAACTTGGA - - - 
AGV-1397 GACTACCCAAAATACTCAGAAGAAGCAAAA - - - 
AGV-1419 AGAACAATGCCAAGGAAATTGGAAACGGCT - ¥ ¥ 
AGV-1436 GGCTGCTTTGAATTTTACCACAAATGTGAT - - - 
AGV-1524 GCCGAATTGTTGGTTCTATTGGAAAATGAA - - - 
AGV-1554 TGCATGGAAAGTGTCAAAAATGGGACTTAT - - - 
AGV-1555 GATTACCCAAAATACTCAGAGGAAGCAAAA - - ¥ 
AGV-1579 CAATGCCAAGGAAATTGGAAACGGATGCTT ¥ - ¥ 
AGV-1581 TCAACAAGGATTTACCAGATCTTGGCGATC ¥ - - 
AGV-1663 CCGAAATACTCAGAGGAAGCAAAATTAAAC - - - 
AGV-1664 ATGGCTTCCTGGACATTTGGACTTACAATG - - - 
AGV-1665 GGACTACCACGATTCAAATGTGAAGAATTT - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
H
1N
1-
H
A
-
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s 
AGV-1710 GCATGGAAAGTGTCAAAAATGGAACTTATG ¥ - - 
AGV-1811 TAAAGCTGGAATCAACAAGGATTTACCAGA ¥ - - 
AGV-1812 CAATGCTAAGGAAATTGGAAACGGCTGCTT - - - 
AGV-1814 GGACTACCATGATTCAAATGTGAAGAACTT - - - 
AGV-1815 CCAGAATACTCAGAGGAAGCAAAATTAAAC - - - 
AGV-1963 CATGGAAAGTGTCAAAAACGGGACTTATGA - - - 
AGV-2000 GCATGAAAAGTGTCAAAAATGGGACTTATG - - - 
AGV-2020 CGTGCATGGAAAGTGTAAAAAATGGGACTT ¥ - - 
AGV-2026 GAATCAACAAGGATTTACCAGATTTTGGCG ¥ - - 
AGV-2028 GCTGAACTGTTGGTTCTATTGGAAAATGAA - - - 
AGV-2102 GCATGGAAAGTGTTAAAAATGGGACTTATG - - - 
AGV-2104 TGAATTTTACCACAAATGCGACAACACGTG - - - 
AGV-2229 CCAGTTAAAAAACAATGCCAAGGAAATTGG ¥ - - 
AGV-2230 GCTGCTTTGAATTTTACCACAAATGCGATA - - - 
AGV-2265 CAATGCCAAGGAAATTAGAAACGGCTGCTT - - - 
AGV-2266 TCAACAAGGATTTACCAGATTCTGGCGATC - - - 
AGV-2268 CCAGTTAAAAAACAATGCCAAGGAAGTTGG ¥ - - 
AGV-2301 TGGTTTCTTGGACATTTGGACTTACAATGC - - - 
AGV-2320 AACTTTGGACTACCACGATTCAAATGTGAA - - - 
AGV-2321 GAACTTGTATGAAAAGGTAAGAAGCCAGTT - - - 
AGV-2322 AATGCCAAGGAAATTGGAAACGGCTGCTTT - - - 
AGV-2323 TTTTACCACAAATGCGATAACACGTGCATG - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
H
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1-
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A
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 eA
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a
y 
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o
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s 
AGV-2324 GAAAGTGTCAAAAATGGGACTTATGACTAC - - - 
AGV-2325 CCCAAATACTCAGAGGAAGCAAAATTAAAC - - ¥ 
AGV-2331 GATGGTTTCCTGGACATTTGGACTTACAAT ¥ - - 
AGV-2352 TGGTTTCCTGGACATTTGGACTTACAATGC - - - 
AGV-2353 CGAACTGTTGGTTCTATTGGAAAATGAAAG - - - 
AGV-2354 GACTACCACGATTCAAATGTGAAGAACTTA - - - 
AGV-2355 AAACAATGCCAAGGAAATTGGAAACGGCTG - ¥ ¥ 
AGV-2356 TGAATTTTACCACAAATGCGATAACACGTG - - - 
AGV-2357 CATGGAAAGTGTCAAAAATGGGACTTATGA - - - 
AGV-2358 CTACCCAAAATACTCAGAGGAAGCAAAATT - - - 
AGV-2359 TCAACAAGGATTTACCAGATTTTGGCGATC ¥ - - 
O
lig
oA
rr
a
y 
pr
o
be
s 
INF-A-H1N1-NA-0005 AAGAGTTGGAGAAACAATATATTGAGAACA - - - 
INF-A-H1N1-NA-0006 AGACACTATCAAGAGTTGGAGAAACAATAT - - ¥ 
INF-A-H1N1-NA-0007 GCATAATAACAGACACTATCAAGAGTTGGA - - - 
INF-A-H1N1-NA-0008 CATATCGAACCCTAATGAGCTGTCCTATTG ¥ - - 
INF-A-H1N1-NA-0009 TGGACAGTCAGTGGTTTCCGTGAAATTAGC ¥ - - 
INF-A-H1N1-NA-0012 AAGACAGGAGCCCATATCGAACCCTAATGA ¥ ¥ ¥ 
INF-A-H1N1-NA-0013 TAATAACCATTGGTTCGGTCTGTATGACAA ¥ - - 
INF-A-H1N1-NA-0014 CATTCCAATGGAACCATTAAAGACAGGAGC ¥ - - 
INF-A-H1N1-NA-0021 CCTATTGGTGAAGTTCCCTCTCCATACAAC - - - 
INF-A-H1N1-NA-0022 CAATTCCTCTCTCTGCCCTGTTAGTGGATG - - - 
INF-A-H1N1-NA-0023 CTTGTCATGATGGCATCAATTGGCTAACAA - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
O
lig
oA
rr
a
y 
pr
o
be
s 
INF-A-H1N1-NA-0025 CTTGCTAAATGACAAACATTCCAATGGAAC ¥ - - 
INF-A-H1N1-NA-0027 AGATATCGTAGGAATAAATGAGTGGTCAGG - - - 
INF-A-H1N1-NA-0028 GGGACAGACAATAACTTCTCAATAAAGCAA - ¥ - 
INF-A-H1N1-NA-0029 TCCAGTATCGTCTAATGGAGCAAATGGAGT - - - 
INF-A-H1N1-NA-0030 CAGGCAGTTGTGGTCCAGTATCGTCTAATG - - - 
INF-A-H1N1-NA-0031 GATTCTAGTGAAATCACATGTGTGTGCAGG - - - 
INF-A-H1N1-NA-0032 CTGTTATCCTGATTCTAGTGAAATCACATG - - - 
INF-A-H1N1-NA-0033 GAAAGATAGTCAAATCAGTCGAAATGAATG - - - 
INF-A-H1N1-NA-0036 CATTCAAATACGGCAATGGTGTTTGGATAG - - - 
INF-A-H1N1-NA-0037 CCAAGTGATGGACAGGCCTCATACAAGATC - - - 
INF-A-H1N1-NA-0038 GAACTAATCAGAGGGCGACCCAAAGAGAAC ¥ ¥ ¥ 
INF-A-H1N1-NA-0039 CAGAACTAACAGGGCTGGATTGTATAAGAC - ¥ - 
INF-A-H1N1-NA-0040 TCTGAATGTGCATGTGTAAATGGTTCTTGC - - - 
INF-A-H1N1-NA-0041 AGGAATGCTCCTGTTATCCTGATTCTAGTG ¥ - - 
INF-A-H1N1-NA-0044 CTGTTAGTGGATGGGCTATATACAGTAAAG - - - 
INF-A-H1N1-NA-0045 CTAACAATTGGAATTTCTGGCCCAGACAAT - - - 
INF-A-H1N1-NA-0047 AATGAGCTGTCCTATTGGTGAAGTTCCCTC - - - 
INF-A-H1N1-NA-0050 GGAATAAATGAGTGGTCAGGATATAGCGGG - - - 
INF-A-H1N1-NA-0051 TATAAGACCTTGCTTCTGGGTTGAACTAAT - - - 
INF-A-H1N1-NA-0052 GGCTGGATTGTATAAGACCTTGCTTCTGGG - - - 
INF-A-H3N2-NA-0022 TTATGTGTCATGCGATCCTGACAAGTGTTA - - - 
INF-A-H3N2-NA-0023 CAAGAGAACCTTATGTGTCATGCGATCCTG - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
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1-
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A
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A
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a
y 
pr
o
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s 
AGV-0947 TCAAATACGGCAATGGTGTTTGGATAGGGA    
AGV-0949 GGATTTTCATTCAAATACGGCAATGGAGTT    
AGV-0968 GGGTTTTCATTCAAATACGGCAATGGTGTT    
AGV-0995 ATATGCAGTGGGATTTTCGGAGACAATCCA - - - 
AGV-1005 AAGACCTTGCTTCTGGGTTGAACTAATCAG - - - 
AGV-1081 GATATCGTAGGAATAAATGAGTGGTCAGGA - - - 
AGV-1082 TATAGCGGGAGTTTTGTTCAGCATCCAGAA - - - 
AGV-1083 AACAGGGCTGGATTGTATAAGACCTTGCTT - - - 
AGV-1437 ATCCTTTTGTGGTGTAAACAGTGACACTGT ¥ - - 
AGV-1438 AGCATATCCTTTTGTGGTGTAAACAGTGAC - - - 
AGV-1472 GTATCGTCTAATGGAGCAAATGGAGTGAAA - - - 
AGV-1585 TGGATTGTATAAGACCTTGCTTCTGGGTTG - - - 
AGV-1586 AATTAATCAGAGGGCGACCCAAAGAGAACA - - - 
AGV-1757 GGGACAGACAATAACTTCTCAATAAAGCAA - - - 
AGV-1758 TAATGATAAGACAGGCAGTTGTGGTCCAGT - - ¥ 
AGV-1759 ATCGTCTAATGGAGCAAATGGAGTAAAAGG - - - 
AGV-1804 TCCAGAACTAACAGGGCTGGATTGTATAAG - - - 
AGV-1979 TTTCGGAGACAATCCACGCCCTAATGATAA - - - 
AGV-2033 ATGGTCAGGATATAGCGGGAGTTTTGTTCA - - - 
AGV-2235 TTTTGTTCAGCATCCAGAACTAACAGGGCT - - - 
AGV-2236 TTGTATAAGACCTTGCTTCTGGGTTGAACT - - - 
AGV-2269 CGTCTAATGGAGCAAATGGAGTAAAAGGAT - - - 
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Probe ID Sequence Cross hybridization H. enteroviruses HMPV HRSV 
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pr
o
be
s 
AGV-2270 ATTCAAATACGGCAATGGTGTTTGGATAGG - - - 
AGV-2327 CGTAGGAATAAATGAGTGGTCAGGATATAG - - - 
AGV-2342 GTATCGTCTAATGGAGCAAATGGAGTAAAA - - - 
AGV-2343 GGATTTTCATTCAAATACGGCAATGGTGTT - - - 
AGV-2344 TGGATAGGGAGAACTAAAAGCATTAGTTCA - - - 
AGV-2346 GGACAGACAATAACTTCTCAATAAAGCAAG - - - 
AGV-2347 TAGGAATAAATGAGTGGTCAGGATATAGCG - - - 
AGV-2348 CATCCAGAACTAACAGGGCTGGATTGTATA - - - 
AGV-2349 AGACCTTGCTTCTGGGTTGAACTAATCAGA - - - 
AGV-2350 TTTGTGGTGTAAACAGTGACACTGTGGGTT - - - 
H
3N
2-
N
A
-
A
gi
le
nt
 eA
rr
a
y 
pr
o
be
s 
AGV-1644 AGGACTTGTTGGAGACACACCCAGAAAAAA - - - 
AGV-1645 GAGGTGATAGGTCCGGTTATTCTGGTATTT - - - 
AGV-1825 TTGTGTTTTGTGGCACCTCAGGTACATATG - - - 
AGV-1878 AACAGTATTGTTGTGTTTTGTGGCACCTCC ¥ - ¥ 
AGV-1990 ACAGTATTGTTGTGTTTTGTGGCACCTCAG - - - 
AGV-2129 CCAAATTGCAGATAAATAGGCAAGTCATAG - - - 
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4.4.4.4.3 Specificity of the human influenza virus A probes  
Many of the OligoArray probes and Agilent eArray probes targeting the HA 
and NA genomic segments of the H1N1 shown in table 4-6 showed cross 
hybridization with the amplicons of the human enterovirus, HMPV and HRSV 
revealed as weak nonspecific signals for most of them (figures 4-30 to 4-32). 
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Figure 4-30: Signals of cross hybridization generated between the H1N1and 
H3N2 probes, and the human enterovirus amplicons. 
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Figure 4-31: Signals of cross hybridization generated between the H1N1and 
H3N2 probes, and the HMPV amplicons. 
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Figure 4-32: Signals of cross hybridization generated between the H1N1and 
H3N2 probes, and the HRSV amplicons. 
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4.5 Discussion  
In spite of the widespread usage of the nucleic acid microarray technology in 
different aspects of researches over the past twenty years, many researchers 
believe that it is still in its infancy as it needs more efforts in order to determine 
the specific detection limit for each microarray assay (Trevino et al., 2007, Wei 
et al., 2012). The limited quantities of viral RNA which can be acquired from 
infected clinical samples, often mixed with human genomic nucleic acids, can 
limit the application of the nucleic acids microarray for the diagnosis of the 
viral infections (Puskas et al., 2002). Since the detection limit of this viral 
microarray assay is still undetermined, the nucleic acids of the selected RNA 
viruses were amplified in order to provide adequate quantities for the 
hybridization reaction. In order to evaluate the performance of the OligoArray 
and Agilent eArray probes which were designed along the whole viral 
genomes, it was necessary to amplify the full genome length of the echovirus 
7, coxsackievirus A-21, clinical enterovirus, HMPV, HRSV, H1N1 and H3N2 
in order to provide complementary sequences of the viral nucleic acid for each 
one of the designed probes. Long-range PCR amplification reaction was used 
in parallel with the MDA process for amplifying the whole genome of the 
above viruses as there was a concern that the amplified viral products 
generated from the MDA may fail to hybridize to the designed viral probes as 
described in the previous chapter. Amplification efficiency of the full length 
viral genomes is mainly affected by the integrity of the cDNA generated from 
the reverse transcription reaction of the viral RNA (Wang, 2005). Therefore, 
Maxima H Minus First Strand cDNA Synthesis kit was used for generating full 
length cDNA of the selected RNA viruses from their RNA extracts especially 
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HMPV and HRSV, whose RNA length exceeds the reverse transcription limit 
(12 kb) of the SuperScript III First-Strand Synthesis SuperMix kit used in 
section 3.3.2.3.  
The specific single bands with the expected size generated from long-range 
PCR of the selected viral genomes as visualized by gel electrophoresis in 
figures 4-3 to 4-9 indicates the success of the amplification process. Moreover, 
the negative control samples did not show any band on the gel indicating the 
specificity of the amplification process.    
Fragmentation of the viral amplicons was performed in order to enhance the 
hybridization sensitivity through minimizing the background fluorescent noise 
which could be generated from the non-specific binding of large-sized 
sequences of the viral amplicons to the slide surface after labelling with the 
fluorescent dyes (Liu et al., 2007).  
Hybridization reactions of the above viral amplicons revealed that many of the 
probes designed specifically for the selected RNA viruses showed high 
specificity as they were hybridized to the nucleic acid of their target viruses 
while many other probes were nonspecific and showed cross hybridization with 
the nucleic acid of other non-target viruses. Some of the unexpected results 
generated from the virochip hybridization reaction, especially those signals 
generated from the different amplicons of the same viral type (HMPV, HRSV 
or Influenza virus A), and the cross hybridization between the HRSV probes 
and the amplicons of the coxsackievirus A-21 and H1N1, could be related to 
unobserved accidental technical mistakes during the preparation of the viral 
nucleic acids for this complex experiment, such as the probable loss of the viral 
amplicon pellet during the precipitation step following the fragmentation 
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and/or labelling processes in spite of the precautions and the meticulous care 
used. On the other hand, most of those cross reacting HMPV OligoArray 
probes generated signals of high fluorescent intensities with the HRSV 
amplicons due to the nucleotides sequence homology in approximately 50% of 
the HMPV and HRSV genomes.  
Apart from the hybridization results of the HMPV amplicons which did not 
show any positive hybridization signal with the HMPV Agilent eArray probes 
the hybridization results of other viral amplicons especially HRSV and H1N1 
revealed that the Agilent eArray probes showed better specificity to their target 
viral amplicons than OligoArray probes as most of the Agilent eArray positive 
probes showed no or weak signals of cross hybridization with other non-target 
viral amplicons. The specificity of the Agilent eArray probes is attributed to 
their designing process which was based on loading the original sequences of 
the human enterovirus, HMPV, HRSV and human influenza virus into the 
Agilent eArray software, while the OligoArray probes were designed by 
loading the consensus sequences of the above viruses which contained 
degenerate nucleotides into the OligoArray software. This means that the 
Agilent eArray probes were better more specific for their target nucleic acids of 
the above viruses than the OligoArray probes.   
Hegde et al (2000) indicated that both sensitivity and specificity of the nucleic 
acid microarray hybridization may be affected by many factors including probe 
characteristics such as their length, GC content and melting temperature, 
hybridization conditions such as hybridization temperature and period, washing 
stringency and signal detection. Wei and his group (2012) however, found that 
the probe melting temperature and GC content, and hybridization period had no 
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effect on the nucleic acid hybridization reaction efficiency. The potential 
formation of secondary structure in some long fragments of the viral amplicons 
which may prevent the probes from accessing their specific targets and/or 
sequence repetition of some probes along the target viral genomes may explain 
the discrepancy of the hybridization results of each of the HMPV, HRSV and 
H1N1 PCR amplicons (Peplies et al., 2003, Ratushna et al., 2005, Liu et al., 
2007, Mueckstein et al., 2010). Wei et al (2012) demonstrated that each nucleic 
acid target may have three different regions: the first one is completely 
complementary and exposed to the probe sequence and generates strong 
hybridization signals; the second region is partially complementary and/or 
exposed to the probe sequence and generates weak hybridization signals, while 
the third region is inaccessible and the probe is incapable to hybridize with it 
resulting in no signals of hybridization.   
Non-specific cross hybridization is a common problem in nucleic acid 
microarray hybridization which is attributed to the potential similarity among 
the target nucleic acids sequences (Kane et al., 2000, Evertsz et al., 2001, 
Barrett and Kawasaki, 2003, Trevino et al., 2007). The nucleotide mismatches 
between the sequences of some probes and the target nucleic acid is considered 
as another reason for variability of the hybridization results (Fotin et al., 1998, 
Southern et al., 1999). Urakawa and his group (Urakawa et al., 2003) reported 
that the stability of the nucleic acid duplexes generated from hybridization 
reactions can be affected by the number, position and type (A, T, G or C) of the 
nucleotide mismatches. Those probes showing nucleotide mismatches at their 
central part would hybridize more strongly to their target nucleic acids than 
other probes showing nucleotide mismatches at their edges (Shchepinov et al., 
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1997, Hughes et al., 2001, Zhang et al., 2007). The fluorescent intensities of 
the signals generated from the hybridization reaction reflect the matching ratio 
between the probes and their targets, but it is not a rule, as many of the probes 
showing nucleotide mismatches generated hybridization signals of higher 
fluorescent intensities than those signals generated from hybridization with 
perfect-matching probes (Naef and Magnasco, 2003, Wei et al., 2012). 
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Viruses cause different types of human infectious diseases accompanied by 
various clinical symptoms, which assist the diagnosis of these infections. 
However, the similarities among the symptoms of some of viral diseases in 
addition to those asymptomatic infections make their clinical diagnosis 
difficult without proper laboratory investigations (Collier and Oxford, 2000). 
The global migration during the past few years has continuously raised the 
emergence and re-emergence of several viral infections in both developed and 
developing countries, which represent 44% of the total infectious diseases 
(Tyler, 2009). The vast majority of these emerged and/or re-emerged viral 
infections are caused by RNA viruses due to the high error rate of their 
polymerases responsible for their genomes replication leading to generate new 
strains of these viruses (Nichol et al., 2000). Proper management of viral 
infections helps in preventing many of their serious complications, such as 
poliomyelitis caused by polioviruses, and reducing the cost of unnecessary 
hospitalization (Ramers et al., 2000).   
It is tempting to identify next generation sequencing (NGS) as an alternative 
method for the microarray assay. However, it is important to keep in mind that 
the NGS method requires relatively higher concentration of viral nucleic acid 
than the microarray assay (Marston et al., 2013). The advantages of the NGS 
method lie in the ability to discover new viral strains and viral SNPs. On the 
other hand, the microarray assay can facilitate the fast and specific diagnosis of 
viral infections from relatively low concentrations of viral nucleic acids 
available in clinical samples. Thus, as far as the current project results show, 
the microarray assay seem to provide a more clinically reliable method for 
detection and diagnosis of viral infections.     
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5.1 Conclusion  
Nucleic acid microarray is being used for early and accurate diagnosis of viral 
infections through detection of viral nucleic acid in a clinical sample. The tiny 
amount of viral nucleic acid presented in some clinical samples such as CSF, 
limits the application of nucleic acid microarray for this purpose. MDA has 
been used in order to overcome this problem through amplifying the whole 
genome of the target viruses. In spite of the efficiency of MDA in generating 
micrograms of high molecular weight of the entire viral genome within less 
than two hours, this process has the following drawbacks: 
a) Samples with very low concentrations (<10 ng) and or short fragments of 
viral nucleic acids, resulted in nonspecific amplification with high rate of 
bias.   
b) Amplifying the contaminated nucleic acid especially those of human 
origin.    
PCR can be used as an alternative method for specific amplification of the 
whole viral genome through designing many sets of specific primers some of 
them containing 1-2 of degenerate nucleotides, targeting conserved sequences 
along the entire genome of each one of the selected viral groups. This method 
was so efficient in amplifying approximately 90% of the entire genome of each 
of the human enteroviruses, human respiratory syncytial viruses, human 
metapneumoviruses and influenza viruses, which facilitated investigating the 
performance of hundreds of probes designed specifically for each of these 
viruses.       
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5.2 Limitations of the study   
Single stranded viral RNA is a fragile structure, highly susceptible for 
degradation, provides a major obstacle to whole genome amplification. The 
scarce concentrations of the viral nucleic acids existing in the positive control 
and clinical samples (few picograms) used for validating the assay was another 
challenge to viral nucleic acid amplification. The unavailability of the CSF 
samples infected with human enteroviruses prevented validating the assay 
against cases with CNS viral infections.  
        
5.3 Future work  
Many of the probes designed specifically for the selected RNA viruses 
generated hybridization signals of high fluorescent intensity which is very 
promising, while many other probes did not generate any signal of 
hybridization with their target viral nucleic acid such as enterovirus probe, or 
showed signals of cross hybridization with other non-target nucleic acid. 
Therefore, it is recommended to re-print the probes designed specifically for 
each of the selected viral groups on a separate grid or slide, and then 
revalidating their performance using single sample per each grid which have 
not been done due to time limitation. It is also recommended to validate the 
performance of the probes designed specifically for human rhinoviruses using 
samples containing these viruses. Using CSF samples infected with human 
enteroviruses in order to validate the designed enterovirus probes against cases 
of CNS viral infections. It is important to build a library of control positive 
samples of viral genomes with preferably a concentration of more than 10 
ng/µl. This library would help validating the hybridization process in order to 
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select the most appropriate probes designed specifically for each viral group. 
Finally, it is very important to define the sensitivity of the designed probes 
using diluted concentrations on viral nucleic acids. This would help to select 
the cut off point for viral genome concentration used, and thus minimize the 
reagents, efforts, time and cost of the experiment.  
It might be worth trying to validate the microarray assay with other methods 
used in the diagnosis of viral infections in clinical samples such as 
conventional PCR and QPCR. 
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